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Thesis Portfolio Abstract 
 
 
Background:  In recent years, there have been many advancements in clinical 
research and rehabilitation of stroke. However, current gaps in the literature remains 
as it is yet to draw conclusions on the best available tools for measuring health-
related quality of life (HR-QOL), and the best evidenced interventions for post-
stroke mood disorders. 
Aim: This research portfolio aimed to provide a comprehensive review of the current 
evidence for stroke-specific HR-QOL measurements, as well as the intervention 
treatments used for post-stroke mood disorders, namely post-stroke depression 
(PSD), post-stroke anxiety (PSA) and post-stroke emotionalism (PSE). 
Design: A systematic review identifies existing HR-QOL measures that are used 
within the stroke population and assessed them for clinical utility, psychometric 
properties and coverage of HR-QOL domains. The empirical paper systematically 
identifies randomised controlled trials (RCTs) on treatment intervention for PSD, 
PSA and PSE domains. Network meta-analyses (NMA) is conducted on the evidence 
for each domain to synthesise the findings based on direct and indirect comparisons. 
Results & conclusions: The systematic review identified seventeen HR-QOL 
measures commonly in stroke, and a flow-chart recommending five measures which 
best met the clinical utility and psychometric criteria. No measure comprehensively 
covered all HR-QOL domains. The NMA presented the wide range of interventions 
available for PSD, PSA and PSE, and highlights the disproportionate focus of 
research within these domains. There is paucity of replicated evidence in the area. 
Thus, the NMA was not able to provide confident predictions of treatment rankings 
for either of the domains. Overall, both the systematic review and empirical paper 
reiterated the need for more quality research in the field. 
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Introduction to the Thesis Portfolio 
 
1.1 Stroke 
 
Every year, approximately 110, 000 people are affected by stroke in England 
(Burton & Tyson, 2015). The consequence of stroke results in a wide range of 
disability (Adamnson, Beswick & Ebrahim, 2004, as cited in Pindus et al., 2016). 
Pinter and Brainin (2012) reported that over 5 million stroke survivors are left 
permanently disabled (WHO, 2009), with complications including impaired 
cognition (43.9%), impaired consciousness (44.7%) (Lawrence et al., 2001), 
language difficulties (30-50%), (Kirmness & Maher, 2010), visual neglect 
(50%)(Buxbaum et al., 2004), and psychological problems (62-70%)(Kauhanen et 
al., 2000) (Paul, Srikanth & Thrift, 2007). Despite the worldwide decrease in stroke 
mortality in recent years, the overall burden caused by stroke (years of life lost and 
years lived with disability) remains great and is increasing (Feigin et al., 2010). 
 
 
1.2 Emotional / mood disorders after stroke 
 
Psychological adjustment to stroke can be a distressing process (Broomfield, 
Kneebone & Laidlaw, 2014; Taylor et al., 2011). Difficulty in adjusting may result 
in significant impact on mood, with about one third of stroke survivors developing 
major depression (Medeiros et al., 2020), and 18-24% affected by anxiety disorders 
(Knapp et al., 2020). There is also evidence of prevalent mood impairment even 
following a Transient Ischemic Attack (Broomfield et al., 2014). Furthermore, 
around 21% of people living with stroke report symptoms of emotionalism (Gillespie 
et al., 2016). A large-scale survey reported only just under one third of stroke 
survivors who report emotional problems receive the support they need (McKevitt et 
al., 2011). 
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Post-stroke depression (PSD) can have a significant impact on a person’s 
response to rehabilitation (Ghose et al., 2005; Jia et al., 2006), quality of life after 
stroke (Bays, 2001; Neau et al., 1998) and functional outcome (Pohjasvaara et al., 
2002; Chemerinski, Robinson & Kosier, 2001). Post-stroke depression may see a 
decrease in patient motivation and engagement with rehabilitation, hence negatively 
impacting recovery and exacerbating their experienced level of disability (Astuti, 
Kusnanto & Novitasari, 2020). Research has also found that stroke survivors’ post- 
stroke depression is associated with a higher mortality rate than those without 
(Morris et al., 1993; House et al., 2001; Townend et al., 2007; Towfighi et al., 2017). 
Similar to depression outside the context of stroke, prevention and treatment for PSD 
typically consists of administration of antidepressant medications and psychotherapy 
(Hildebrand, 2015; NICE, 2013). However, to date, the evidence for psychological 
interventions for this population remains inconclusive (Wang et al., 2018). 
Generalised anxiety, as well as phobic anxiety are the most common forms of 
post-stroke anxiety (PSA) (Burton et al., 2013). This is often co-morbid with PSD, 
with papers reporting as many as 85% of people with PSA having co-morbid 
depression post-stroke (Castillo et al., 1993, 1995). Despite its prevalence, very few 
studies have evaluated the effectiveness of potential treatments of PSA (Chun et al., 
2018). Systematic reviews have included few trials (Burton et al., 2011; Knapp et al., 
2017) and found limited evidence for the use of pharmaceutical drugs, and reported 
no significant additional benefits in combining pharmaceutical treatment with 
psychotherapy. 
Psychologically, post-stroke emotionalism (PSE) describes a reduced ability to 
control emotional expression. Sufferers typically experience episodes of increased 
tearfulness and may cry uncontrollably at events that are only moderately sad. PSE 
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can cause severe distress, embarrassment, social avoidance, and impaired quality of 
social interactions for the persons experiencing it (Carota & Calabrese, 2013; 
McAleese, 2019). To date, there are several papers which have reviewed 
pharmacological interventions for PSE (House et al., 2004; Hackett et al., 2010), 
with a growing body of recent research to add to this literature (Zorowitz et al., 
2016; Patatanian & Casselman, 2014;Imarhiagbe &Abidakun, 2018; Allida et al., 
2019). In comparison to pharmacological interventions, psychological interventions 
for PSE are poorly understood and under researched. Despite noting two case 
reports of psychological therapy (Brookshire 1970; Sacco, 2008), Hackett et al. 
(2010) did not find any RCTs evaluating psychological interventions to include in 
their review, indicating a marked gap in current research and literature. 
 
1.3 Health-related quality of life 
 
 
Of growing interest within stroke rehabilitation is the impact of stroke on a 
person’s health-related quality of life (HR-QOL) (Golomb, Vickrey & Hays, 2001). 
HR-QOL specifically refers to an individual’s health and how it affects their ability 
to function, as well as their perceived well-being in physical, mental and social 
domains of life (Coons et al., 2000). Measurements of HR-QOL can provide 
clinicians and patients with a comprehensive assessment of a person’s health status, 
as well as serve as a baseline for clinical treatment and for assessment of 
intervention effectiveness (Solari, 2005). As such, HR-QOL measures are important 
and routinely used in primary care settings when working with patients who 
experience a range health conditions, such as atrial fibrillation (Badia et al., 2007), 
multiple sclerosis (Solari, 2007) and chronic conditions (Hand, 2016), including 
stroke (Hackett et al., 2000). 
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To assess the HR-QOL of patients with stroke, a variety of measures can be 
used. These measures can vary in design, where some are used generically across 
health conditions, and others are designed for a particular clinical population 
(Golomb, Vickrey & Hays, 2001). Therefore, it is important to understand and 
compare the content and psychometric properties of HR- QOL scales to aid the 
clinical decision-making in selecting the appropriate tools (Hand, 2016). 
Identifying specific HR-QOL measures for patients with stroke can allow for 
better assessment of the impact of the disease and in turn significantly improve 
patient outcomes (Badia et al., 2007). 
In a review conducted by Golomb, Vickrey and Hays (2001), 32 measures of 
HR-QOL were identified for use in patients with stroke. This paper presented the 
strengths, limitations and information needed for each identified measure to aid in a 
clinician’s decision-making about which tools will best suit their purpose. Whilst 
many measures assess the domains of HR-QOL of interest in stroke settings, there 
were no measures identified to cover all domains relevant to stroke patients 
(Golomb, Vickrey & Hays, 2001). Since then, more work has been done to address 
the gap in developing a HR-QOL scale that can address all the domains of interest 
in patients with stroke. Updated versions of existing measures have been introduced 
with improved sensitivity, such as the EuroQoL-5-Dimensions-3-Level (EQ-5D-5L) 
questionnaire (Herdman et al., 2011), as opposed to the EQ-5D version included in 
the Golomb, Vickrey and Hays (2001) review. Newer measures such as the Stroke 
Impact Scale (Duncan et al., 2003) and the SEIQoL-DW (LeVasseur, Green & 
Talman, 2005) have since been introduced. 
 
 
1.4 Rationale for empirical paper and systematic review 
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It is clearly established in the literature that stroke has profound and wide- 
ranging consequences on the physical, emotional, cognitive, and social domains of a 
person’s life, which in turn impacts their quality of life (Golomb, Vickrey & Hays, 
2001). Therefore, more work needs to be done in the research of post-stroke mood 
interventions to evaluate the impact of these interventions on a person’s quality of 
life. The current portfolio presents a review of research to explore both these 
themes, with the aim to provide recommendations for clinicians and to identify gaps 
for further research. 
Firstly, the systematic review summarizes a comparison of existing HR-QOL 
measures to identify the most suitable tool for stroke clinical practice. The review 
explores the characteristics and psychometric properties of the tools used to assess 
the impact of stroke and intervention on a person’s functioning and perceived well- 
being. A discussion of the clinical implications and recommendations for further 
research was also presented. 
Secondly, the empirical paper presents a network meta-analysis of current 
evidence for post-stroke depression (PSD), post-stroke anxiety (PSA) and post- 
stroke emotionalism (PSE) treatments. Despite the growing body of research on 
post-stroke mood interventions, there remains no clear consensus on the most 
efficacious treatment. As such, the empirical paper explores the evidence in head-to-
head comparisons using a network meta-analysis. Network meta-analysis is also 
known as multiple-treatments meta-analysis or mixed- treatment comparison (Salanti 
et al., 2008), and allows for a method of ranking different interventions against one 
another (Sun et al., 2017). This assimilates evidence for both pharmacological and 
non-pharmacological treatment interventions, therefore providing a comprehensive 
and overarching view of current evidence. 
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Abstract (243 words) 
 
Purpose: Most people who experience a stroke will survive the initial condition, 
but often with detriment to their emotional, cognitive and functional abilities. The 
long-term consequences for patients after a stroke can have a direct impact on their 
health-related quality of life (HR-QOL), which may in turn affect their rehabilitative 
outcomes. Although there is growing interest in assessing HR-QOL ass part of a 
person’s progress and clinical outcome, there is no consensus on which tools are best 
to measure this. This paper aims to systematically review the existing HR-QOL 
measures that are used with the stroke population and compare them to provide a 
conclusion with recommendations on the most suitable HR-QOL measures for 
stroke. Method: Electronic databases (MedLine, PsycINFO, and Embase) were 
searched to identify studies assessing HR-QOL measures for the stroke population. 
Identified measures were then assessed for clinical utility, psychometric properties 
and coverage of HR-QOL domains following methodology set out by previous 
reviews (Burton & Tyson, 205; Golomb, Vickrey & Hays, 2001). Findings: Twenty-
four papers examining 17 HR-QOL measures were identified. This included 11 
stroke-specific and 6 generic HR-QOL measures. Discussion and Conclusion: 
Through assessment of clinical utility and availability of psychometric data, a flow 
chart resulted in a recommendation of 1 generic measure (SF-12), which takes 
approximately ≤5 minutes to administer, and 4 stroke-specific measures (SIS 2.0; SIS 
3.0; SAQOL-39; SS-QOL), all of which take ≥11 minutes to administer. No HR-QOL 
measure comprehensively covered all HR-QOL domains. 
 
 
Keywords: Stroke, Health-Related Quality of Life, Assessment Tools 
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Assessment of Health-Related Quality of Life after Stroke: A Review of 
Psychometric Properties and Clinical Utility 
 
 
Introduction 
 
 
Stroke is one of the leading causes of death and disability impacting people 
worldwide (Harshfield et al., 2020; GBD, 2015 DALYs and HALE Collaborators, 
2015; GBD 2015, Mortality and Causes of Death Collaborators, 2015). Although 
mortality rates have declined in recent years (Feigin et al., 2014), stroke continues to 
significantly impact the lives of stroke survivors and their families (Feigin, et al., 
2014). It is well established that stroke affects an individual’s physical, mental and 
social domains of life such as their ability to practise self-care, their mobility, speech, 
language, memory, problem-solving abilities and socialisation skills (Golomb, 
Vickrey & Hays, 2001). Moreover, stroke may result in emotional disturbances, as 
reported by approximately 50% of stroke survivors (Hildebrand, 2015). Hence, 
clinicians should consider the multi-faceted impacts of stroke when assessing post- 
stroke outcomes among stroke survivors. 
Stroke rehabilitation measures have traditionally been based on objective 
indicators of physical function, such as the Barthel Index (BI) and modified Rankin 
scale (mRS; Lam, McMillan, Li & McGarth, 2014). Although commonly used, these 
scales are limited in assessing psychosocial outcomes such as pain, mood and 
cognitive qualities. This suggests that they may misrepresent, or may not consider the 
full impact of stroke on a person’s life (Carod-Artal & Edigo, 2009; Lam, McMillan, 
Li & McGarth, 2014). For example, disabilities such as cognitive impairment, mood 
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disturbance or communication impairments that result from a stroke may be 
overlooked when denoting outcomes, or when it interferes with the assessment process 
and impacts functional recovery (Golomb, Vickrey & Hays, 2001). Thus, it is vital for 
quality of life measures to be incorporated when assessing health outcomes, 
particularly in populations with chronic disease (Burckhardt & Anderson, 2003), 
including stroke (Russell, Dempster & Donnelley, 2011). 
Conceptualising and defining ‘quality of life’ (QOL) can be difficult as no 
universal definition for this term exists (Burckhardt & Anderson, 2003). QOL is often 
used interchangeably with concepts of health status and functional status, however it 
may also include ‘non-health-related’ aspects such as a person’s socioeconomic status 
and environmental factors (Guyatt, Feeny & Patrick, 1993). Although these aspects 
can influence a person’s health, focusing on health-related quality of life (HR-QOL) 
may be more appropriate in measuring the impact of stroke and the rehabilitative 
outcomes of its treatments (Carod-Artal & Egido, 2009). 
HR-QOL refers to the impact of health on an individual’s ability to function and 
their perceived well-being, encompassing critical physical, mental and social outcome 
domains (Coons et al., 2000). HR-QOL differs from general QOL, which  considers 
the perceptions of a person’s status, culture and value in relation to their goals, 
expectations, standards and concerns (Carod-Artal & Egido, 2009). Conversely, 
assessment of HR-QOL includes functional capacity (e.g. daily activities) and 
emotional well-being (e.g. feelings or perceptions about one’s life) (Golomb, 
Vickrey & Hays, 2001), both areas in which patients are most interested and familiar 
(Guyatt, Feeny & Patrick, 1993). Measuring HR-QOL also takes a person- centred 
approach whereby it is acknowledged that post-stroke functional and emotional 
impacts vary across patients with similar clinical criteria (Guyatt, Feeny & 
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Patrick, 1993). As HR-QOL measures significantly influence therapeutic decisions for 
people with chronic diseases (van Uem et al., 2016), and are often a primary 
outcome variable in clinical trials (van Uem et al., 2016; Martinez-Martin et al., 
2011; Gurcay, Bal & Cakci, 2009), there should be more caution in using the terms 
‘QOL’ and ‘HR- QOL’ interchangeably (Carod-Artal & Edigo, 2009). 
Existing HR-QOL measures vary in design and utility, and can be categorised 
as two approaches: 1) generic instruments – used within the normal population to 
provide a summary of HR-QOL, and 2) specific instruments – target problems 
associated with specific disease states, patient groups, or areas of function, such as 
stroke (Guyatt, Feeny & Patrick, 1993). The clinical utility of measures depends on 
its validity, reliability, appropriateness, interpretability and practicality (Chen, Li & 
Kochen, 2005). Specifically, among stroke survivors, HR-QOL measures may also 
need to take into account specific post-stroke limitations such as cognitive 
impairment and fatigue (Golomb, Vickrey & Hays, 2001). Thus, it is important for 
the clinical utility of HR-QOL measures to be demonstrated specifically for the 
stroke population, rather than only being extrapolated from other groups (Golomb, 
Vickrey & Hays, 2001). 
In considering HR-QOL measures for stroke patients, it is important for 
researchers and clinicians to make decisions on the most appropriate instrument and 
mode of administration that is suited to the individual’s abilities. Although self- 
reported assessments are ideal (Lam, 1997), this may be difficult for stroke survivors 
with cognitive and communication difficulties (Golomb, Vickrey & Hays, 2001). In 
such instances, a surrogate respondent (Guyatt, Feeny & Patrick, 1993) such as a 
caregiver or proxy can respond on behalf of the patient based on what they believe the 
patient would say had they been capable of answering. Hence, where available, the 
validity of proxy ratings for an instrument is vital in instrument selection. 
25  
 25 
 
HR-QOL is gaining increased attention from healthcare professionals (Chen, Li 
& Kochen, 2005) as an important health outcome indicator (Lam, 1997). To evaluate 
the impacts of stroke and stroke interventions, Golomb, Vickrey and Hays (2001) 
identified important criteria which HR-QOL measures should meet, namely; 1) 
domain coverage of HR-QOL post-stroke, 2) modes of administration suitable for 
stroke patients, and 3) instruments have undergone reliability and validity assessment 
completed specifically for stroke patients. Although Golomb, Vickrey and Hays 
(2001) conducted a comprehensive summary of HR-QOL measures in stroke, this 
was over nineteen years ago. The present review therefore aims to replicate and update 
this prior review, again using a systematic review methodology that will consider the 
present scope of HR-QOL instruments in stroke. Other stroke-specific reviews have 
either focused on the participation of stroke caregivers (Opara & Jaracz, 2010) or 
used specific frames of reference, such as the International Classification of 
Functioning, Disability and Health (ICF), which may come with its limitations (Geyh 
et al., 2007). Moreover, where Golomb, Vickrey and Hays (2001) and Geyh et al. 
(2007) examined the domain coverage of HR-QOL measures and reported on 
psychometric information, this review will additionally assess each measure for its 
clinical utility, which is its feasibility of use in clinical practice (Burton & Tyson, 
2015a; 2015b). 
In summary, this paper will systematically review and identify effective HR-
QOL measures from existing stroke literature. This paper aims to provide an updated 
review and recommendation of measures to inform both clinical practice and research 
(Duncan et al., 1999) in the measurement of HR-QOL in stroke rehabilitation and 
stroke trial settings. Comparisons will first be made on the clinical utility of the 
measures and the methods set out by research within the stroke literature (Burton & 
Tyson, 2015a; 2015b) to determine the most suitable HR-QOL tools for clinical 
practice. Psychometric properties (e.g. validity, reliability) will be identified and 
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synthesised for each measure. The HR-QOL domain coverage for measures will then 
identified as done by Golomb, Vickrey and Hays (2001). 
27  
 27 
 
 
 
Method 
 
Protocol and Registration 
 
The review was reported according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) Statement (Moher, Liberati, Tetzlaff & 
Altman, 2009) and is registered with PROSPERO: International prospective register of 
systematic reviews (ID: CRD42019158565). 
Search strategy 
 
Electronic databases MedLine, PsycINFO, and Embase were searched from their 
inception to 2nd February 2020, using the following keywords: stroke OR 
cerebrovascular accident OR CVA and screen* OR tool OR measure* OR 
questionnaire OR scale AND quality of life OR wellbeing OR well-being OR life 
satisfaction OR health OR health-related quality of life. All searches were limited to 
human studies that are published in the English language. 
The specific search terms used are adapted across different databases to match 
different search interfaces and options, whilst following as close as possible to the 
keywords identified (see Appendix A). Using a Boolean strategy, all searches 
included the clinical population of interest (‘stroke’) and instrument of interest 
(‘health-related quality of life’, ‘measurement’, ‘tool’). 
Eligibility Criteria 
 
Following the initial search, all titles and abstracts were screened by one author (JP) for 
its relevance to the research question. They were later further screened by two authors 
(JP & KH) against the eligibility criteria set for this systematic review. 
The inclusion criteria included: 
 
1) Studies published in the English language within a peer-reviewed journal; 
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2) Studies with adult stroke (ischemic and/or haemorrhagic) survivors over 18 years of 
age; 
3) Studies with original data on stroke patients using measurements that assessed some 
aspect of HR-QOL; 
4) Studies outlining the properties of the HR-QOL tool (e.g. HRQOL domains being 
measured, measure characteristics and psychometric properties such as validity and 
reliability) 
The exclusion criteria were as follows: 
 
1) Studies validating a language translation of a tool; 
 
2) Conference papers or abstracts where data could not be extracted; 
 
3) Studies with less than 50% stroke participants or data from stroke patients could not 
be extracted; 
4) Studies including participants with Transient Ischemic Attacks (TIA) and 
Subarachnoid Haemorrhage (SAH). This exclusion is because TIAs are 
defined by focal neurological symptoms that last for <24 hours (Easton et 
al., 2009). In contrast, stroke patients typically experience severe 
debilitating symptoms which require further rehabilitation treatment (Lam, 
Bloom & Kha, 2019). Although SAHs can be associated with stroke, it 
includes trauma resulting from head injuries, and may therefore be 
diagnosed and treated differently from a stroke (Chong, 2020). Exclusion of 
TIA and SAH participants from post-stroke studies and reviews have been 
noted within the literature (Hackett, Anderson, House & Xia, 2008; Sagen 
et al., 2009; Knapp et al., 2017). 
5) Studies with restrictive assessments, e.g. of neurological function, social function or 
mental status, which although may influence HR-QOL, were not HR-QOL measures 
and/or were not constructed for this purpose (Golomb, Vickrey & Hays, 2001). 
Data extraction & management 
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The primary author (JP) extracted data independently from the selected articles which 
met the eligibility criteria. Data were extracted based on the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidance, as set out by 
Von Elm et al. (2007). Following this guidance, demographic information (e.g. patient 
samples, settings), selection criteria, name of tools evaluated, domains assessed, and 
data for reliability and validity of the measures were extracted where available. 
Moreover, the following data were extracted from each HR-QOL measure: (i) clinical 
utility (following Burton & Tyson, 2015), (ii) psychometric properties, and (iii) HR-
QOL domain coverage (following Golomb, Vickrey & Hays, 2001). 
Clinical Utility 
 
To assess a measure’s clinical utility, the criteria and scores are as follows: 
 
1) Administration and scoring times: ≤5 min (score 2); 6–10 min (score 1); ≥11 min 
(score 0). 
2) Initial costs to purchase measures (e.g. starter kit including manual): 2=freely 
available; 1=cost<£100; 0=cost >£100 or unavailable. 
3) Additional cost per record form: 1=no additional costs; 0=additional cost or 
unavailable. 
4) Need for specialist training for administration and scoring: 1=no specialist training 
required; 0=specialist training required. 
The sum of these scores comes to a maximum of six points, with higher scores 
indicating greater clinical utility. 
Psychometric Properties 
 
Information on the psychometric properties, namely reliability and validity of each 
measure was extracted. 
Where available, this included inter-rater reliability (‘IR’), test-retest reliability (‘TR’), 
and internal consistency reliability (‘IC’). Where additional information was available 
on construct validity, criterion validity and content validity, this data was also recorded. 
This included information on proxy administration. 
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HR-QOL Domains 
 
In their review, Golomb, Vickrey and Hays (2001) identified a set of HR-QOL 
domains which may be affected by the onset of stroke. These domains cross the 
traditional boundaries of classifying clinical outcomes, which places emphasis on 
impairments and disabilities (Ford, 1984). The HR-QOL domains include physical 
functioning, role functioning, emotional well-being, cognitive functioning, 
communication, social functioning, recreation, energy, general health perceptions, 
overall QOL and symptoms. Selected measures were evaluated for their domain 
coverage, and given the following ratings: ‘no coverage’, which is represented by the 
symbol (‘-’) , ‘limited coverage’ (1 item), represented by the symbol (‘+’) and 
‘noteworthy coverage’ (≥2 items), represented by the symbol (‘++’). 
Assessment of Quality 
 
The methodological quality of all included articles was considered to screen for risk of 
bias in studies to ensure quality and trustworthiness of content (Mokkink et al.,2018; 
Prinsen et al., 2018; Terwee et al., 2018). The Consensus-based Standards for the 
selection of health Measurement Instruments (COSMIN)’s risk of bias checklist, which 
was developed to standardize systematic reviews of Patient Reported Outcome 
Measures and identify areas of refinement, was used (Mokkink et al., 2018). This 
checklist comprised of eight domains, all of which match the guidelines set out by the 
Medical Outcomes Trust (MOT; Terwee et al., 2007). The domains included content 
validity, internal consistency, criterion validity, construct validity, reproducibility, 
responsiveness, floor or ceiling effects and interpretability. All items were rated on a 
four-point rating system: ‘inadequate’. ‘doubtful’, ‘adequate’, or ‘very good’ (Mokkink 
et al., 2018). For each domain, the quality judgement was made by its lowest rated item 
(Terwee et al., 2012).  
The methodological qualities of each domain are then labelled ‘poor’, ‘fair’, ‘good’ or 
‘excellent’. The final overall quality rating for each study was arrived as a mean across 
all domains. The domain-level and overall quality ratings for each study can be found 
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as Appendix C.  
Quality of study was assessed by the primary author (JP). To ensure process rigour, a 
second-rater (KH) randomly selected and co-rated 30% of the articles. Any 
inconsistencies in assessments between the two independent reviewers were discussed 
until a shared conclusion was agreed. There were minimal differences in ratings 
between the reviewers, which did not change the overall quality rating of the study. 
Appendix C indicates the studies that were co-rated for quality.  
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Results 
 
 
The search strategy yielded 1056 papers, and 1 additional paper was identified 
through scanning reference lists from relevant articles. After removing 109 duplicates, 948 
abstracts were available for screening. These abstracts were screened for relevance to the 
research question, resulting in 894 papers to be excluded and 54 papers remaining to be 
examined for full text eligibility. Of the 54 relevant articles, 12 used a non-English 
translation of the HR-QOL tool and 1 involved non-adult stroke participants. Additionally, 
14 articles did not have sufficient information or data for the review and 1 article was not 
published in a peer reviewed journal. There were 2 studies were excluded as it was 
assessed to not fit with the aims of the review, such that it explored novel modifications of 
an existing HR-QOL scale for its use over the telephone, and tools specific for the brain-
injury population. This process resulted in 24 studies meeting the inclusion criteria for the 
review. Figure 1 shows a flow chart for the article identification and selection process. 
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Figure 1. Study selection flow diagram, N= Number of articles 
 
Figure 1 Diagram adapted from PRISMA; detailing flow of articles retrieved from 
searches through to inclusion. N= Number of studies 
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Included studies / articles 
 
Table 1 shows the 24 articles considered for this systematic review, as well as the key 
information about each study. The included studies comprise a total of 4469 stroke 
participants at different stages of recovery. Fifteen articles studied the measurement 
properties of an already existing HR-QOL measure, whereas nine described the development 
and validation of a new HR-QOL measure. 
From the 24 studies, seventeen HR-QOL measures applied in stroke participants were 
identified. Several papers identified the same HR-QOL scale, as detailed in Table 2. The 
measures identified included six ‘generic’ measures and eleven ‘stroke-specific’ measures, 
some of which are shortened or updated versions of each other (see Table 2). 
Ten of the 24 studies were conducted in North America; seven in the United States 
and three in Canada. There were also articles from the United Kingdom (n=3) and European 
countries (n=2). Non-western studies included those conducted in Asia (n=4), South America 
(n=1), Australia (n=1) and Africa (n=1). Two studies were conducted on a multi-national 
level, using cross-cultural data. 
Clinical utility 
 
Table 2 presents the clinical utility ratings of included measures. In terms of 
administration time, seven tools took approximately 5 minutes, whereas other took up to 20 
minutes. This criterion is important in selecting measures as it considers response burden in 
patients which is particularly salient for stroke survivors who may experience reduced 
attention and/or fatigue. Conversely, longer measures may assess a wider number of domains 
and provide more useful clinical information about a person’s HR-QOL. Most measures were 
freely available and easily accessible for non-commercial use, although the availability for 
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clinical use of some newer tools (beyond the published paper) was unclear (HSQuale, Stroke- 
PROM, NEWSQOL and HRQOLISP-40). All but one measure did not require a licensing fee 
(HUI) and specialised training to administer the tool. For some of the measures, the training 
required to administer the tool was described as  ‘minimal’ (n= 8), involving studying a 
manual or having basic skills and experience in test administration. 
Psychometric properties 
 
Psychometric properties for each measure are presented in Tables 3 and 4. The 
results in Tables 3 and 4 illustrate that information on reliability and validity of these 
measures in patients with stroke is limited and have not been thoroughly assessed.   
Table 3 synthesises information on reported reliability tests for each measure (IC, 
TR and IR). As seen in Table 3, only ten of the seventeen HR-QOL measures had 
information on reliability. Of the ten measures reporting reliability data, seven were stroke-
specific HR-QOL tools and three were generic HR-QOL tools. No reliability data was 
identified for seven measures (three of which are stroke-specific tools and four generic 
tools. 
Table 4 presents the available data for validity tests. Where information was 
available, various constructs of validity were recorded. Evaluations of validity were 
reported for thirteen of the seventeen HR-QOL measures. Information on validity was 
reported on a range of concepts (e.g. content-related and criterion-related validity).The 
thirteen measures included all eleven stroke-specific measures and three of the generic HR-
QOL tools. No validity data was identified for three generic HR-QOL measures.  
Recommended measures 
 
The information gathered from this review is summarised in Table 5. Table 5 presents 
the recommended HR-QOL measures for clinical and research practice. Starting from the top, 
this table differentiates between generic and stroke-specific HR-QOL measures. It then 
outlines the process for excluding recommended HR-QOL measures by stages. At each stage, 
information on deciding factors such as clinical utility, psychometric properties (reliability 
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and validity data) and availability of the measure were used to ‘eliminate’ tools that do not 
provide sufficient information, may incur additional costs or is not widely available for use. 
This results in five recommended HR-QOL measures. The recommended measures include 
one generic measure (SF-12; ≤5 minutes administration time) and four stroke-specific 
measures (SIS 2.0; SIS 3.0; SAQOL-39; SS-QOL; ≥11 minutes administration time). 
Clinicians and researchers following information from this table are then encouraged to make 
decisions on the best tool to use based on its domain coverage, and whether it fits the patient 
or participant’s presentation.  
To aid the use of this information, a print-friendly design of this table was created as a 
flow chart (Appendix K). This flow-chart identifies clearly the key questions for clinicians 
and researchers, such as ‘Is the person presenting with stroke-specific symptoms?’, ‘Does the 
person have aphasia?’, and lastly, ‘How much time do you have to administer the tool?’. It is 
also supplemented with information on HR-QOL domains covered by each of the 
recommended measures.  
Domain coverage 
 
Table 6 shows the domain coverage HR-QOL measures identified in previous 
research as pertinent to the stroke population (Golomb, Vickrey & Hays, 2001). As some 
measures also assessed additional unlisted domains, this was noted in the presenting table. 
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It is apparent from Table 6 that some generic measures had appropriate HR-QOL domains 
coverage and were comparable to stroke-specific measures. Some shorter measures (e.g. EQ-
5D-5L, SF-6D) were unable to evaluate a wider range of domains in comparison to longer 
measures. No measure was found to cover all domains. 
Quality of studies 
 
In accordance with the COSMIN rating, nineteen of the 24 studies were rated to be 
of ‘Fair’ quality, five of ‘Good’ quality and one of ‘Poor’ quality. 
Proxy administration 
 
Most measures identified were self-reported tools but with the option for interviewer- 
administration. For nine measures, the use of proxy administration was specified. Notably, 
either no or minimal instructions were available to guide this process. Only the EQ-5D-5L 
provided a specific proxy version, whereas the HUI had a separate measure for interview- 
administration. Overall, information on proxy administration of HR-QOL measures is scarce. 
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Table 1. Description of selected papers 
Study 
author 
and year 
Setting and 
country 
Stroke 
participants, N 
(Mean Age) 
Inclusion 
criteria 
Exclusion 
criteria 
Proxy 
respondent 
HR-QOL 
Measure 
used 
Time post- 
stroke 
assessment was 
made (SD) 
Quality 
Rating 
Bohannon, Neurology N= 90 (70.4) Ischemic NA NA SF-12 3 months & Fair* 
Maljanian, Service,  stroke    12 months  
Lee & Hospital,  patients      
Ahlquist United States        
(2004)         
Buck et al. 3 stroke Phase NA NA NA NEWSQOL NA Fair* 
(2003) services, 1 1:N=28;       
 rehabilitation N=30; N=       
 unit, United 100       
 Kingdom Phase 2: N=       
  106 (70)       
Chen et al. 7 study sites, N= 126 (i) first-ever (i) excessive NA SS-QoL-12 16.87 (16.1) Fair 
(2012) Taiwan (55.26) stroke, (ii) spasticity at     
   demonstratio any joint of     
   n of the arm     
   brunnstrom (Modified     
   stage II or Ashworth     
   higher for the Scale score <     
   proximal and 2), and (ii)     
   distal parts of severe     
   the affected physician-     
   upper limb determined     
   (13), (iii) no medical     
   severe problems     
   cognitive (e.g. severe     
   deficits aphasia, a     
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   (Mini-Mental 
State 
examination 
score > 21) 
(14), and (iv) 
ability to 
understand 
the study and 
respond to 
questions. 
vision 
problem, or 
poor physical 
condition) 
   
Chen et al. 
(2016) 
5 medical 
centres, 
Taiwan 
N= 70 (52.8) (i) No serious 
cognitive 
function 
deficits 
(based on 
Mini-Mental 
State 
Examination) 
; (ii) No 
excessive 
spasticity in 
the upper 
extremity 
(Modified 
Ashworth 
Scale <3); 
(iii) Able to 
follow 
instructions 
to complete 
questionnaire 
                                                                                and perform  
NA NA EQ-5D-5L; 
EQ-VAS; 
SIS 3.0 
17 months 
(median, 
range 0.4-94) 
Fair 
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   therapeutic 
activity; (iv) 
Aged 20-80 
     
Duncan et al. Subset Minor stroke, Diagnosis of NA NA SIS 2.0 1, 3 & 6 Fair 
(1999) participants N =33 (69.2); minor or    months  
 of a wider Moderate moderate      
 stroke study, stroke, N= 58 stroke      
 United States (71.9)       
Guo, Togher, Subset N=97 (63.7) First-time Participants Proxy SAQOL-39 3 months, Fair 
Power & Koh participants N= 36 stroke with a known respondent  repeated  
(2016) of a wider English survivors as history of for  again within  
 stroke study, subset (60.4) evidenced by dementia participants  1 week  
 Singapore  brain and/or major with severe    
   imaging psychiatric aphasia    
    illness or results not    
    other severe / reported    
    potentially     
    terminal co-     
    morbidities     
Hamedani et Subset Phase 1: Patients (i) Patients NA HSQuale 1 year Poor* 
al. (2001) participants N=71 (63.4) hospitalized who are     
 of a wider  for a primary, unable to     
 stroke study,  nontraumatic communicate     
 44 hospitals  intracranial within 30     
 across 6  haemorrhage days of their     
 states, United   stroke; (ii)     
 States   History of     
    prior stroke     
    or other brain     
    lesion     
    predisposing     
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    to 
haemorrhage. 
    
Hilari, Byng, 2 speech and N=83 (61.67) Participants (i) Known Frenchay SAQOL-39 3.5 years Good 
Lamping & language  with long- pre-stroke Aphasia  (3.09)  
Smith (2003) service  term aphasia history of Screening    
 providers, 1  resulting severe Test (FAST)    
 inner city, 1  from stroke cognitive receptive    
 semirural, 1  (of at least 1- decline or core of 7 (of    
 not-for-profit  year mental health 15) was used    
 organisation  duration) (ii) problems; (ii) as a cut-off,    
 for people  Participants Unable to below which    
 with aphasia,  living at self-report on significant    
 United  home before questionnaire others    
 Kingdom  the stroke s provided    
     proxy reports    
Hilari et al. Hospitals, 2-weeks: (i)Over 18 (i)Did not Frenchay SAQOL-39 2 weeks, 3 Fair 
(2009) United N=87;3- years; (ii) live at home Aphasia  months & 6  
 Kingdom months: N= admitted with prior to Screening  months  
  87; 6- first ever stroke; (ii) Test (FAST)    
  months: stroke; (iii) known receptive    
  N=76 hospital stay history of core of 7 (of    
   due to stroke mental health 15) was used    
   of at least 3 problems or as a cut-off,    
   days cognitive blow which    
    decline prior significant    
    to stroke; (iii) others    
    other severe provided    
    or potentially proxy reports    
    terminal     
    comorbidity;     
    (iv) unable or     
    too unwell to     
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    give 
informed 
consent; (v) 
does not 
speak 
English pre- 
morbidly 
    
Hobart et al. 3 hospital N=177 (62) (i) Patients History of NA SF-36 1-11 months Fair* 
(2009) sites, United  with dementia     
 States  ischemic      
   stroke; (ii)      
   National      
   Institutes of      
   Health Stroke      
   Scale      
   Language      
   Score <2;      
   (iii)      
   Completed      
   the SF-36      
Hunger et al. Participants N=212 (12.8) (i)Diagnosis (i)Impairmen No proxies EQ-5D; SIS NA Fair 
(2012) part of a  of stroke ts that will used 2.0   
 wider stroke  based on hinder     
 study,  ICD-10; (ii) participation     
 Germany  Age 18-80; in a group     
   (iii) intervention;     
   Cognitively (ii) Memory     
   able to deficits; (iii)     
   participate in History of     
   group psychiatric     
   intervention; disorders     
   (iv) Good      
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   command of 
the German 
Language; 
(v) Barthel 
index score 
>35; (vi) 
Signed 
consent 
prior to 
stroke 
    
Kerber et al. Participants N=45 (66.0) (i)Patients (i)Assessmen No proxies SSQOL 90 days Fair 
2013) part of a  with ts performed used    
 wider stroke  validated in Spanish;     
 study, United  ischemic (ii)     
 States  stroke and Incomplete     
   self-reported assessment     
   assessments measures (>5     
    missing     
    items); (iii)     
    Proxy     
    interviews     
Kwon et al. 13 hospital Telephone (i)Diagnosis NA NA SIS 12 weeks; 16 Fair* 
(2006) sites, United responders: of stroke,    weeks  
 States N=136 confirmed by      
  (68.04); Non- medical      
  telephone reports      
  responders:       
  N=62 (68.05)       
Luo et al. 9 hospital Phase 1: (i)Diagnosis Individuals Investigators Stroke- NA Good 
(2015) sites, China N=133; of stroke, with helped PROM   
  Phase 2: based on tetraplegia, patients with    
  N=475 ICD-9 psychosis or severe visual    
    serious impairments    
     fill in the    
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    comorbidities 
(e.g. cancer) 
questionnaire 
s according 
to patient’s 
verbal 
responses 
   
MasIsaac et 
al. (2016) 
Data from the 
Virtual 
International 
Stroke Trial 
Archive 
N=5549 
(68.5) 
NA NA NA SF-SIS NA Fair 
OjoOwolabi 
et al. (2010) 
Hospital sites; 
Nigeria, 
Germany 
N=100 
(59.4); 
N=103 (66.9) 
(i)Clinical or 
radiological 
diagnosis of 
stroke; 
(ii)Stroke 
occurrence 1 
or more 
months prior 
to the 
interview 
(i)Ambiguou 
s diagnosis of 
stroke; (ii) 
Has other 
medical 
conditions 
that were 
neither risk 
factors for 
nor 
complication 
s of stroke 
but could 
interfere with 
HRQOL 
Proxies were 
judged to be 
reliable if 
they lived 
with the 
participant, 
had close 
relations to 
them and 
were sure of 
the answers 
to 
questionnaire 
items 
HRQOLISP- 
40 
NA Fair 
Pickard et al. 
(2005) 
2 hospital 
sites; Canada 
N= 98 (67.0) (i)Ischemic 
stroke, 
confirmed via 
computerized 
tomography 
or imaging 
(i)Diagnosis 
of 
haemorrhagic 
stroke, lower 
brain stem 
stroke, coma, 
global 
No proxies EQ-5D; SF- 
6D; HUI2; 
HUI3 
NA Fair 
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   scans; (ii) aphasia,     
Aged 18 Wernicke’s 
years or aphasia, 
older; (iii) dementia, 
Able to cognitive 
comprehend impairment; 
an English (ii)Life 
questionnaire expectancy 
; (iv) Lives <6 months 
within for any 
150km of medical 
Edmonton, reason 
Alberta (judgement 
 of clinical 
 assessor) 
Possiant et al. Community; Phase 1: NA NA NA PBSI NA Good 
(2003) Canada N=493       
  (70.0); Phase       
  2:       
  N=91(69.0);       
  Phase 3:       
  N=68 (72.0);       
  Phase 4:       
  N=32 (68.0);       
  Phase 5:       
  N=91 (69.0)       
Post et al. Data from 3 N=105(60.8) (i)Aged <85 (i)Pre- NA SS-QoL-12 6 – 11 Fair 
(2011) previous  years; (ii)No existing drug   months  
 studies of  comorbidity abuse/depress     
 inpatient and  that might ion/activities     
 outpatient  affect of daily life     
   outcome and dependence/c     
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 sites;  testable ognitive     
Netherlands within 21 impairment; 
 days after (ii) disturbed 
 stroke; consciousnes 
 (iii)Stroke s or inability 
 diagnosis to 
 based on comprehend 
 imaging task 
 scans instructions; 
  (iii) recurrent 
  stroke; (iv) 
  comorbidity 
  that might 
  affect 
  outcome 
Richardson et Community Baseline=164 NA NA NA SIS 3.0 NA Fair* 
al. (2016) stroke (66.7); 6-       
 service; months:       
 Canada N=108       
  (66.2); 12-       
  months:       
  N=37 (69.35)       
Silva et al. Outpatient N=81 (i)Diagnosis (i)Clinical NA SS-QoL NA Good* 
(2016) clinic; Brazil  of primary or conditions     
   recurring other than     
   stroke more hemiparesis     
   than 6 stemming     
   months from a     
   earlier; stroke, those     
   (ii)Weakness with motor     
   and/or aphasia and     
   spasticity in      
47 
 
 47 
 
   the affected 
half of body 
impaired 
cognition 
    
Strum et al. 
(2002) 
Participants 
part of a 
wider stroke 
study, 
Australia 
 (i)First ever 
or recurrent 
stroke, with 
neuroimaging 
scans 
NA 16% were 
assessed by 
means of a 
proxy 
response 
from the best 
available 
informant 
AQoL NA Fair 
 N=93 (72.0)     
VincentOnab Hospital, N=55 (58.0) (i)First- (i)Patients Proxy HRQOLISP- NA Fair* 
ajo et al. Nigeria  incidence with administratio 40   
(2013)   stroke; (ii) impaired n was carried    
   Able to cognition and out by family    
   communicate severe members    
    comorbidities who are    
     primary    
     caregivers for    
     participants    
     who had    
     difficulty    
     communicati    
     ng or    
     exhibited    
     frailties that    
     impeded self-    
     report    
Williams et 3 hospital N=32(61.0) (i)Diagnosis (i)Prior No proxy SS-QOL NA Fair* 
al. (1999) sites; United  of acute stroke with respondents    
 States  ischemic persistent     
   stroke; (ii) deficit; (ii)     
   Aged >18 intracerebral     
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years; 
(iii)Able to 
return for 
follow-up 1 
month after 
stroke 
or 
subarachnoid 
haemorrhage; 
(iii)dysphasia 
at 1 month 
after stroke 
affecting 
communicati 
on; (iv) 
significant 
comorbidities 
likely to 
concurrently 
affect HR- 
                                                                                                          QOL  
 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue 
scale; (HUI2, Health Utility Index Mark 2; HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP- 
40, Health-Related Quality of Life in Stroke Patients 40-items; NEWSQOL, Newcastle Stroke-Specific Quality of Life Measure; PBSI, 
Preference-Based Stroke Index; SF-12, SF-6D, SF-36, Medical Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); 
Quality ratings marked * indicate papers that were co-rated.
49 
 
 49 
 
 
 
Table 2. Brief description of each identified measure and the derivation of its clinical utility score for each criteria. 
 
 
Measure Brief Description Type of 
tool 
Administration Time to 
administer 
Training 
required 
Initial costs Recurring 
costs 
Clinical 
utility 
score /6 
AQoL-4D Patients choose one of 
four statements (graded 
according to severity) 
for 12 items, spanning 4 
dimensions. Items are 
scored between 1 to 4 
points. This has a total 
minimum score of 12 
and maximum score of 
48. 
Generic Self-report; 
interview; proxy 
5 minutes No Freely 
available 
NA 6 
EQ-5D-5L Patients choose one of 5 
responses (graded 
according to severity) 
for 5 items. Each item 
refers to different 
dimensions to reflect a 
person’s current health 
state. 
Generic Self-report; 
interview; (proxy 
version 
available); 
Includes visual 
analogue scale 
(VAS) 
< 5 minutes No Freely 
available for 
non- 
commercial 
use 
NA 6 
HUI (2 & 3) HUI encompasses 8 
standard questionnaires 
specific to mode of 
administration 
(self/interview) and 
recall periods (‘usual 
Generic Self-report (15- 
item); Interview 
(40-item) 
5 – 10 
minutes 
(15Q); 3 
minutes 
(40Q) 
Yes Minimum 
licensing fee 
of $USA 
3,000 
Depending 
on license 
type 
1 
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 health’; ‘during past 4- 
weeks’; ‘…-2- 
weeks’;’…-1 week’). 
Responses to the 
questions are then 
mapped to two 
classification systems, 
HUI2 and HUI3. 
       
HSQuale Patient is interviewed 
on this 54-item scale, 
where 38 items are 
scored and 16 unscored. 
The items cover 7 
domains. For each item, 
patients choose one of 
four statements (graded 
according to severity). 
Domain scores are 
determined by 
averaging item scores 
included in a domain. 
Specific; 
Stroke 
Interview 15 minutes No Unavailable Unavailable 1 
HRQOLISP- 
40 
Patient responds to 40 
statement on a 5-point 
Likert scale. Items 
correspond to 7 
domains. Domain scores 
are the sum of all item 
scores, with a maximum 
transformed score of 
100. 
Specific; 
Stroke 
Self-report; proxy 19 minutes No Unavailable Unavailable 1 
NEWSQOL Patient responds to 56 
statement items on a 4- 
Specific; 
Stroke 
Interview 20 minutes Minimal Unavailable Unavailable 1 
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 point Likert scale. These 
items correspond to 11 
domains, 
       
PBSI Stroke-specific health 
index consisting of 10 
items, developed 
primarily for use as an 
outcome in cost- 
effectiveness studies. 
For each item, patient 
chooses one of 3 
statements (graded 
according to severity) 
based on their ability to 
perform different 
activities. 
Specific; 
Stroke 
Self-report; Proxy 10 - 15 
minutes 
No Unavailable NA 5 
SF-6D The SF-6D is a variation 
of the SF-36 scale, 
which derivates a single 
quality-of-life index. It 
focuses on 6 domains of 
the SF-36 
Generic Self-report; 
interview 
<5 minutes No / 
Minimal 
Freely 
available 
NA 6 
SF-12 The SF-12 is a 
shortened version of the 
SF-36, created to reduce 
response burden. It uses 
the same 8 domains of 
the SF-36. On the SF- 
Generic Self-report; 
interview 
<5 minutes No / 
minimal 
Freely 
available 
NA 6 
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 12, the patient responds 
to statements and 
questions on a 2 
(YES/NO), 3 and 5- 
point Likert scale. 
       
SF-36 Patient scores 36 items, Generic Self-report; 10 minutes No / Freely NA 5 
 which is categorised  interview  Minimal available   
 into 8 subscales. Each        
 of the subscales is        
 scored separately using        
 item weighting and        
 additive scaling.        
 Summed data are        
 transformed onto a 0-to-        
 100-point scale. The 8        
 subscales can be        
 combined into 2        
 summary health status        
 measures, physical        
 function and mental        
 health.        
SIS 2.0 This scale consists of 64 Specific; Self-report; 15 – 20 Minimal Freely NA 4 
 items, grouped into 8 Stroke Proxy; Includes minutes  available   
 domains. Each item is  VAS.      
 rated on a 5-point Likert        
 scale about the patient’s        
 difficulties in the past        
 week. Scores for each        
 domain range from 0 to        
 100, where a higher        
 score indicates better        
 HRQOL. There is no        
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 overall score, but a 
combination of 4 
subscales can provide a 
physical domain score. 
There is also a VAS of 0 
to 100, for patients to 
rate their percentage of 
recovery. 
       
SIS 3.0 Patient responds to 59- 
items on the scale, 
which is grouped into 8 
domains. Scores for 
each domain range from 
0 to 100, where a higher 
score indicates better 
HRQOL. There is no 
overall score, but a 
combination of 4 
subscales can provide a 
physical domain score. 
There is also a VAS of 0 
to 100, for patients to 
rate their percentage of 
recovery. 
Specific; 
Stroke 
Self-report; 
Proxy; Includes 
VAS. 
15 – 20 
minutes 
Minimal Freely 
available 
NA 4 
SF-SIS The SF-SIS is a shorter 
version of the SIS 2.0 
and 3.0. The patient 
responds to 8 statement 
items on a 5-point 
Likert scale, graded 
according to severity of 
difficulties experienced. 
Specific; 
Stroke 
Self-report; Proxy < 1 minute Minimal Freely 
available  
NA 6 
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Stroke- 
PROM 
This scale consists of 46 
items describing 4 
domains, further 
categorised into 10 
subdomains. Patient 
responds to each item 
on a 5-point Likert scale 
ranging from 0 - 4 
(graded by severity), on 
how often they 
experience a difficulty. 
Each item produces a 
score of 1 – 5 for each 
item. Higher scores 
reflect a more positive 
outcome. 
Specific; 
Stroke 
Self-report 9 minutes No Unavailable Unavailable 2 
SAQOL-39 The SAQOL-39 is an 
adapted version of the 
SS-QOL, for use with 
stroke patients with 
aphasia. For those with 
receptive aphasia, 
people who score ≥ 7/15 
on the receptive 
domains of the FAST 
(Enderby et al., 1987) 
able to self-report 
reliably on the SAQOL- 
39 (Hilari et al., 2001; 
2003). The patient 
responds to 39 items on 
                            a 5-point Likert scale,  
Specific; 
Stroke 
Interview 10 – 15 
minutes 
Minimal Freely 
available 
NA 4 
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 which corresponds to 3 
domains. 
       
SS-QOL Patient responds to 49 
items that are assessed 
on 5-point Guttman- 
type scales. Each item is 
answered using 1 of 3 
different response sets. 
This covers 12 domains, 
providing domain and 
summary scores 
(unweighted averages) 
that range from 49-245. 
Higher scores indicate 
better functioning. 
Specific; 
Stroke 
Self-report; Proxy 15 – 20 
minutes 
No Freely 
available 
NA 4 
SS-QOL-12 One item was selected 
from each of the 12 
domains of the SS-QoL. 
These are then grouped 
into two dimensions, 
physical and 
psychosocial. 
Specific; 
Stroke 
Self-report; Proxy 10 min No Unavailable NA 4 
 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue 
 
scale; (HUI2, Health Utility Index Mark 2; HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP-40, 
Health-Related Quality of Life in Stroke Patients 40-items; NEWSQOL, Newcastle Stroke-Specific Quality of Life Measure; PBSI, Preference- 
Based Stroke Index; SF-12, SF-6D, SF-36, Medical Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); SIS 2.0, 3.0, 
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Stroke Impact Scale (Version 2.0, 3.0); SF-SIS, Short-Form Stroke Impact Scale; Stroke-PROM; Stroke-Patient Reported Outcome Measure, 
SAQOL-39, Stroke and Aphasia Quality of Life Scale-39; SS-QOL, 12-item Stroke-Specific Quality of Life Scale, NA; Not Available 
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Table 3. Reliability of measures for health-related quality of life in stroke 
 
Measure Study Sample and 
settings 
Reliability   
  Internal consistency reliability (IC) Test-retest 
reliability 
(TR) 
Inter-rater 
reliability (IR) 
Proxy 
agreemen 
t 
AQoL-4D Strum et al. 
2002 
N/A NDI NDI NDI NDI 
EQ-5D-5L Chen et al. 
2016 
N/A NDI NDI NDI NDI 
 Hunger et 
al. 2012 
N/A NDI NDI NDI NDI 
 Pickard et 
al. 2005 
N/A NDI NDI NDI NDI 
HUI Pickard et 
al. 2005 
N/A NDI NDI NDI NDI 
HSQuale Hamedani et 98 stroke Cronbach’s α The OSQ had NDI NDI 
 al. 2001 participants For HSQuale domains: excellent test-   
   General outlook (0.78), physical functioning retest   
   (0.89), cognitive functioning (0.88), social & reliability (=   
   leisure activities (0.85), emotional well-being 0.833) on   
   (0.83), work & financial status (0.89) and Cicchetti   
   relationship (0.56). weighted    
    ratings.   
HRQOLISP- 
40 
OjoOwolabi 
et al. 2010 
100 stroke 
participants in 
Cronbach’s α was ≥.7 in every domain in both 
cities 
In both cities, 
the single- 
NDI NDI 
  Ibadan, 103 stroke  rater test-   
  participants in  retest   
  Berlin  weighted κ   
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    statistics were 
excellent 
(>0.75) for 
most items 
(37 in Ibadan 
and 39 in 
Berlin) and 
good for the 
remainder 
items 
  
 Vincent- 
Onabajo et 
al. 2013 
N/A NDI NDI NDI NDI 
NEWSQOL Buck et al. 
2003 
106 stroke 
patients at Phase 2 
of measure 
development. 
High for all domains (Cronbach’s α 
0.71 – 0.90) 
Intraclass 
correlation 
coefficients 
(ICC) based 
on 50 
informants, 2 
weeks apart 
was high 
(0.78 – 0.92) 
NDI NDI 
PBSI Poissant et 
al. 2003 
N/A NDI NDI NDI NDI 
SF-6D Pickard et 
al. 2005 
N/A NDI NDI NDI NDI 
SF-12 Bohannon et 
al. 2004 
90 ischemic stroke 
patients admitted 
to a neurology 
service 
Cronbach’s α 
 
Before stroke (0.833) 
3 months after stroke (0.878) 
12 months after stroke (0.894) 
NDI NDI NDI 
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SF-36 Hobart et al. 
2002 
177 stroke 
participants 
Cronbach α coefficients ranged from 0.68 – 
0.90 
Intraclass 
correlation 
coefficients 
for test-retest 
reliability of 
SIS domains 
ranged from 
0.16 – 0.55 
NDI NDI 
SIS 2.0 Duncan et 
al. 1999 
91 participants 
with minor and 
moderate stroke 
Cronbach α coefficients ranged from 0.83 to 
0.90 and meet criteria for measuring change 
over time 
Intraclass 
correlation 
coefficients 
for test-retest 
reliability of 
SIS domains 
ranged from 
0.70 to 0.92, 
except for the 
emotion 
domain (0.57) 
NDI NDI 
SIS 3.0 Richardson 
et al. 2016 
 Cronbach α coefficients ranged from 0.81 to 
0.97 
NDI NDI NDI 
SF-SIS MasIsaac et 
al. 2016 
N/A NDI NDI NDI NDI 
Stroke- 
PROM 
Luo et al. 
2015 
475 stroke 
participants, 104 
Cronbach α coefficients for overall = 0.905, 
Domains = 0.861-0.908 
NDI NDI NDI 
60 
 
 60 
 
  control 
participants 
    
SAQOL-39 Guo et al. 
2016 
24 stroke 
participants 
Cronbach α coefficients for overall = 0.96, for 
domain scores = 0.94-0.98. 
Item-total correlations range from 0.37 – 0.79 
(overall) and 0.42 to 0.98 (domains). 
Intraclass 
correlation 
coefficients 
Overall = 
0.99 
Physical 
domain = 
0.99 
Psychosocial 
= 0.98 
Communicati 
on = 0.99 
NDI NDI 
 Hilari et al. 
2003 
83 stroke 
participants 
Cronbach α coefficients for overall = 0.93, 
Subdomains = 0.74-0.94 
Intraclass 
correlation 
coefficients 
Overall = 
0.98 
Subdomains = 
0.89-0.98 
NDI NDI 
 Hilari et al. 
2009 
87 stroke 
participants 
Cronbach α coefficients for overall = 0.95, 
Subdomains = 0.92-0.95 
Intraclass 
correlation 
coefficients 
Overall = 
0.96 
Subdomains = 
0.92-0.98 
NDI NDI 
SS-QOL Chen et al. 
2012 
N/A NDI NDI NDI NDI 
 Kerber et al. 
2013 
N/A NDI NDI NDI NDI 
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 Silva et al. 
2016 
75 stroke 
participants 
NDI Intraclass 
correlation 
coefficients= 
0.95 (inter- 
rater), 0.96 
(intra-rater) 
NDI NDI 
 Williams et 
al. 1999 
 Cronbach’s α values for each domain>0.73, 
ranging from 0.73-0.89 
  
SS-QOL-12 Post et al. 
2011 
N/A NDI NDI NDI NDI 
 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue scale; (HUI2, Health Utility Index Mark 2; 
 
HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP-40, Health-Related Quality of Life in Stroke Patients 40-items; NEWSQOL, Newcastle Stroke- 
Specific Quality of Life Measure; PBSI, Preference-Based Stroke Index; SF-12, SF-6D, SF-36, Medical Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); SIS 2.0, 
3.0, Stroke Impact Scale (Version 2.0, 3.0); SF-SIS, Short-Form Stroke Impact Scale; Stroke-PROM; Stroke-Patient Reported Outcome Measure, SAQOL-39, Stroke and Aphasia Quality of 
Life Scale-39; SS-QOL, Stroke-Specific Quality of Life Scale ; SS-QOL-12, 12-item Stroke-Specific Quality of Life Scale, N/A; Not Applicable, NDI; No data identified 
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Table 4. Validity of measures for health-related quality of life in stroke 
 
Measure Study Validity Findings Sample 
AQoL-4D Strum et al. 2002 Spearman’s rank correlation 
with Barthel Index 
Independent living dimension; 
Rho 
= 0.85 
Physical senses dimension; 
Rho= 0.45 
AQoL total score; Rho = 0.77 
92 patients with a first-ever or 
recurrent stroke 
  Spearman’s rank correlation 
with SF-36 
Independent living dimension 
with SF-36 physical functioning 
subscale; R = 0.77 
Social relationships dimension 
with SF-36 social functioning; R 
= 0.48 and SF-36 mental health 
subscale; R = 0.50. 
Psychological well-being 
dimension with SF-36 bodily 
pain; R = 0.61 and mental health 
subscale (R = 0.41). 
 
  Other findings When adjusted for age, sex and 
3-month impairment score, 
AQOL score at 3 months is a 
significant predictor of death or 
institutionalization (p = 
0.006). 
 
EQ-5D-5L Chen et al. 2016 Concurrent validity, 
predictive validity and 
acceptable responsiveness 
for detecting HR-QOL in 
stroke patients.  
EQ-Index has reasonable concurrent 
validity and performed better than its 
visual analogue scale component (EQ-
VAS). 
EQ-Index has better power for 
predicting the rehabilitation outcome 
in activities of daily living than other 
motor-related outcome measures.  
 
65 stroke patients 
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   EQ-Index is moderately 
responsive to change 
(SRM=0.63), whereas 
EQ_VAS is only mildy 
responsive to change.  
 Hunger et al. 
2012 
NDI NDI N/A 
 Pickard et al. 
2005 
NDI NDI N/A 
HUI Pickard et al. 
2005 
NDI NDI N/A 
HSQuale Hamedani et al. 
2001 
Construct validity. 
 
Discriminant validity. 
Construct validity was 
strong when comparing 
HSQuale and SF-36 
domains. Of 5 possible 
correlations, 4 were 
found to be strong 
(Pearson correlation 
coefficients > 0.50). 
 
Strong evidence for 
discriminant validity 
(mean Overall 
Summary Question 
scores significantly 
different for patients 
dichotomized into 
clinically distinct 
groups (pP<0.05). 
98 stroke participants 
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HRQOLISP-40 OjoOwolabi et 
al. 2010 
Discriminant validity. 
 
Construct validity. 
 
 
Good content and face validity.  
 
There is good discriminant validity 
between stroke and control participants, 
particularly for domains in the physical 
sphere (physical, psychological, 
cognitive and eco-social domains). 
 
Interdomain correlations among 
National Institutes of Health Stroke 
Scale (NIHSS), Stroke Levity Scale 
(SLS), modified Rankin Scale (mRS) 
and the domains pf HRQOLISP-40 
demonstrate convergent validity among 
domains within the same sphere and 
discriminant validity between domains 
in different spheres. This demonstrates 
construct validity.   
100 stroke participants in Ibadan, 103 
stroke participants in Berlin 
 Vincent-Onabajo 
et al. 2013 
NDI NDI N/A 
NEWSQOL Buck et al. 2003 Construct validity.   
 
 
 
 
Discriminant validity. 
 
Construct validity was supported 
by all but 1 of the predicted 
correlations (cognition) with the 
NIHSS.  
 
Evidence of discriminant validity 
is provided by significant 
differences between participants 
of different age, NIHSS score and 
comorbidity in relevant 
NEWSQOL scores. 
106 patients at Phase 2 of 
development. 
PBSI Poissant et al. 
2003 
Convergent validity Pearson correlations between the 
PBSI and most of the SF-36 
subscales were moderately high 
and significant (p<0.005), ranging 
from r = 0.33 (role emotional) to 
r=0.48 (bodily pain). 
67 stroke participants 
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   Pearson correlations between the 
PBSI and EQ-5D was moderately 
high (r=0.76). 
 
SF-6D Pickard et al. 
2005 
NDI NDI N/A 
SF-12 Bohannon et al. 
2004 
Content  
validity. 
A principal components analysis 
without varimax rotation calculated 
component scores of the SF-12. Pre-
stroke, 3- and 12-month post-stroke 
HRQOL scores were compared to one 
another and to age-grouped reference 
values. These scores were consistent 
over time.  
 
SF-36 Hobart et al. 
2002 
NDI NDI N/A 
SIS 2.0 Duncan et al. 
1999 
Discriminant validity, 
assessed by 
comparison with 
Rankin scale levels. 
Discriminant validity was 
addressed by comparing mean 
scores for each domain to the 
groups defined by the Rankin 
scale. 6 of 8 domains were 
significantly different (p>0.02 to 
p<0.0001) 
across the Rankin levels. The 
91 participants with minor and 
moderate stroke 
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memory and thinking domain and 
emotion scores are not 
significantly different across the 
Rankin levels. 
 
  Criterion validity, assessed 
by Spearman Rank 
correlation coefficients with 
the following measures; 
Barthel Index, Functional 
Independence Measure, 
Fugl-Meyer, the Mini-
Mental State Examination, 
the NIH Stroke Scale, the 
SF-36, the Duke Mobility 
Scale and the Geriatric 
Depression Scale.  
Measures of disability were 
highly correlated with the 
established measures (correlation 
coefficients ranging 0.82 to 0.84). 
Correlations for domains that 
measure memory and 
communication were modest 
(0.44 to 0.58). 
Participation domain showed 
moderate correlation with SF-36 
social function domain (0.70), but 
low correlations with SF-36 
emotional (0.28) and physical role 
functions (0.45). 
Correlations between SIS 2.0 
domains and patient’s global 
rating of recovery was good (0.53 
to 0.63), but weaker for 
correlations with memory, 
communication and emotion 
(0.21 to 0.39). 
 
SIS 3.0 Richardson et al. 
2016 
Concurrent validity 
assessed by correlating 
with EQ-5D-5L domains 
and EQ-VAS scores. 
Pearson’s correlation between 
SIS and EQ-5D-5L domains was 
moderate at baseline (r=0.50) and 
increased to r=0.74 at 6 and 12 
months. 
164 stroke participants at baseline, 108 
stroke participants at 6 months, 37 
stroke participants at 12 months 
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   The independent domain 
correlations between SIS and 
EQ-5D-5L Index score vary 
from weak – high across time. 
Correlation was moderate ate 
baseline (r= 0.50) but 
increased to high correlation 
at six and twelve months (r = 
0.74). 
Weak to moderate correlation 
(r=0.23-0.593) was found for SIS 
cognition, memory and thinking, 
and communication domain. High 
correlation (r=0.71-0.76) was 
found for SIS 
physical domain at baseline. 
 
SF-SIS MasIsaac et al. 
2016 
Content, convergent and 
discriminant validity. 
Correlation assessed using 
Spearman’s ρ for each 
domain item relative to the 
domain total score.  . 
Acute: Agreement of SF-SIS with 
SIS-16 was excellent, Cornbach’s 
α=0.92. SF- SIS showed strong 
correlations with all our chosen 
outcome measures: mRS (-0.83), BI 
(0.82), NIHSS (- 
0.77), EQ-5D (0.82), and EQ-VAS 
(0.72); correlations were equivalent 
to those seen for full SIS (-0.87, 
0.89, -0.77, 0.88, and 0.73, 
respectively) 
Rehabilitation: Agreement of SF- 
SIS with SIS was excellent, 
Cornbach’s α=0.96. SF-SIS showed 
significant (P<0.0001) correlation 
with BI (ρ=0.65), EQ-5D (ρ0.69), 
EQ-VAS 
(ρ=0.45), and SIS-VAS (ρ=0.57). 
Correlations were roughly equivalent 
to those seen for full SIS (0.72, 0.69, 
0.46, and 0.58, respectively) 
5549 acute study patients, 332 
rehabilitation patients’ part of a wider 
stroke trial 
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Stroke-PROM Luo et al. 2015 Content, construct and 
discriminantvalidity 
Content validity was achieved and 
confirmed using the content validity 
index (CVI). Authors referred to 
relevant literature and consulted experts 
as well as patients to ensure that all 
items were appropriate and relevant.  
 
Construct validity was met by using 
confirmatory factor analysis with the 
index of model fit. 
 
Discriminant validity was assessed by 
comparing the mean scores for every 
subdomain of the Stroke-PROM among 
healthy participants with those among 
groups of stroke patients as defined by 
the Rankin Scale, except for the 
subdomain of treatment. Overall, the 
Stroke-PROM was able to differentiate 
varying degrees of disability and 
dependence as defined by the modified 
Rankin scale. 
 
SAQOL-39 Guo et al. 2016 Convergent validity, 
assessed by correlating with 
Barthel Index (BI), 
modified Rankin Scale 
(mRS), EQ-5D-Index, EQ-
5D-Visual Analogue Scale, 
center for epidemiologic 
studies depression scale 
(CES-D) 
Correlation, r 
BI, r =0.64 
MRS = -0.71 
EQ5D Index, r = 0.74 
EQ5D VAS, r =0.27 
CES-D, r = -0.81 
36 stroke participants 
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  Discriminant validity, 
assessed by correlating with 
the Mini Mental State 
Examination (MMSE), 
Frontal Assessment Battery 
(FAB), National University 
Health System Aphasia 
Screening Test (NUHS-
AST), and Boston 
Diagnostic Aphasia 
Examination Severity 
Rating Scale  (BDAE 
Severity).  
 Correlation, r 
MMSE, r= 0.35 
FAB, r = 0.53 
NUHS-AST, r = 0.51 
BDAE Severity, r =0.37 
 Hilari et al. 2003  Within-scale analyses  
Construct validity, assessed 
by correlating with the 
Frenchay Aphasia 
Screening Test (FAST), 
American Speech and 
Hearing Associaion 
Functional Assessment of 
Communication Skills for 
Adults (ASHA-FACS), 
Raven’s Colored 
Progressive Matrices 
(RCPM), General Health 
Questionnaire (GHQ-12),  
Frenchay Activities Index 
(FAI), Social Support 
Survey (SSS). 
Intercorrelations between subscale 
scores ( r=0.10 to 0.47) and 
domain-total correlations (r = 0.38 
to 0.58) 
 
Convergent validity (r = 0.55 to 
0.67) 
 
Discriminant validity (r=0.02 to 
0.27) 
83 stroke participants 
 Hilari et al. 2009 Convergent validity, 
assessed by correlating with 
BI, FAI, GHQ-12,  
Overall (r= 0.36-0.70) 
Domains (r= 0.47-0.78)) 
87 stroke participants. 
  Discriminant validity, 
assessed by correlating on 
the FAST 
Overall (r= 0.26) 
Domains (r=0.03-0.40) 
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SS-QOL Chen. 2012 NDI NDI N/A 
 Williams et al. 
1999 
Construct validity of 
Domains 
SS-QOL scores were 
significantly linearly associated 
with corresponding scores of 
energies, family roles, mobility, 
mood, personality and self-care 
on other measures. 
32 stroke patients 
SS-QOL-12 Post et al. 2011 Criterion validity, assessed 
in comparison with SS-QOL 
(49 item). 
The mean difference between scores on 
the SS-QOL 12- and 49-item measures 
were negligible, well within the limits of 
agreement (criterion) stated. This was true 
across domains and in overall scores for 
all 3 samples.  
105 ischemic stroke participants 
 Kerber et al. 
2012 
Validity of SS-QOL-12, 
assessed by correlating with 
the full-scale SS-QOL (49 
item) 
Correlation between the two tests 
was very high (intraclass 
correlation coefficient, 0.98) 
45 ischemic stroke participants 
 
 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue scale; (HUI2, Health Utility Index Mark 2; 
 
HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP-40, Health-Related Quality of Life in Stroke Patients 40-items; NEWSQOL, Newcastle Stroke- 
Specific Quality of Life Measure; PBSI, Preference-Based Stroke Index; SF-12, SF-6D, SF-36, Medical Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); SIS 2.0, 
3.0, Stroke Impact Scale (Version 2.0, 3.0); SF-SIS, Short-Form Stroke Impact Scale; Stroke-PROM; Stroke-Patient Reported Outcome Measure, SAQOL-39, Stroke and Aphasia Quality of 
Life Scale-39; SS-QOL, 12-item Stroke-Specific Quality of Life Scale, N/A; Not Applicable, NDI; No data identified
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Table 5. Recommended measures considering clinical utility and psychometric 
properties. 
Screening tools meeting selection criteria (n = 17) 
Generic HR-QOL tool (n = 6) Stroke-specific HR-QOL tool (n = 11) 
Administrati on 
time 
≤5 minutes 
(n=4) 
Administration 
time 6-10 minutes 
(n=2) 
Administrati on 
time 
≥11 minutes 
(n=0) 
Administrati on 
time 
≤5 minutes 
(n= 1) 
Administration 
time 6-10 
minutes 
(n= 2) 
Administrati on 
time 
≥11 minutes 
(n=8) 
Tools excluded as they require a cost > £100 
(n=1; HUI) 
Tools excluded as they require a cost > £100 
(n=0) 
Tools excluded as they require specialist training 
(n=1; HUI) 
Tools excluded as they require specialist training 
(n=0) 
Remaining tools with Remaining Remaining Remaining tools Remaining Remaining 
administration time tools with tools with with administration tools with tools with 
≤5 minutes administrati administratio time administrati administratio 
(n=4) on time n time ≤5 minutes on time n time 
 6-10 ≥11 minutes (n=1) 6-10 ≥11 minutes 
 minutes (n=0)  minutes (n=8) 
 (n=1)   (n=2)  
Tools excluded following lack of reliability data 
(n= 4; AQol; Eq-5D-5L;SF-6D) 
Tools excluded following lack of validity data 
(n = 1; SF-36) 
Tools excluded following lack of reliability data 
(n= 3; PBSI; SF-SIS; SS-QOL-12) 
Tools excluded following lack of validity data 
(n = 0) 
Remaining tools Remaining tools Remaining Remaining tools Remaining Remaining 
with with tools with with administration tools with tools with 
administration administration administrati time administrati administrati 
time time on time ≤5 minutes on time on time 
≤5 minutes 6-10 minutes ≥11 (n=0) 6-10 ≥11 
(n=1; SF-12) (n=0
) 
minutes  minutes minutes 
  (n=0)  (n=1; (n= 6; 
    Stroke- HRQLISP- 
    PROM) 40; 
     NEWSQOL 
     ; SIS 2.0; 
     SIS 3.0; 
     SAQOL- 
     39;SS-QOL) 
Tools excluded for unavailability of measure 
(n= 0) 
Tools excluded for unavailability of measure 
(n= 3; HRQOLISP-40; NEWSQOL; Stroke- 
PROM) 
Remaining tools with administration time 
≤5 minutes 
(n=1; SF-12) 
Remaining tools with administration time 
≥11 minutes 
(n=4; SIS 2.0; SIS 3.0; SAQOL-39; SS-QOL) 
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Table 6. Domains covered by selected measures 
 
Measure Physical 
function 
Role 
function 
Pain Emotional 
wellbeing 
Cognitive 
function 
Communication Social 
function 
Recreation Energy General 
health 
Overall 
Quality 
of Life 
Comments 
AQoL-4D ++ + + + - + ± - - - - Other questions about a person’s 
vision, relationship with others and 
sleep were included 
EQ-5D-5L ++ - + + - - - - - + - Other domains include activities of 
self-care. A visual analogue scale 
(VAS) asks the person to 
rate their general health status. 
HUI ++ - + + + + - - - - - HUI questionnaire can be categorised 
using two multi-attribute systems, 
HUI2 and HUI3 with its own domain 
classifications. 
HSQuale ++ ++ - ++ ++ + + ++ + - + Other domains include questions 
about a person’s general outlook and 
perception of themselves, 
relationships, impact of stroke on 
their work and financial status. 
HRQOLISP- 
40 
++ + + ++ ++ + + + + - - Other domains include questions 
about a person’s soul/spirituality and  
religious faith. It also asks questions 
on the context of their 
surrounding environment and their 
access to support/health care. 
NEWSQOL ++ - ++ ++ ++ ++ - - +/++ - - Questions relating to fatigue on this 
scale are assumed to link to an 
‘Energy’ domain. Other domains 
include mobility, self-care, vision, 
interpersonal relationships and sleep. 
PBSI ++ + - +/++ + + - + - + - Other domains include questions 
about a person’s ability to drive, their 
rating of coping abilities with 
difficulties and their self-esteem. 
SF-6D + + + ± - - + - + - - Some but not all of the statements for 
the ‘role limitation’ domain include 
responses that provide insight to a 
person’s emotional wellbeing. 
SF-12 ++ - + ++ - - + - + ++ - N/a 
SF-36 ++ ++ ++ ++ - - ++ - ++ ++ - N/a 
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SIS 2.0 ++ + - ++ ++ ++ + ++ - ± - Other domains include a person’s 
ability to carry out daily activities, 
mobility at the home and in the 
community. A VAS asks the person 
to rate their recovery. 
SIS 3.0 ++ + - ++ ++ ++ + ++ - ± - Other domains include a person’s 
ability to carry out activities of daily 
living, ability to be mobile at the 
home and in the community. A VAS 
asks the person to rate their recovery. 
SF-SIS ++ + - + + - + - - - - Includes specific questions about the 
strength of a person’s most affected 
leg and the most affected hand in 
picking up a coin. 
Stroke- 
PROM 
++ - - ++ ++ ++ ++ - - + - Other questions include views about 
receiving treatment (‘Therapeutic 
Domain’) 
SAQOL-39 ++ - - + ++ ++ ++ + ++ - - Scores are categorized into 3 
domains: physical, communication 
and psychosocial 
SS-QOL ++ - - ++ ++ ++ ++ + ++ - - Other domains included family roles, 
self-care, work/productivity, 
personality and vision. 
SS-QOL-12 + - - + + + + + + - - Other domains included family roles, 
self-care, work/productivity, 
personality and vision. 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue scale; (HUI2, Health Utility Index Mark 2; 
 
HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP-40, Health-Related Quality of Life in Stroke Patients 40-items; NEWSQOL, Newcastle Stroke- 
Specific Quality of Life Measure; PBSI, Preference-Based Stroke Index; SF-12, SF-6D, SF-36, Medical Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); SIS 2.0, 3.0, 
Stroke Impact Scale (Version 2.0, 3.0); SF-SIS, Short-Form Stroke Impact Scale; Stroke-PROM; Stroke-Patient Reported Outcome Measure, SAQOL-39, Stroke and Aphasia Quality of Life 
Scale-39; SS-QOL, 12-item Stroke-Specific Quality of Life Scale, (‘-’) , no coverage; (‘+’),  limited coverage (1 item); (‘++’), noteworthy coverage (2 or more items), (‘±’), coverage equivocal 
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Discussion 
 
The objective of this paper was to evaluate HR-QOL measures among stroke survivors, 
based on clinical utility, psychometric properties and HR-QOL domain coverage, and in turn 
to provide recommendations for clinicians and researchers on the most suitable HR-QOL 
measures. Twenty-four studies were included in this systematic review, comprising  4469 
stroke participants at different stages of stroke recovery worldwide. Most studies were of ‘Fair’ 
– ‘Good’ quality, with only one paper rated as ‘Poor’ quality. A total of 17 published HR-QOL 
measures were validated for stroke use. 
To meet the purpose of this review, key findings compared the HR- QOL measures 
identified. In regard to clinical utility (administration time, training requirement, cost), six of 
seventeen scales scored adequately, with the SF-12 scoring the highest. Whilst the SF-12 is a 
shorter measure requiring approximately less than 5 minutes administration time, other 
measures require approximately more than 11 minutes to administer.  
Moreover, reliability and validity data for HR-QOL measures were also gathered. 
Although validity was reported for most scales, only ten measures had data on reliability. 
Where reliability data was excluded, authors tended to acknowledge reliability based on 
previous research rather than report original analysis data. The available information on 
reliability and validity for these HR-QOL measures for stroke suggest are limited. More work 
needs to be carried out to thoroughly assess psychometric properties of these tools before 
they are recommended for clinical use. This indicates direction for future research to ensure 
reliability and validity data of a measure is based on original data. 
Finally, each measure was evaluated based on their different ranges of HR-QOL 
domains coverage. The SF-12 provides the least coverage of the domains (six of eleven 
domains) in comparison to the other measures such as the SIS 3.0, which covers the most 
(eight of eleven domains). This variance in coverage is expected across measures, especially 
when taking into account the number of the questions and administration time. 
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Whilst assessing clinical utility, psychometric properties and HR-QOL domains 
coverage, a flow chart was formed to determine the most suitable measures for clinical and 
research settings. Five recommended measures were identified using this process, namely; the 
SF-12, SIS 2.0, SIS 3.0, SAQOL-39 and SS-QOL. 
Amongst the recommended tools, the SF-12 is the only generic HR-QOL identified, 
which may also explain its reduced domain coverage, compared to the other stroke-specific 
recommended measures. For example, in comparison to the other measures, the SF-12 
excludes questions regarding a person’s cognitive functioning or communication abilities. 
However, in cases where a person does not experience cognitive or communicative 
difficulties post-stroke, the SF-12 may still be an appropriate clinical measure because of its 
succinct length in considering the wider aspects of assessment. 
Amongst the stroke-specific recommended measures, some differences in its properties 
may contribute to judgement of the most suitable tool. All stroke-specific measures obtained 
similar clinical utility scores for their administration time (≥11 minutes) and coverage of HR- 
QOL domains. Whilst the SAQOL-39 has the least number of items and takes the shortest time 
(10-15 minutes), the SIS 2.0, SIS 3.0 and SS-QOL estimate an administration time of 15-20 
minutes. In terms of domain coverage, both the SIS 2.0 and SIS 3.0 have an additional 
advantage of a visual analogue scale (VAS) for patients to rate their recovery. It should also 
be noted that the SIS 3.0 was developed as an improvement of the SIS 2.0 – while its domain 
coverage and administration time are similar to its predecessor, the SIS 3.0 consists of 59 
items instead of 64 items on the SIS 2.0. 
Ultimately, professionals should exercise clinical judgement in deciding the best tool 
for specific situations, considering its practical utility and relevant domains. Although the 
difference of administration time is minimal, clinicians, researchers and trialists should 
consider the length of clinical interviews and other assessment measures to prevent response 
burden in stroke participants. For example, one should consider a patient or participants’ 
energy and attentional abilities when selecting an assessment tool or planning a session. This 
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is particularly important for post-stroke patients, who are likely to experience fatigue.  
To date, there is only one comparable systematic review for HR-QOL measures 
within the stroke literature. In comparison to the review by Golomb, Vickrey and Hays (2001), 
the present review identified fewer HR-QOL measures, 17 in total, comparing to their 32. This 
is because Golomb and colleagues (2001) also reviewed measures of physical functioning (e.g. 
Barthel Activities of Daily Living Index; Functional Ambulation Classification), and mood 
(e.g. Beck Depression Inventory; Hospital Anxiety and Depression Scale), both of which assess 
different domains of well-being and were assumed by the authors to measure HR-QOL. Where 
Golomb and colleagues (2001) identified 1 stroke-specific measure of 32 measures, this review 
indicates an improvement in stroke-specific measures development across the years. 
Additionally, a review by Geyh, Cieza, Kollerits and Grimby (2007) used alternative 
frameworks of reference, such as the international classification of functioning (ICF) to 
compare HR-QOL measures. The ICF uses a different approach and concept in mapping 
measure/questionnaire items to category sets. Although ICF has its strengths, it has also been 
criticised for its lack of subjective dimensions of functioning and disability (Ueda & Okawa, 
2003). Nevertheless, it is noted that there is yet to be a HR-QOL measure that meets all the HR-
QOL domains listed by Golomb, Vickrey and Hays’s (2001)  . In comparison to existing 
literature, the present review provides an updated search of HR-QOL measures, which 
includes more stroke-specific tools. In addition to reporting psychometric properties and HR-
QOL domain coverage, this review also measures clinical utility with methods established by 
Burton and Tyson’s (2015a; 2015b) work on stroke cognition and mood screens to aid in 
clinical decision-making. 
This review has several limitations. Firstly, the present study emphasised HR-QOL- 
specific measures and excluded other measures that may also influence a person’s HR-QOL. 
It may be that a person’s emotional, physical and functioning state and abilities can provide a 
better indication of a person’s HR-QOL. Some of these specific measures (e.g. mood screens, 
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cognitive screens, performance-based assessments of physical abilities) may already be 
included in stroke rehabilitation assessments. 
Moreover, when interpreting indices of clinical utility and HR-QOL domains, this review 
replicated methods from previous researches,  specifically those of Burton and Tyson (2015a; 
2015b) and Golomb, Vickrey and Hays (2001). However, it is noted that there may be other 
definitions and methods of assessing clinical utility and HR-QOL domains that are not included 
in the replicated frameworks. These were indicated in Table 6, whereby notes were taken when 
the measure evaluated other domains. Thus, the results of the content comparison of the 
measures in this review may only hold relative to the frame of methodology utilised. 
Additionally, this review did not identify comprehensive information about the 
different modes of administration of the measures. It is clinically important to recognise the 
conceptual differences in using self-, interviewer- or proxy-administered HR-QOL measures 
and the impact this can have on outcomes. Future research could look to address this and offer 
a more comprehensive commentary on this aspect of scale usage. 
Although not a primary aim, the present review identified nine of the seventeen measures 
as suitable for use with proxy administration. However, only one measure indicated the 
availability of a specific proxy version (EQ-5D-5L) and interview-administration version 
(HUI). In one study, data collected by proxy-administration was not included in the analysis 
(Kerber et al., 2012). Overall, clear information on proxy administration is scarce. This may 
significantly impact up to a one-third of stroke survivors with post-stroke communication 
difficulties such as aphasia, dysarthria or apraxia of speech, thus potentially affecting 
assessment outcomes (Wray & Clarke, 2017). Specific research on proxy responses for HR- 
QOL stroke measures have found moderate agreement between responses from patients and 
their proxies (Carod-Artal et al., 2009; Dorman et al., 1997; Williams et al., 2006), despite 
findings that proxies tend to report more dysfunction on certain domains (Williams et al., 
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2006). Additionally, existing research show that interviewer-administered assessments of HR- 
QOL measures tend to elicit more positive scores on domains related to mental health when 
compared to self-administered assessments such as postal interviews (Caute et al., 2012). As 
such, future research would need to consider the importance of proxy respondents for stroke 
patients, particularly in developing HR-QOL measures. This should come with clear guidance, 
instruction or specific versions for proxy administrators to ensure that responses are reliable 
and valid. This calls for future studies to report on proxy-administered data, adding to the body 
of evidence and ensuring that people with post-stroke communicative difficulties are not 
excluded in HR-QOL research. 
Finally, only 30% of the studies included for this review were co-rated for quality. This 
suggests that quality ratings provided may be subjected to bias by the author’s interpretation. 
The final rating in each COSMIN domains required subjective interpretations from 
respondents. Furthermore, assessment of eligibility and quality ratings are influenced by the 
extent to which they answered the review’s question. 
80 
 
 80 
Conclusions & recommendations 
 
This paper presents a systematic review of existing HR-QOL measures used within the 
stroke population. It outlines information important to make informed decisions on which 
identified measures are most valid, reliable and suitable for use in clinical or research settings 
to measure HR-QOL. The review identifies the strengths and limitations of each HR-QOL 
measures and recognises the gaps in the domains assessed. It remains that no existing HR-
QOL measure addresses all the  HR-QOL domains specified by Golomb, Vickrey and Hays 
(2001). This provides an indication and direction for future development of new measures. 
The information synthesised and presented also highlights a need for more psychometric data 
in testing the reliability and validity of HR-QOL measures. It is hoped that with additional 
research, more recently developed measures can become widely used and openly available to 
clinicians. Lastly, although this review attempts to systematically present and narrow down 
findings to a few recommended measures, it is important to remember that there is no perfect 
assessment scale for stroke survivors – the choice of instrument will always depend on 
professional judgement about the properties of that scale and more importantly, the purpose 
of its testing in both clinical and research settings (MasIsaac et al., 2016). 
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CHAPTER THREE: Bridging Chapter 
 
This chapter provided a summary of the systematic review and leads into the rationale for the 
empirical paper. 
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Bridging Chapter 
 
 
The systematic review in Chapter Two investigated the current HR-QOL measures that 
are used for stroke, and considered them in reference to their clinical utility, psychometric 
properties and HR-QOL domains covered. By incorporating established methods of 
assessing clinical utility and synthesizing psychometric information gathered, this review 
was able to form a flow-chart and thus allow for ease of decision-making by researchers and 
clinicians when choosing HR- QOL measures to employ. The review therefore contributed 
to the research of HR-QOL in stroke and concluded in calling for future research in the area 
to build on this body of work. 
 
When inspecting the HR-QOL measures identified for Chapter Two with respect to their 
coverage of HR-QOL domains, it was observed that all of the seventeen identified measures 
included at least one question about a person’s emotional wellbeing, or mood. This gives an 
indication of the importance of a mood to a person’s HR-QOL following stroke. Given the 
high prevalence of post-stroke depression (PSD), post-stroke anxiety (PSA) and post-stroke 
emotionalism (PSE), it is of course unsurprising that it is strongly linked to HR-QOL. A 
study comparing participants with similar neurological impairment found that stroke 
participants who were later diagnosed with anxiety were reported to be more dependent and 
rated lower on HR-QOL domains than those who did not receive a post-stroke anxiety 
diagnosis (Chun et al., 2018). 
 
Recent years have seen researchers and clinicians include HR-QOL as a useful outcome 
measure for stroke rehabilitation and post-stroke mood interventions. However, despite 
advancements in the field, there remains no clear consensus on the best available 
interventions for PSD, PSA nor PSE. Thus, the empirical paper of this portfolio presents a 
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network meta-analysis to review the available evidence for the treatment intervention of PSD, 
PSA and PSE, considering both pharmacological and non-pharmacological approaches. 
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Abstract 
 
Purpose: It is common after the traumatic event of a stroke for people to experience a 
wide range of changes, including in their mood. Post-stroke depression (PSD), anxiety (PSA) 
and emotionalism (PSE) are often observed in the months following a stroke and can play a 
large role in a person’s rehabilitative outcome and quality of life. Yet, there is no consensus 
on the best way to treat these post-stroke mood disorders. This paper aims to provide an 
overarching view of current evidence-based treatments for mood disorders after stroke and to 
highlight research gaps. 
Method: Electronic databases MEDLINE, PubMed, The Cochrane Database of 
Systematic Reviews, EMBASE and Database of Research in Stroke (DORIS) were searched 
to identify randomised controlled trials (RCTs) on treatment interventions for PSD, PSA and 
PSE domains. Network meta-analyses (NMA) were conducted on the evidence for each 
domain to synthesise the findings based on direct and indirect comparisons. 
Findings: Twenty-three trials were included in the final NMA for PSD, followed by 
eleven for PSA and none for PSE. The NMA categorised the interventions with reference to 
the type of control group used, and calculated treatment estimates and rankings based on 
direct and inferred evidence. 
Discussion and Conclusion: The paper presents the wide range of interventions 
available for PSD and PSA. It highlights the disproportionate focus of present research within 
each domain. There is paucity of replicated evidence in the area. Thus, the NMA was not able 
to provide confident predictions of treatment rankings for either of the domains. 
Keywords: stroke, post-stroke depression, post-stroke anxiety, post-stroke 
emotionalism, intervention, treatment 
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Introduction 
 
 
Stroke occurs when a blood clot, ruptured artery or ruptured blood vessel causes an 
interruption of blood flow to the brain (Lincoln, Kneebone, MacNiven & Morris, 2011). 
Blockages in a brain artery lead to ischemic stroke, which accounts for 87% of stroke cases 
(Puig, Brenna & Magnus, 2018). When this happens, brain blood flow can stop, leading to 
hypoperfusion in the affected area and potentially lethal neuronal injury, or cell death (Puig, 
Brenna & Magnus, 2018). In haemorrhagic strokes, a hydrostatic jet of blood emerging from a 
ruptured blood vessel can cause immediate destruction to neuronal tissue (Zille et al., 2017). 
Up to 25% of those affected by stroke die within a month (Wolfe, 2000), whereas those who 
survive can be left with brain damage and a myriad of consequences. Depending on lesion 
location and severity, stroke can cause chronic disabilities involving physical dysfunction 
(Rossini, Calautti, Pauri & Baron, 2003; Mayo et al., 1999), cognitive impairments (Sun, Tan 
& Yu, 2014) and speech and language difficulties (Brady et al., 2016), all of which have a 
profound impact on a person’s daily functioning. Accordingly, stroke is the leading cause of 
disability in the UK (Wilkins et al., 2017). 
The sudden and life-threatening onset of a stroke can be a frightening and traumatic 
experience. Its aftermath can be devastating for patients and their families (Hole, Stubbs, 
Roskell & Soundy, 2014), requiring a person to reorder their life, renegotiate social 
relationships and find ways to cope with newly acquired difficulties (Lewinter & Mikkelsen, 
1995). It is therefore not surprising that psychological and emotional difficulties are common 
after stroke, affecting up to a third of stroke survivors (Burton & Tyson, 2014). Post-stroke 
emotional disturbances negatively impact a person’s quality of life (Carod-Artal & Egido, 
2009), and may become a factor in impeding rehabilitative progress and outcome (Kneebone, 
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2016). Post-stroke depression (PSD) is associated with poor functional recovery (Pohjasvaara 
et al., 2001), increased length of hospital stays, heightened risk of suicide (Pompili et al., 2015), 
eroded quality of life and increased mortality (Razmara, et al., 2017; Bartoli et al., 2013; House 
et al. 2001). There is far less research conducted on post-stroke anxiety (PSA) and post-stroke 
emotionalism (PSE) although some evidence associates PSA with poor social functioning, 
activities of daily living (Shimoda & Robinson, 1998) and quality of life (Burton et al., 2013). 
Whilst recognising the complexity and myriad of emotional difficulties that people 
may experience after stroke, this paper focuses on the more commonly observed emotional 
and mood difficulties; PSD, PSA and PSE. Other emotional disturbances, post-stroke fatigue 
(Lerdal et al., 2009), aggression, and anger proneness (Rosa et al., 2016) are not 
discussed. 
 
Post-Stroke Depression (PSD) 
 
Approximately one third of stroke survivors will experience symptoms of post-stroke 
depression within the 12 months following a stroke (Lanctot et al., 2019). The complex, 
multifactorial and wide-ranging nature of PSD is reflected in the current literature. Work that 
emphasises the neurobiological variables and changes as the main factors associated with PSD 
(Villa, Ferrari & Moretti, 2018) is contrasted with other work suggesting that PSD may be a 
psychological, reactive response associated with sudden functional impairments (Taylor, 
Todman & Broomfield, 2011; Kim, 2016). 
Of all the available treatments, pharmacological interventions have been the most 
researched strategy for PSD (Deng et al., 2017). In recent reviews and meta-analyses, 
antidepressants such as fluoxetine, sertraline, citalopram and nortriptyline have been shown 
to be effective in reducing depressive symptoms for stroke patients (Hackett et al., 2008; 
Kneebone & Lincoln, 2012; Xu et al., 2016; Deng et al., 2017). However, even when 
considering pharmacological interventions alone, stroke clinicians have difficulties deciding 
the most appropriate treatment from more than 40 different antidepressants (Sun et al., 2017). 
Sun et al. (2017) investigated this problem with a network meta-analysis, concluding that 
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paroxetine might be the best choice in starting treatment for PSD, whereas fluoxetine 
performs the worst in comparison. Nevertheless, choosing pharmacological interventions for 
PSD is problematic given the high rate of adverse events (Hackett et al., 2009) particularly to 
the gastrointestinal and central nervous systems (Hackett et al., 2008). Notably, randomised 
controlled trials studying the effects of fluoxetine on functional outcomes after stroke 
(FOCUS)(Dennis et al., 2019), found that fluoxetine does not improve functional outcomes 
and despite a reduction of PSD, an increment of frequency in bone fractures is also observed. 
This is echoed in other trials: Assessment of fluoxetine in stroke recovery trial (AFFINITY) 
(Grp, A.T.C., 2015) and efficacy of fluoxetine – a randomised controlled trial in stroke 
(EFFECTS)(Lundström et al., 2020), both similarly found fluoxetine did not improve 
functional outcomes, but increased adverse effects and risk of falls, bone fractures, epileptic 
seizures and hyponatraemia (Hankey et al., 2020; Lundström et al., 2020). This is particularly 
worrying, given that older people are at much higher risk of stroke. The high rate of adverse 
effects that anti-depressant medication can also promote noncompliance to treatment 
(Bhardwaj, Arumugam & Gambhir, 2018), and not all patients wish to take anti- depressant 
medicine to improve their mood. 
Non-pharmacological interventions such as CBT have been shown comparable in 
efficacy to pharmacotherapy treating moderate-severe depression in the general population 
(DeRubeis et al., 2005), for patients with acquired brain injuries (Ponsford et al., 2016) and 
multiple sclerosis (Hind et al., 2014). Components of CBT such as motivational interviewing, 
work on grief, adjustment (Broomfield et al., 2011) and problem solving (Hackett et al., 2008) 
may be particularly useful in addressing the role of cognition and behaviour in PSD (Allida et 
al., 2020). A review found that in comparison to usual care, CBT had very low evidence in 
treating depression and often treatment effect was not sustained (Hackett et al., 2008). 
However, a more recent meta-analysis of 23 studies by Wang et al. (2018) found CBT to 
have positive effects in treatingPSD, providing supportive evidence for non-pharmacological 
interventions. Nevertheless, both these reviews acknowledged that the overarching evidence 
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for psychological interventions remain inconclusive. 
Beyond pharmacological and psychological interventions for PSD, there is growing 
interest in alternative treatments. Non-invasive brain stimulation techniques such as repetitive 
transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) 
takes advantage of neuronal plasticity and reorganisation in exciting or inhibiting areas of a 
neuronal or brain activity to create temporary or long-lasting desirable changes (Hallett, 2007; 
Miniussi, 206). High frequency rTMS on the left dorsolateral prefrontal cortex (DLPFC) has 
been found to benefit treatment-resistant depression (Slotema, Blom, Hoek & Sommer, 2010). 
Although rTMS and tDCS demonstrates promising efficacy for PSD in recent research and 
meta-analysis (Frey, Najib, Lily & Adcock, 2020; Shen et al., 2017; Bueno et al., 2011), further 
research and randomised controlled trials are needed (Bucur & Papagno, 2018). There is also 
emerging evidence for other interventions such as ecosystem-focused therapy, life review, 
music therapy, exercise and robotic-assisted neurorehabilitation in improving PSD (Baker et 
al., 2017; Hadidi et al., 2017). 
Post-Stroke Anxiety (PSA) 
 
Post-stroke anxiety disorders describe a person’s difficulty with excessive anxiousness 
or worries (Kim, 2016). To categorise anxiety sub-types after stroke, Chun et al. (2018) 
differentiates post-stroke phobic and generalised anxiety, the former of which is associated 
with poorer recovery outcomes. Difficulties with anxiety can be manifested in a number of 
different ways and broadly include physical changes (e.g. shortness of breath), cognitive 
changes (e.g. fearful thoughts), and consequent behavioural responses (e.g. avoidance) (Knapp 
et al., 2017). PSA is estimated to affect between 18-25% of people after stroke, and is closely 
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linked with PSD (Campbell Burton et al., 2012; Kim, 2016). Although some studies propose a 
connection between PSA and lesion location, a recent meta-analysis found this inconclusive 
(Campbell Burton et al., 2012). 
PSA has received comparably less research attention than PSD (Mitchell et al., 2017). 
Pharmacological studies are restricted to those investigating PSA with cooccurring depression 
(Kneebone & Jeffries, 2013), while a review (Campbell Burton et al., 2012) found that  
studies for psychological treatment of PSA did not provide sufficient information about the 
proportion of study participants no longer meeting their anxiety criteria, or the clinical 
significance of this decrease. 
Behavioural and cognitive-behavioural psychotherapies are proven in the treatment of 
anxiety in the general population (Hall et al., 2016), and in older adults (Ayers, Sorrell, Thorp 
& Wetherell, 2007). Some authors propose for CBT to be successful for PSA with modified 
approaches that consider cognitive and communication problems (Lincoln & Flannaghan, 
2003; Thomas et al., 2013; Kneebone & Jeffries, 2013). In the most comprehensive review to 
date, Knapp et al. (2017) found pharmacological therapies paroxetine and buspirone effective 
in treating anxiety after stroke, and that psychotherapy did not offer any significant benefits. 
However, there still remains a significant gap in evidence for treatment of PSA. 
Post-Stroke Emotionalism (PSE) 
 
Post-stroke emotionalism, otherwise known as emotional lability, emotional 
incontinence or pseudobulbar affect involves abnormal displays of emotion, usually 
uncontrollable outbursts of crying, occasionally laughter, not under normal personal control 
(Wilson, 1924; House et al., 1989). In the acute/subacute stages of stroke, prevalence of PSE 
varies from 6-34% (Kim, 2016). Gillespie et al.  (2016)’s review found that PSE affects 
approximately 1 in 5 stroke survivors at the acute and post-acute phases, and 1 in 8 survivors 
beyond 6 months. Of the three mood disorders reviewed in this paper, studies of PSE tend to 
focus most on aetiological factors such as location of brain lesions (House et al., 1989) 
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although some research has considered psychological factors (Calvert, Knapp & House, 1998; 
Eccles, House & Knapp, 1999; McAleese et al., 2019). Kim (2016) reported that lesion location 
(in particular, the subcortical area) is associated with PSE only at the time of admission, 
whereas other factors such as functional status and social support are more strongly associated 
to PSE three months after the stroke. 
Pathogenesis studies have considered the theoretical perspective of neuroanatomical 
lesions and neurotransmitter regulation on PSE (Kim, 2016). This might explain the emphasis 
of intervention studies focused on tricyclic antidepressants (e.g. imipramine) Selective 
Serotonin Reuptake Inhibitors (SSRI), (e.g. sertraline and citalopram), anticonvulsants (i.e. 
lamotrigine), dopamine precursors (e.g. levodopa) and NMDA receptor (glutamate and ion 
channel protein receptor) antagonists (e.g. dextromethorphan) (Imarhiagbe & Abidakun, 
2018) for PSE. A recent Cochrane review by Allida, Patel and House (2019) concluded that 
antidepressants may be an effective PSE intervention, with no specific effect from one drug or 
class of drugs. However, researchers and clinicians cannot draw information on the effects of 
psychological therapy for PSE, with the exception of two case reports (Allida, Patel & House, 
2019). To date, there are no controlled investigations of psychological therapies for PSE. This 
is despite the fact we know that a high proportion of stroke clinicians regularly utilize non- 
pharmacological approaches to treat PSE (Gillespie et al., 2020), thus further highlighting the 
existing gap and important need for research to better understand PSE and the behavioural 
interventions for it. 
Rationale for this paper 
 
The general scope of research and evidence for post-stroke mood interventions is 
unbalanced, with particular attention paid to PSD, and other common mood / emotional 
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problems following stroke still relatively neglected. Despite emerging evidence and support 
for non-pharmacological interventions in each of these conditions, particular emphasis has 
been drawn to pharmacological treatments. This paper intends to address this gap in literature 
by making head-to-head comparisons between pharmacological and non-pharmacological 
interventions for each of these post-stroke mood disorders using a network meta-analysis 
(NMA). A network meta-analysis will provide an advantage to a traditional meta-analysis, 
where all interventions that have been tested in randomized controlled trials (RCTs) can be 
simultaneously compared and their effects estimated relative to each other and to a common 
reference condition (e.g. waitlist) (Mayo-Wilson, 2016). Although there may be limitations 
due to the availability and scope of evidence within the existing literature, an NMA can 
nevertheless be useful in providing an overarching review of existing evidence and 
highlighting gaps in post-stroke mood research.  
In comparison to NMAs carried out by Deng et al. (2017) and Sun et al., (2017), this 
paper is not limited to PSD nor pharmacological interventions. By conducting a network 
meta-analysis for PSD, PSA and PSE, for both pharmacological and non- pharmacological 
interventions, the present review gives researchers and clinicians an overarching view of the 
current evidence and scope of research conducted to evaluate post- stroke mood 
interventions. Employing an NMA also allows for computing a stepped ranking of treatment 
efficacy for each intervention, based on the available literature to date. 
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Method 
 
Protocol and registration 
 
This review is registered with PROSPERO: International prospective register of 
systematic reviews (ID: CRD42019141421). The review was reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 
(Moher, Liberati, Tetzlaff & Altman, 2009). 
Search strategy 
 
Electronic databases MEDLINE, PubMed, The Cochrane Database of Systematic 
Reviews, EMBASE and Database of Research in Stroke (DORIS) were searched from their 
inception to 2nd February 2020. The search used Boolean strategies to identify keywords and 
specific terms for the searches across each domain and database (Appendix A). 
Eligibility Criteria 
 
After the initial searches for articles were conducted on the electronic databases, all 
titles and abstracts were screened by one author (JP) for relevance to the research question. 
Following that, all articles were then further screened independently by two authors (JP & EH) 
against the eligibility criteria set for this systematic review. 
Inclusion criteria for all three analyses (for PSD, PSA and PSE) comprised the 
following: 
1) Studies published in the English language within a peer-reviewed journal; 
 
2) Participants include adult stroke survivors over 18 years of age. 
 
The exclusion criteria were as follows: 
 
1) Studies that were not randomized clinical trials; 
 
2) Less than 50% of the participants had suffered a stroke; 
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3) In mixed samples, where data from people with stroke could not be specifically 
extracted; 
4) Studies specific to participants with transient ischemic attacks (TIA) and 
subarachnoid haemorrhage. This exclusion is because TIAs are defined by focal neurological 
symptoms that last for <24 hours (Easton et al., 2009). In contrast, stroke patients typically 
experience severe debilitating symptoms which require further rehabilitation treatment (Lam, 
Bloom & Kha, 2019). Although SAHs can be associated with stroke, it includes trauma 
resulting from head injuries, and may therefore be diagnosed and treated differently from a 
stroke (Chong, 2020). Exclusion of TIA and SAH participants from post-stroke studies and 
reviews have been noted within the literature (Hackett, Anderson, House & Xia, 2008; Sagen 
et al., 2009; Knapp et al., 2017).; 
5) Interventions delivered to the caregivers of persons who had a stroke; 
 
6) Studies where PSD/PSA/PSE was not listed as a primary outcome; 
 
7) Studies where the intervention was categorized as Traditional Chinese Medicine 
 
(TCM). Due to the majority of research on TCM being published in Mandarin language, the 
inclusion of any TCM studies published in English will not provide a representative view of 
TCM. 
This review included studies conducted in any setting (e.g. hospitals, community), 
using any outcome measures related to post-stroke depression, post-stroke anxiety and post- 
stroke emotionalism. The outcomes were conceptualized broadly to ensure that all eligible 
interventions were included. The inclusion criteria within the selected studies, as well as the 
mode of delivery for interventions (e.g. face-to-face, telephone) did not serve as exclusion 
criteria. 
Data extraction & management 
 
The primary author (JP) extracted demographic and methodological information for 
each selected study. The reviewer then extracted information on the study’s design, participant 
characteristics, interventions, outcomes, and adverse events from each of the selected studies 
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to be included. 
The primary outcome extracted was the overall efficacy of the interventions 
employed, measured by its effect size. Effect size was calculated using the mean difference of 
total score and standard deviation of the mood- rating scales used.  
Where trials reported results from more than one outcome measure, the most 
commonly reported outcome measure (from the selected studies) was used for analysis. 
Tables 1, 2 and 3 describe the selected studies, including all the outcome measures used.  
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Effect size choice 
 
Due to the fact that the studies used different scales, the treatment effect cannot be 
readily converted to a common measure (Morton et al., 2018). Therefore, the standardized 
mean difference (SMD) for each study was pooled across all the studies. The SMDs of each 
study were calculated using Hedges’ g as a common metric, which was computed using this 
formula(Hedges & Olkin, 1985): 
 
 
 
 
 
 
Hedges’g  helped reduce measurement error, taking into account between-scale 
correlation  (Wei & Higgins, 2013, as cited in Mayo-Wilson et al., 2014). 
Where multiple data time points were reported, the longest follow-up data was 
extracted. 
Data analysis and synthesis 
 
A frequentist random effects network meta-analysis (Dias, Sutton, Ades & Welton, 
2013)     was     performed,     using     the     statistical     package     ‘netmeta’ (https://cran.r- 
project.org/package=netmeta), which applies R programming language.  
 
Where more than one type of treatment control group is used within the pool of 
studies, sub-networks were identified within each domain, which are differentiated by the type 
of control group used. These sub-networks were visualised using network plots, where the 
geometry of the treatment network comprising the included trials can be explored. 
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For each sub-network, a table of treatment estimates is presented. This includes 
firstly the direct data estimates (i.e. reported outcomes from articles included), and secondly 
the pooled estimates of treatment efficacy, which are inferred indirect treatment comparisons. 
NMA allows for all treatments in the network to be considered for ranking in terms of 
their likely impact on treatment outcomes, based on both direct and inferred comparisons. This 
is done by computing the surface under the cumulative ranking (SUCRA) probabilities 
(Rücker, & Schwarzer, 2015). For a frequentist framework, the P-score, which is an analogue 
to the SUCRA, is based on frequentist point estimates and standard errors (Rücker & 
Schwarzer, 2015). The P-score “expresses the total efficacy or acceptability within each sub- 
network of every intervention relative to an imaginary intervention that is always the best, and 
without uncertainty on a continuous 0- 1 scale” (Chaimani et al;, 2013). Thus, a larger P-score 
indicates a more efficacious intervention. To interpret treatment ranking based on P-scores, a 
forest plot was produced for comparison. This allowed for further investigation of efficacy, 
taking into account confidence intervals for each treatment effect. 
Consistency (i.e., indirect effects can be derived from differences in the corresponding 
direct effects) was assumed during modelling. The relative effect sizes were reported as mean 
differences along with 95% confidence intervals. Broader intervals reflect higher uncertainty 
about the estimated effect. Main effects were reported compared to the control conditions 
reported, used as the ‘reference treatment’  e.g. placebo as the reference treatment. 
Heterogeneity assessment. Study heterogeneity was assessed using the I2 statistic, 
whereby a score of more than 50% indicates moderate, and a score of 75% represents high 
levels of heterogeneity respectively (Higgins & Thompson, 2002). The random effects model 
takes into account between-study heterogeneity. Therefore, differences between studies are 
believed to be due, at least in part, to real differences in the underlying population (Shadish & 
Haddock, 1994). 
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Sensitivity analysis. This was undertaken in respect of the methodological quality 
(randomization process and blinding of outcome assessor) of the included studies. To aid this 
process, a criteria list and tick box format was created with the predefined methodological 
quality requirements. 
Quality Assessment 
 
All included articles were considered with regard to methodological quality. The 
Cochrane Collaboration’s tool for assessment of the risk of bias (Sterne et al., 2019; Version 
2) was used, as it is a common tool for assessing RCTs (Farrah, Young, Tunis & Zhao, 2019). 
This was further supplemented with selected items from the NICE quality appraisal checklist 
for quantitative intervention studies (NICE, 2012), given they capture other essential 
information for considering meta-analyses that are not covered in the Cochrane risk of bias 
tool. A list of the selected NICE quality appraisal items and its ratings can be found as 
Appendix E.  
The Cochrane risk of bias tool and the NICE quality appraisal checklist is comprised 
of five domains each. The domains are rated on three levels (‘high risk’, ‘some concerns’ and 
‘low risk’ on the Cochrane tool; ‘-‘. ‘+’ and ‘++’ on the NICE checklist). The overall quality 
rating for each study was arrived as a mean of the agreed domain ratings for both the Cochrane 
risk of bias toll and the NICE quality appraisal checklist. The domain ratings for both tools and 
overall quality rating for each paper can be found as Appendix F. 
Each study was assessed for quality by the primary author (JP), and a second-rater 
(EH) co-rated 30% of the articles, randomly selected to check for quality. For each domain on 
both the Cochrane risk of bias tool and the NICE quality appraisal checklist, where there were 
any inconsistencies in assessments between the two independent reviewers, this was discussed 
until a shared conclusion was agreed. There were minimal differences in ratings between the 
reviewers, which did not change the overall quality rating of the studies.  
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Results 
 
 
 
Search and selection. 
 
 
Overall, the search strategy yielded 2168 papers. Of these, twenty-five randomised 
controlled trials (fifty-six treatment arms) for PSD, eleven randomised controlled trials (ten 
treatment arms) for PSA and four randomised controlled trials (three treatment arms) for PSE 
met the inclusion criteria. The article identification and selection processes for each of these 
domains are presented in Figure 1. 
 
Characteristics of studies and participants. 
 
 
Post-Stroke Depression 
 
 
From the twenty-five included trials, twenty were two-armed, and five were three- 
armed. The trials recruited patients from various settings, including 56% inpatient, 16% 
outpatient and 4% mixed, and 20% community settings, across thirteen countries. 
Pharmacological interventions were reported the most (8 studies), followed by psychological 
(individual and group) interventions, most of which focused on behaviour (6 studies). Three 
studies considered the efficacy of exercise on treating post-stroke depression. Other 
treatments included brain stimulation techniques, skill-based groups, music therapy and novel 
interventions such as educational and ecosystem focused therapy. Two trials (Andersen, 
1994; Lauritzen, 1994) did not fit within the networks. For these studies, neither its treatment 
nor control conditions matched any study arms from the other papers. This meant that it was 
not possible to make direct nor indirect comparisons with other studies and were therefore 
excluded from further analyses. Details of the PSD studies are described in Table 1. 
As can be seen in Figure 1, a large number of texts were not included due to the 
accessibility (n=60). For a number of these texts, the researcher was unable to access the 
publications in Chinese (n=28) and Japanese (n=1) journals. For the remaining articles (n=31), 
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full texts were not available within the database that the researcher had access to.  
 
Post-Stroke Anxiety 
 
 
From the eleven included trials, ten were two-armed, and one was three-armed. The 
trials recruited patients from various settings, including 45.5% inpatient, 19% outpatient and 
36% community settings, across seven countries. Exercise/physical interventions were 
reported in three studies, as were psychological interventions (three studies). Other 
interventions included self-help techniques, muscular electrical stimulation and creative art 
therapy, and one study reported pharmacological interventions. One trial did not fit within the 
networks and was therefore excluded from further analyses (Karaiskos et al., 2012). Details of 
the PSA studies are described in Table 2. 
 
Post-Stroke Emotionalism 
 
 
Four PSE intervention trials were considered for network meta-analysis. These trials 
recruited a similar mix of patients from inpatient and outpatient settings, two of which were 
from the United Kingdom, one from Denmark and one from South Korea. Unfortunately, all 
four articles reported insufficient or inappropriate data needed for this meta-analysis (mean 
scores and standard deviation for outcome measures), thus a meta- analysis could not be 
performed. A description of these studies is reported in Table 3. 
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Figure 1. PRISMA Flow chart of selected studies across the three mood domains. 
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Table 1. Description of PSD papers selected and included in network meta-analyses 
 
 
Study author, 
Year 
Setting, 
Country 
Stroke 
participants, N 
(mean age) 
Intervention / 
control (N) 
Diagnostic 
criteria 
(depression) 
Outcome 
rating scale 
Treatment 
duration 
Quality 
Rating 
Andersen 1994 Outpatient, 
Denmark 
Subjects, N=33 
(68.2) 
Control, N=33 
(65.8) 
Citalopram (33)/ 
Placebo (33) 
DSM-III-R; 
HAMD (17 
items)> 12 
HAMD (17 
items) 
6 weeks Low 
Aidar et al., 2013 Community, 
Brazil 
Subjects, N=15 
(50.3) 
Control, N=13 
(52.5) 
Aquatic exercise 
(15)/ 
No intervention (13) 
N/A BDI 12 weeks Moderate 
Aidar et al., 2018 Community, 
Brazil 
Subjects, N=19 
(51.8) 
Control, N=17 
(52.7) 
Aquatic exercise 
(19)/ 
No intervention (17) 
N/A BDI 12 weeks High 
Cravello, 
Caltagirone & 
Spalletta, 2009 
Hospital, 
Italy 
Subjects, N= 25 
(64.2) 
Control, N= 25 
(65.9) 
Venlafaxine, 75- 
100mg daily (25)/ 
Fluoxetine, 20-40mg 
daily (25) 
Diagnosis of post- 
stroke major 
depressive-like 
episode, DSM-IV 
HAMD 8 weeks Low 
Gao et al., 2017 Inpatient, 
China 
Subjects, 
Citalopram, N=91 
(66.0) 
Subjects, CBT, 
N=92 (64.9) 
Control, N=91 
(67.2) 
Citalopram,20 mg 
daily (91)/ 
Cognitive 
behavioural therapy, 
2 hours weekly (92)/ 
Placebo (tablet and 
psychological 
Intervention) (91) 
N/A *HAMD, 
BDI, 
MES 
3 months Moderate 
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Golding, 
Kneebone & 
Fife-Shaw, 2016 
Community, 
UK 
Subjects, N=9 
(67.8) 
Control, N=10 
(62.4) 
Self-help relaxation 
training, 20 minutes, 
5 times a week (9)/ 
No intervention (10) 
N/A HADS-D 3 months Moderate 
Gu & Chang, 
2017 
Inpatient, 
South Korea 
Subjects, N= 12 
(58.1) 
Control, N=12 
(58.3) 
Repetitive 
Transcranial 
magnetic 
stimulation (rTMS) 
(12) / 
Placebo (12) 
BDI >12 
HAM-D17> 6 
BDI 
*HAM-D 
2 weeks Low 
Hoffmann, 
Ownsworth, 
Eames & Shum, 
2015 
Inpatient, 
Australia 
Subjects, Coping 
skills, N= 11 
(63.6) 
Subjects, Self- 
management, N= 
12 
(60.8) 
Control, N= 10 
(57.0) 
Coping skills (11)/ 
Self-management 
(12)/ 
Treatment as usual 
(10) 
N/A MADRS 
HADS 
8 weeks Low 
Holmgren, 
Gosman- 
Hedstrom, 
Lindstrom & 
Wester, 2010 
Inpatient, 
Sweden 
Subjects, N= 13 
(77.7) 
Control, N= 18 
(79.2) 
High-intensive 
exercise program 
(13)/ 
Education program 
control (15) 
N/A GDS 5 weeks Moderate 
Karaiskos et al., 
2012 
Outpatient, 
Greece 
Subjects, 
Duloxetine,N= 20 
(51.1) 
Subjects, 
Citalopram, N= 20 
(54.3) 
Subjects, 
Sertraline, N= 20 
Citalopram (20)/ 
Duloxetine (20)/ 
Sertraline (20) 
DSM-IV HAMD 12 weeks Low 
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  (52.4)      
Kerr, McCann, 
Mackey & 
Wijeratne, 2017 
Inpatient, 
Australia 
Subjects, N= 18 
(66.4), 
Control, N= 20 
(69.9) 
Motivational 
interviewing (18)/ 
Treatment as usual 
(69.9) 
N/A PHQ-9 
*HADS 
3 sessions Moderate 
Kim et al., 2010 Mixed, 
South Korea 
Subjects, Low- 
rTMS, N= 6 
(68.3), 
Subjects, High- 
rTMS, N= 6 
(53.5), 
Control, N= 6 
(66.8) 
Low frequency 
rTMS (6)/ 
High frequency 
rTMS (6)/ 
Placebo (6) 
N/A BDI 2 weeks Moderate 
Kiosses et al., 
2012 
Inpatient, 
USA 
Subjects, N= 12 
(72.3) 
Control, N=12, 
(69.4) 
Ecosystem Focused 
Therapy (12)/ 
Education on stroke 
and depression 
control (12) 
PHQ-9 > 10 
DSM-IV 
HAM-D 12 weeks High 
Kirkness et al., 
2017 
Hospitals, 
USA 
Subjects, 
Telephone 
behavioural 
therapy N=37 
(61.7), 
Subjects, In-person 
behavioural 
therapy N=35 
(58.5), 
Treatment as usual 
N=28 (60.7) 
Behavioural therapy 
(telephone) (37)/ 
Behavioural therapy 
(in-person) (35)/ 
Treatment as usual 
(28) 
GDS  11, 
Diagnostic 
Interview, 
Structured 
Hamilton, 
DSM-IV 
HDRS 6 weeks High 
Lai et al., 2005 Community, 
USA 
Subjects, N= 44 
(68.5) 
Exercise (44)/ 
Treatment as usual 
(49) 
N/A GDS 12 weeks Low 
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  Control, N=49 
(70.4) 
     
Lauritzen et al., 
1994 
Inpatient, 
Denmark 
Subjects, N=10 
(68.3) 
Control, N=10 
(74.1) 
Imipramine plus 
mianserin (10)/ 
Desipramine plus 
mianserin control 
(10) 
HAMD (17 items) 
 15 
MES 
*HAMD (17 
items) 
MES 
6 weeks Moderate 
Majumdar & 
Morris, 2019 
Outpatient, 
Wales 
Subjects, N= 26 
(65.3) 
Control, N=27 
(60.0) 
Acceptance and 
Commitment 
Therapy Group, 2 
hours, weekly (26)/ 
Treatment as usual 
(27) 
N/A PHQ-9 4 weeks High 
Mitchell et al., 
2009 
Inpatient, 
USA 
Subjects, N=44 
(57) 
Control, N=48 (57) 
Psychological- 
behavioural plus 
antidepressant (44)/ 
Treatment as usual, 
plus antidepressant 
(48) 
GDS 11 
DISH 
DSM-IV 
HDRS 8 weeks High 
Raffaele et al., 
1996 
N/A, 
Italy 
Subjects, N=11 
(69.5) 
Control, N=11 
(70.4) 
Trazodone (11)/ 
Placebo (11) 
DSM-III-R ZDS 45 days High 
Raglio et al., 
2017 
Inpatient, 
Italy 
Subjects, N=19 
(70.4) 
Control, N=19 
(75.4) 
Relational active 
music therapy (19)/ 
Treatment as usual 
(19) 
N/A HADS-D 6-8 weeks Moderate 
Robinson et al., 
2000 
Hospitals, 
USA & 
Argentina 
Subjects, 
Fluoxetine N=23 
(65) 
Fluoxetine (23)/ 
Nortriptyline (16)/ 
Placebo (17) 
DSM-IV, 
HAMD (28 items) 
 12 
HAMD (28 
items) 
12 weeks High 
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Subjects, 
Nortriptyline N=16 
(64) 
Control, N= 17 
(73) 
Thomas et al., 
2012 
Outpatient / 
community, 
UK 
Subjects, N= 43 
(68.5) 
Control, N=46 
(65.5) 
Behavioural therapy 
(43)/ 
Treatment as usual 
(46) 
SAD-Q  6 
Visual analogue 
mood scale (‘sad’ 
items)  50 
*SAD-Q 
Visual 
analogue 
mood scale 
(‘sad’ items) 
3 months Moderate 
Thomas et al., 
2019 
Community, 
UK 
Subjects, N=25 
(62.6) 
Control, N=23 
(68.8) 
Behavioural 
activation therapy 
(25)/ 
Treatment as usual 
(23) 
PHQ-9  10 
Visual analogue 
mood scale (‘sad’ 
items) 50 
*PHQ-9 
SAD-Q 
Visual 
analogue 
mood scale 
(‘sad’ items) 
4 months Moderate 
Wiart 2000 Inpatient, 
France 
Subjects, N=16 
(66.3) 
Control, N=15 
(68.9) 
Fluoxetine (16)/ 
Placebo (15) 
ICD-10 
MADRS 19 
MADRS 45 days Low 
Zhang et al., 
2013 
Inpatient, 
China 
Subjects, N=48 
(64.1) 
Control, N=49 
(64.7) 
Duloxetine (48)/ 
Treatment as usual 
(49) 
DSM-IV 
HAMD-17 
HAMD 12 weeks Low 
DSM-III/R, Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., revised; DSM-IV, Diagnostic and Statistical Manual of Mental 
Disorders; HAMD, Hamilton Depression Scale, ICD, International Classification of Diseases; MADRS, Montgomery Asberg Depression Rating 
Scale; ZDS, Zung Depression Scale; BDI, Beck Depression Inventory; DASS-42, Depression, Anxiety Stress scale, 42-item; GDS-15, MES, 
Bech-Rafaelsen Melancholia Scale (MES); GDS-15, Geriatric Depression Scale, 15-item; HDRS, Hamilton Depression Rating Scale; MES, 
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Melancholia Scale; WDI, Wakefield Depression Inventory; DISH, Diagnostic Interview and Structured Hamilton; SAD-Q, Stroke Aphasic 
Depression Questionnaire (10-item), MINI, Mini-International Neuropsychiatry Interview; Where multiple measures were used, * denotes the 
selected measure based on its frequency used in the selected articles. 
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Table 2. Description of PSA papers selected and included in network meta-analyses 
 
 
Study author, Year Setting, 
Country 
Stroke 
participants, N 
(mean age) 
Intervention / control (N) Diagnostic 
criteria 
(anxiety) 
Outcome 
rating 
scale 
Treatment 
duration 
Quality 
Rating 
Aidar et al., 2013 Community, 
Brazil 
Subjects, N=15 
(50.3) 
Control, N=13 
(52.5) 
Aquatic exercise (15)/ 
No intervention (13) 
N/A *IDATE 
(STAI) I 
(State) 
IDATE 
(STAI) II 
(Trait) 
12 weeks Moderate 
Aidar et al., 2018 Community, 
Brazil 
Subjects, N=19 
(51.8) 
Control, N=17 
(52.7) 
Aquatic exercise (19)/ 
No intervention (17) 
N/A *IDATE 
(STAI) I 
(State) 
IDATE 
(STAI) II 
(Trait) 
12 weeks High 
Golding, Kneebone 
& Fife-Shaw, 2016 
Community, 
UK 
Subjects, N=9 
(67.8) 
Control, N=10 
(62.4) 
Self-help relaxation training, 
20 minutes, 5 times a week 
(9)/ 
No intervention (10) 
HADS-A  6 HADS-A 3 months Low 
Immink, Hillier & 
Petkov, 2014 
Community 
Australia 
Subjects, N= 10 
(56.1) 
Control, N=10 
(63.2) 
Yoga intervention (11)/ 
No intervention (10) 
N/A *IDATE 
(STAI) I 
(State) 
IDATE 
(STAI) II 
(Trait) 
10 weeks Low 
Karaiskos et al. 
2012 
Outpatient, 
Greece 
Subjects, N= 20 
(51.1) 
Duloxetine, 60-12mg daily 
(20)/ 
Citalopram, 20-40mg daily 
(20)/ 
N/A HAM-A 3 months Low 
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  Control 
(Citalopram), 
N=20 (54.3), 
Control 
(Sertraline), 
N=20 (52.4) 
Sertraline, 50-200mg daily 
(20) 
    
Kerr, McCann, 
Mackey & 
Wijeratne, 2017 
Inpatient 
(multi- 
centre), 
Australia 
Subjects, N= 18 
(66.4) 
Control, N=20 
(69.9) 
Motivational interviewing, 
30 minutes, 3 sessions (18)/ 
Treatment as usual (20) 
N/A HADS 3 days Low 
Kongkasuwan et al., 
2016 
Inpatient, 
Thailand 
Subjects, N= 54 
(67.1) 
Control, N=59 
(65.5) 
Creative art therapy, twice a 
week (54)/ 
Treatment as usual (59) 
N/A HADS 4 weeks Moderate 
Kotov, Isakova & 
Sheregeshev, 2020 
Inpatient, 
Russia 
Subjects, N= 50 
(65.02) 
Control, N=50 
(64.8) 
Mechanotherapy, 30 
minutes daily (50/ 
Treatment as usual (50) 
N/A BAS 2 weeks Low 
Majumdar & 
Morris, 2019 
Outpatient, 
Wales 
Subjects, N= 26 
(65.3) 
Control, N=27 
(60.0) 
Acceptance and 
Commitment Therapy 
Group, 2 hours, weekly 
(26)/ 
Treatment as usual (27) 
N/A GAD-7 4 weeks Low 
Wu et al., 2012 Inpatient, 
China 
Subjects, N= 60 
(56.1) 
Control, N=60 
(56.7) 
Psychological intervention, 
20 minutes, 5 times a week 
(60)/ 
Treatment as usual (60) 
N/A SCL-90 3 weeks Low 
Zeng et al., 2018 Inpatient, 
China 
Subjects, N= 59 
(67.92) 
Control, N= 53 
(66.13) 
Neuromuscular electrical 
stimulation (59)/ 
Treatment as usual (53) 
N/A HAM-A 12 days Moderate 
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HADS-A, Hospital Anxiety and Depression Scale – Anxiety subscale; IDATE I & II, Trace State Anxiety Inventory/ State-Trait Anxiety Inventory- 
STAI: Form Y; GAD-7, Generalized Anxiety Disorder-7 measure; SCL-90, Symptom Check List-90 item; HAMA, Hamilton Anxiety Scale; Where 
multiple measures were used, * denotes the selected measure based on its frequency used in the selected articles. 
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Table 3. Description of PSE papers selected, not included in network meta-analyses 
 
 
Study 
author, 
Year 
Setting, 
Country 
Stroke 
participants, N 
(mean age) 
Intervention 
/ control (N) 
Diagnostic criteria Outcome 
rating scale 
Treatment 
duration 
Quality 
Rating 
Andersen 
1993 
Inpatient, 
Denmark 
Subjects, N= 
16, No 
Control 
Group 
Citalopram, 
10/20mg 
daily, 
Placebo 
Lawson & Macleod semi- 
structured interview 
Qualitative clinical evaluation 
Frequency of crying scale 
Crying episode context scale 
Patient-recorded diary 
Number of 
crying 
episodes 
21 days Low 
Brown, 
Sloan & 
Pentland, 
1998 
Inpatient, 
Scotland 
Subjects, N=9 
(61.4) 
Controls, N=10 
(63.7) 
Fluoxetine, 
20mg daily 
(9)/ 
Placebo (10) 
DSM-III-R, 
History of emotionalism of at 
least 4 weeks 
*Hamilton 
Rating 
Scale, 
Lawson and 
MacLeod 
rating scale 
10 days Low 
Burns et 
al., 1999 
Inpatient / 
Outpatient / 
Community, 
England 
Subjects, N=11 
(73.4) 
Controls, N=12 
(67.6) 
Sertraline, 
50mg daily 
(11)/ 
Placebo (12) 
Presence of lability of mood 
observed by the referring 
clinician 
Lability 
Scale 
(House et 
al., 1989), 
CIBIC, 
*MADRS 
8 weeks Moderate 
Choi- 
Kwon et 
al., 2006 
Outpatient 
clinics, South 
Korea 
Subjects, N=19 
(58.41) 
Controls, N=12 
(58.18) 
Fluoxetine, 
20mg daily 
(19)/ 
Placebo (32) 
Presence of PSEI considered if 
patients exhibited excessive or 
inappropriate laughing (EIL), 
crying (EIC), or both, reported 
on  2 occasions by the patient 
or their relative 
*VAS 3 months Moderate 
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CIBIC, Clinician’s Interview-Based Impression of Change;MADRS, Montgomery and Asberg Depression Rating Scale; VAS, Visual Analogue 
Scale, Where multiple measures were used, * denotes the selected measure based on its frequency used in the selected articles and availability of 
interpretable data. 
 
 
 
Network groups 
 
 
The interventions from the articles identified for this paper were not able to form a singular network within each mood domain, but 
instead three sub-networks were identified for PSD and two sub-networks for PSA. It was not possible to form a network for PSE interventions. 
These sub-networks are separated by means of the type of control group treatment, that is used as the reference group for each network. The 
geometrical relationships between the interventions are depicted in Figure 2, where a ‘drug placebo’ is the basis for PSD sub-network one 
(Figure 2a), ‘treatment as usual’ for PSD sub-network two (Figure 2b) and ‘experimental placebo’(placebo or sham treatment) for PSD sub-
network three (Figure 2c) is the reference control group. Similar cases can be seen with ‘no intervention’ for PSA sub-network one (Figure 2d) 
and ‘treatment as usual’ for PSA sub- network two (Figure 2e). The shaded areas in the figures indicate multi-arm studies between the 
treatments. 
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Figure 2. Sub-network groups for PSD, & PSA 
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It was not possible to fit interventions from Andersen (1994) and Lauritzen (1994) 
from the PSD studies, as well as Karaiskos et al. (2012) from PSA studies into any of the 
above networks. For these studies, neither its treatment nor control conditions matched any 
study arms from the other papers. Therefore, analyses of these studies were excluded. 
 
 
Pairwise and network result 
Post-Stroke Depression 
Three sub-networks were identified for network meta-analysis of the post-stroke 
depression interventions. The first network consists of seven studies, comprising  ten 
treatments and thirteen pairwise comparisons, with Placebo (Drug) conditions as the 
reference control. This network includes studies primarily evaluating pharmacological 
treatments, as well as CBT, which was the only psychological treatment that had been 
considered in a placebo- controlled trial. The results of pairwise comparisons and calculated 
standardized mean difference (SMD) based on a random effects model is shown in Table 4. 
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Table 4. Pairwise comparisons based on the random effects model for PSD sub-network one 
 
Study Treatment Control Standardized 
Mean 
Difference, 
SMD 
95% Confidence Intervals 
    Lower Upper 
*Gao et al., 
2017 
Citalopram Placebo 
(Drug + 
Experiment) 
0.0341 -2.0226 2.0908 
*Gao et al., 
2017 
Citalopram CBT 0.0002 -2.0563 2.0567 
*Gao et al., 
2017 
CBT Placebo 
(Drug + 
Experiment) 
0.0339 -2.0227 2.0905 
*Karaiskos, 
2012 
Citalopram Duloxetine 0.2950 -1.8342 2.4242 
*Karaiskos, 
2012 
Citalopram Sertraline -0.1762 -2.3048 1.9524 
*Karaiskos, 
2012 
Duloxetine Sertraline -0.4712 -2.6023 1.6599 
Cravello, 
2009 
Fluoxetine Venlafaxine -1.7499 -3.8886 0.3888 
*Robinson, 
2000 
Fluoxetine Nortriptyline 0.6844 -1.3555 2.7242 
*Robinson, 
2000 
Fluoxetine Placebo 
(Drug) 
-0.0519 -1.5903 1.4865 
*Robinson, 
2000 
Nortriptyline Placebo 
(Drug) 
-0.7363 -2.7761 1.3035 
Raffaele 
1996 
Placebo 
(Drug) 
Trazodone 1.2319 -1.0013 3.4651 
Wiart, 2000 Fluoxetine Placebo 
(Drug) 
-0.0519 -1.5903 1.4865 
Zhang, 2013 Duloxetine Placebo 
(Drug) 
-1.0393 -3.1191 1.0405 
* signifies multi-arm studies, for which standard error was corrected 
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Table 5. Summary treatment estimates and credible intervals from network meta-analysis of treatment effects, PSD sub-network one. 
 
Citalopram 0.00 (-0.29; 0.29) 0.28 (-0.35; 0.90) . . 0.03 (-0.26; 0.32) . -0.16 (-0.78; 0.46) . . 
0.00 (-0.29; 0.29) Cognitive 
Behavioural 
Therapy 
. . . 0.03 (-0.26; 0.32) . . . . 
0.29 (-0.33; 0.92) 0.29 (-0.39; 0.98) Duloxetine . . . -1.04(-1.46; -0.61) -0.49 (-1.12; 0.14) . . 
-0.63 (-1.56; 0.30) -0.63 (-1.60; 0.34) -0.93 (-1.61; -0.24) Fluoxetine 0.81 (0.03; 1.60) . 0.01 (-0.53; 0.55) . . -1.75 (-2.40; -1.10) 
0.02 (-1.03; 1.07) 0.02 (-1.07; 1.11) -0.27 (-1.12; 0.57) 0.65 (-0.08; 1.38) Nortriptyline . -0.61(-1.39; 0.18) . . . 
0.03 (-0.26; 0.32) 0.03 (-0.26; 0.32) -0.26 (-0.95; 0.43) 0.67 (-0.31; 1.64) 0.01 (-1.08; 1.10) Placeb o (Drug + 
Experiment) 
. . . . 
-0.74 (-1.50; 0.01) -0.74 (-1.55; 0.06) -1.04 (-1.46; -0.61) -0.11 (-0.65; 0.43) -0.77 (-1.50; -0.04) -0.78(-1.59; 0.03) Placebo (Drug) . 1.23 (0.31; 2.15) . 
-0.18 (-0.80; 0.44) -0.18 (-0.86; 0.51) -0.47 (-1.10; 0.16) 0.46 (-0.48; 1.39) -0.20 (-1.25; 0.86) -0.21(-0.90; 0.48) 0.57 (-0.19; 1.33) Sertraline . . 
0.49 (-0.70; 1.67) 0.49 (-0.73; 1.71) 0.19 (-0.82; 1.20) 1.12 (0.05; 2.18) 0.47 (-0.71; 1.64) 0.45 (-0.77; 1.68) 1.23 (0.31; 2.15) 0.66 (-0.53; 1.85) Trazodone . 
-2.38 (-3.52; -1.25) -2.38 (-3.55; -1.21) -2.68 (-3.63; -1.73) -1.75 (-2.40; -1.10) -2.40 (-3.38; -1.42) -2.42(-3.59; -1.24) -1.64 (-2.49; -0.79) -2.21 (-3.34; -1.07) -2.87 (-4.12; -1.62) Venlafaxine 
 
Table 5 reports a summary of direct and indirect treatment estimate results from the network meta-analysis. Treatment interventions are 
reported with outcomes of standardized mean differences (SMDs; 95% confidence intervals). Comparisons between treatments should be read 
from left to right and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment.  
This table shows when two treatments have been directly compared against each other in the literature. This information is displayed in 
the upper- right triangle of the table, displaying the pooled effect sizes of the direct comparisons available in the network, as one would obtain 
from performing a conventional meta-analysis for each comparison.  
The data in the boxes in the lower-left triangle of the table contains the indirect network meta-analysis effect sizes estimated for each 
comparison. This provides a calculated estimate of how two treatments may compare against each other, despite having not yet been compared 
to in existing research literature.  
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Overall, this table shows all the possible comparisons within this network in terms of its relative effectiveness (reported as estimated 
SMDs and confidence intervals) against the different interventions, whether as a product of a direct or indirect pooled estimate.   
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Table 6. Treatment ranking efficacy of interventions from the first PSD subnetwork 
 
Intervention P-score N, appearances in the 
network 
Trazodone 0.6889 1 
Duloxetine 0.6674 3 
Nortriptyline 0.5856 2 
Placebo (Drug + 
Experiment) 
0.5671 2 
Citalopram 0.5640 4 
Cognitive 
Behavioural 
Therapy 
0.5576 2 
Sertraline 0.5139 2 
Fluoxetine 0.3999 4 
Placebo (Drug) 0.3622 5 
Venlafaxine 0.0935 1 
 
 
Using frequentist modelling, the network meta-analysis calculated a prediction of 
treatment ranking using the data available from the selected studies. This was done using P- 
scores (measured from a score of 0-1, where a higher score indicates better efficacy) to 
measure the extent that one treatment is relatively better than the other, averaging over all 
competing treatments. 
Within this network, Trazodone (P= 0.6889) ranked the highest, shortly followed by 
Duloxetine, at face value suggesting that these may be the most helpful treatments. 
Conversely, Venlafaxine ranked the lowest at P=0.0935, indicating that it may be the least 
efficacious of this network. However, these estimates should be interpreted with caution, 
taking into account the small number of studies and sample size of each intervention arm in 
forming this result. A network forest plot (Figure 3) is graphed against Placebo (Drug). 
This shows that several high-performing treatments have widely overlapping confidence 
intervals. 
The network estimates presented assimilates data from both direct and indirect 
estimates. A visual depiction of this can be found as Appendix H, and a detailed evidence 
plot of direct and indirect estimates for this network can be found at Appendix G. 
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Figure 3. Forest plot for PSD subnetwork one 
 
 
 
 
 
 
 
 
 
 
 
The second sub-network for PSD interventions consists of twelve studies, of which 
thirteen treatments are analysed with fourteen pairwise comparisons, with ‘Treatment as 
Usual’ (TAU) control as the reference. The results of pairwise comparisons and calculated 
effect size for each comparison are listed in Table 7. 
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Table 7. Pairwise comparisons based on the random effects model for PSD sub-network two 
 
Study Treatment Control Standardized 
Mean 
Difference, 
SMD 
95% Confidence Intervals 
    Lower Upper 
Aidar, 2013 Aquatic 
Exercise 
No 
Intervention 
-0.4891 -0.9878 0.0096 
Aidar, 2018 Aquatic 
Exercise 
No 
Intervention 
-0.2891 -0.9878 0.0096 
*Hoffman, 
2015 
Coping Skills 
Group 
Self- 
management 
group 
-0.3135 -1.1373 0.5103 
*Hoffman, 
2015 
Coping Skills 
Group 
Treatment As 
Usual 
-0.5877 -1.4633 0.2878 
*Hoffman, 
2015 
Self- 
management 
Group 
Treatment As 
Usual 
-0.2743 -1.1180 0.5695 
Holmgren, 
2010 
Exercise No 
Intervention 
-0.2816 -0.9986 0.4354 
Kerr, 2017 Motivational 
Interviewing 
Treatment As 
Usual 
-0.1021 -0.7654 0.5612 
Kirkness, 
2017 
Psychosocial 
Intervention 
Treatment As 
Usual 
-0.1019 -0.5654 0.3616 
Lai, 2005 Exercise Treatment As 
Usual 
-0.1444 -0.5521 0.2633 
Majumdar, 
2019 
Group 
Acceptance 
Commitment 
Therapy 
Treatment As 
Usual 
-0.2077 -0.7477 0.3323 
Mitchell, 
2009 
Psychological 
Behavioural 
Treatment As 
Usual 
0.0458 -0.3448 0.4364 
Ragalio, 2017 Relational 
Active Music 
Therapy 
Treatment As 
Usual 
0.0409 -0.5951 0.6769 
Thomas, 
2012 
Behavioural 
Therapy 
Treatment As 
Usual 
-0.4574 -0.8990 -0.0158 
Thomas, 
2019 
Behavioural 
Activation 
Therapy 
Treatment As 
Usual 
-0.7027 -1.3520 -0.0534 
* signifies multi-arm studies, for which standard error was corrected 
 
 
Table 8 reports a summary of direct and indirect treatment estimate results from the 
network meta-analysis. 
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Table 8. Summary treatment estimates and credible intervals from network meta-analysis of treatment effects, PSD sub-network two. 
 
Aquatic Exercise . . . . . . -0.49 (-0.99; 0.01) . . . . . 
0.35 (-0.81; 1.51) Behavioural 
Activation Therapy 
. . . . . . . . . . -0.70 (-1.35; -0.05) 
0.11 (-0.95; 1.17) -0.25 (-1.03; 0.54) Behavioural Therapy . . . . . . . . . -0.46 (-0.90; -0.02) 
0.24 (-1.07; 1.54) -0.11 (-1.20; 0.98) 0.13 (-0.85; 1.11) Coping Skills 
Group 
. . . . . . . -0.32 (-1.15; 0.50) -0.58 (-1.45; 0.30) 
-0.21 (-1.08; 0.67) -0.56 (-1.33; 0.21) -0.31 (-0.91; 0.29) -0.44 (-1.41; 0.52) Exercise . . -0.28 (-1.00; 0.44) . . . . -0.14 (-0.55; 0.26) 
-0.14 (-1.25; 0.96) -0.50 (-1.34; 0.35) -0.25 (-0.95; 0.45) -0.38 (-1.41; 0.65) 0.06 (-0.61; 0.74) Group 
Acceptance 
Commitment 
Therapy 
. . . . . . -0.21 (-0.75; 0.33) 
-0.25 (-1.42; 0.92) -0.60 (-1.53; 0.33) -0.36 (-1.15; 0.44) -0.49 (-1.58; 0.61) -0.04 (-0.82; 0.74) -0.11 (-0.96; 0.75) Motivational 
Interviewing 
. . . . . -0.10 (-0.77; 0.56) 
-0.49 (-0.99; 0.01) -0.84 (-1.89; 0.21) -0.59 (-1.53; 0.34) -0.72 (-1.93; 0.48) -0.28 (-1.00; 0.44) -0.34 (-1.33; 0.64) -0.24 (-1.30; 0.82) No 
intervention 
. . . . . 
-0.40 (-1.44; 0.64) -0.75 (-1.51; 0.01) -0.50 (-1.09; 0.09) -0.63 (-1.59; 0.33) -0.19 (-0.75; 0.37) -0.25 (-0.92; 
0.41) 
-0.15 (-0.92; 0.62) 0.09 (-
0.82; 1.00) 
Psychological 
Behavioural 
. . . 0.05 (-0.34; 0.44) 
-0.25 (-1.32; 0.82) -0.60 (-1.40; 0.20) -0.36 (-1.00; 0.28) -0.49 (-1.48; 0.50) -0.04 (-0.66; 0.57) -0.11 (-0.82; 0.61) -0.00 (-0.81; 0.81) 0.24 (-
0.71; 1.19) 
0.15 (-0.46; 0.75) Psychosocial 
intervention 
. . -0.10 (-0.57; 0.36) 
-0.39 (-1.55; 0.76) -0.74 (-1.65; 0.17) -0.50 (-1.27; 0.28) -0.63 (-1.71; 0.45) -0.19 (-0.94; 0.57) -0.25 (-1.08; 
0.59) 
-0.14 (-1.06; 0.78) 0.10 (-
0.95; 1.14) 
0.00 (-0.74; 0.75) -0.14 (-0.93; 0.64) Relational Active 
Music Therapy 
. 0.04 (-0.60; 0.68) 
-0.08 (-1.36; 1.20) -0.43 (-1.49; 0.64) -0.18 (-1.14; 0.77) -0.31 (-1.14; 0.51) 0.13 (-0.81; 1.07) 0.07 (0.94; 
1.07) 
0.17 (-0.90; 1.25) 0.41 (- 
0.77; 1.59) 
0.32 (-0.61; 1.25) 0.17 (-0.79; 1.14) 0.32 (-0.74; 1.37) Self- 
management 
group 
-0.28 (-1.13; 0.56) 
-0.35 (-1.32; 0.61) -0.70 (-1.35; -0.05) -0.46 (-0.90; -0.02) -0.59 (-1.46; 0.29) -0.14 (-0.55; 0.26) -0.21 (-0.75; 0.33) -0.10 (-0.77; 0.56) 0.14 (- 
0.69; 0.96) 
0.05 (-0.34; 0.44) -0.10 (-0.57; 0.36) 0.04 (-0.60; 0.68) -0.27 (-1.12; 0.57) Treatment As Usual 
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Table 9. Treatment ranking for efficacy of interventions, PSD subnetwork two 
 
Intervention P-score N, number of 
appearances in the 
network 
Behavioural Activation 
Therapy 
0.8574 1 
Coping Skills Group 0.7678 2 
Behavioural Therapy 0.7407 1 
Aquatic Exercise 0.6236 2 
Self-management group 0.5525 2 
Group Acceptance 
Commitment Therapy 
0.5210 1 
Exercise 0.4681 2 
Motivational Interviewing 0.4266 1 
Psychosocial intervention 0.4228 1 
Relational Active Music 
Therapy 
0.3067 1 
Treatment As Usual 0.2987 10 
Psychological Behavioural 0.2735 1 
No intervention 0.2406 3 
 
 
Frequentist treatment ranking was calculated using P-scores for prediction of efficacy 
of these treatments relative to each other (Table 9). Behaviour Activation Therapy (P= 
0.8574) ranked the highest, a face value indicating that it may be the most helpful treatment. 
Conversely, ‘No Intervention’ ranked the lowest at P=0.2406, indicating that it may be the 
least efficacious of this network. Again, these estimates should be interpreted with caution, 
taking into account the number of studies and limited sample size of each intervention arm in 
forming this result. As seen in Table 9, most estimated treatment effects were derived from 
direct effects reported in a single study. Further, when a network forest plot (Figure 4) is 
graphed against ‘Treatment As Usual’, again there is evidence that all treatment have widely 
overlapping confidence intervals. 
A detailed evidence plot of direct and indirect estimates for this network can be 
found at Appendix H. 
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Figure 4. Forest plot, PSD subnetwork two 
 
 
 
 
 
 
 
 
 
The third sub-network for PSD interventions consists of two studies, of which four 
treatments are analysed with four pairwise comparisons, with ‘Placebo (Experiment)’ control 
as the reference. The results of pairwise comparisons and calculated effect size for each 
comparison are listed in Table 10. This network details the efficacy of low and high 
frequency rTMS interventions.. A ‘Placebo Experiment’ group describes a sham intervention 
treatment commonly used in TMS studies. 
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Table 10. Pairwise comparisons based on the random effects model for PSD sub- 
network three 
Study Treatment Control Standardized Mean 
Difference, SMD 
95% Confidence 
Intervals 
    Lower Upper 
Gu2017 Placebo 
(Experiment) 
rTMS(high) 2.0048 1.1918 2.8179 
*Kim2010 rTMS(low) rTMS(high) 1.8244 0.6858 2.9629 
*Kim2010 Placebo 
(Experiment) 
rTMS(low) 0.1805 -0.8810 1.2420 
*Kim2010 Placebo 
(Experiment) 
rTMS (high) 2.0048 1.1918 2.8179 
* signifies multi-arm studies, for which standard error was corrected 
 
 
Table 11 reports a summary of direct and indirect treatment estimate results from the 
network meta-analysis. 
 
 
 
Table 11. Summary treatment estimates and credible intervals from network meta- 
analysis of treatment effects, PSD sub-network three. 
Placebo 
(Experiment) 
0.02(-1.11; 1.15) 2.03 (1.22; 2.84) 
0.18 (-0.88; 1.24)  rTMS 
(low) 
1.56 (0.24; 2.87) 
2.00 (1.19; 2.82) 1.82 (0.69; 2.96)   rTMS(high) 
 
 
 
Frequentist treatment ranking was calculated using P-scores for prediction of efficacy 
of these treatments relative to each other. As shown in Table 12, rTMS (high), where the 
frequency is at 10Hz ranked the highest (P= 0.9996), indicating that it may be the most 
helpful treatment, compared to rTMS (low) (1 Hz), P=0.3157 and Placebo (Experiment), 
P=0.1847. This difference is depicted in a network forest plot (Figure 5), where rTMS (low) 
and rTMS (high) are graphed against Placebo (Experiment). 
136 
 
 136 
 
 
Table 12. Treatment ranking for efficacy of interventions in PSD subnetwork three 
 
 P-score N, number of 
appearances in the 
network 
rTMS(high) 0.9996 3 
rTMS (low) 0.3157 2 
Placebo (Experiment) 0.1847 3 
 
 
 
Figure 5. Forest plot, PSD subnetwork three 
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Post-Stroke Anxiety 
 
 
Network meta-analysis of the post-stroke anxiety articles identified two sub-networks. 
The first network consists of four studies, comprising  four treatments and pairwise 
comparisons, with ‘No Interventions’ condition as the reference control. The results of 
pairwise comparisons are shown in Table 13. 
 
 
Table 13. Pairwise comparisons based on the random effects model for PSA sub- 
network one 
Study Treatment Control Standardized 
Mean 
Difference, 
SMD 
95% Confidence Intervals 
    Lower Upper 
Aidar 2013 Aquatic 
Exercise 
No 
Intervention 
-0.4504 -0.9485 0.0477 
Aidar 2018 Aquatic 
Exercise 
No 
Intervention 
-0.4504 -0.9485 0.0477 
Golding 
2016 
No 
Intervention 
Self-help 
relaxation 
1.0292 0.0657 1.9927 
Imink 2014 No 
Intervention 
Yoga 0.6227 -0.2150 1.4604 
 
 
 
Table 14 reports a summary of direct and indirect treatment estimate results from the 
network meta-analysis. 
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Table 14. Summary treatment estimates and credible intervals from network meta- 
analysis of treatment effects, PSA sub-network one. 
Aquatic 
Exercise 
-0.45 (- 
0.95; 0.05) 
. . 
-0.45 (- 
0.95; 0.05) 
No 
Intervention 
1.03 ( 0.07; 
1.99) 
0.62 (- 0.21; 
1.46) 
0.58 (- 0.51; 
1.66) 
1.03 ( 0.07; 
1.99) 
Self-help 
Relaxation 
. 
0.17 (- 0.80; 
1.15) 
0.62 (- 0.21; 
1.46) 
-0.41 (-1.68; 0.87) Yoga 
 
 
 
Table 15. Treatment ranking for efficacy of treatments, PSA subnetwork one 
 
Intervention P-score N, number of 
appearances in the 
network 
Self-help 
Relaxation 
0.8559 1 
Yoga 0.6097 1 
Aquatic 
Exercise 
0.4914 2 
No 
Intervention 
0.0430 4 
 
 
Frequentist treatment ranking was calculated using P-scores for prediction of efficacy 
of these treatments relative to each other. Self-help relaxation ranked the highest (P= 0.8559), 
indicating that it may be the most helpful treatment, whereas ‘no intervention’ ranked the 
lowest (0.0430), as shown on Table 15. The treatment estimates are visualised in Figure 6, 
where a forest plot is graphed against ‘No Intervention’. 
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Figure 6. Forest plot, PSA subnetwork one 
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The second PSA subnetwork consists of six studies, comprising seven treatments 
and six pairwise comparisons, with ‘Treatment As Usual’ condition as the reference control. 
The results of pairwise comparisons shown in Table 16. 
 
 
Table 16. Pairwise comparisons based on the random effects model for PSA sub-network two 
 
Study Treatment Control Standardized 
Mean 
Difference, 
SMD 
95% 
Confidence 
Intervals 
    Lower Upper 
Kerr 2017 Motivational 
Interviewing 
Treatment 
As Usual 
0.0494 -0.5874 0.6862 
Kongkasuwan 
2016 
Physical therapy 
+ Creative Art 
Treatment 
As Usual 
-0.0239 -0.3930 0.3452 
Kotov 2020 Mechanotherapy Treatment 
As Usual 
0.3481 -0.0468 0.7430 
Majumdar 
2019 
Group ACT Treatment 
As Usual 
0.2952 -0.2463 0.8367 
Wu 2012 Psychological 
Intervention 
Treatment 
As Usual 
2.4294 1.8412 3.0176 
Zheng2018 Neuromuscular 
Electrical 
Stimulation 
Treatment 
As Usual 
-0.4686 -0.8447 -0.0925 
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Table 17 reports a summary of direct and indirect treatment estimate results from the 
network meta-analysis. 
 
 
Table 17. Summary treatment estimates and credible intervals from network meta- 
analysis of treatment effects, PSA sub-network two. 
Group ACT . . . . . 0.30  
(- 0.25; 
0.84) 
-0.05 (- 
0.72; 0.62) 
Mechanotherapy . . . . 0.35 (- 
0.05; 0.74) 
0.25 (- 
0.59; 1.08) 
0.30 (-0.45; 1.05) Motivational 
Interviewing 
. . . 0.05 (- 
0.59; 0.69) 
0.76 ( 
0.10; 1.42) 
0.82 ( 0.27; 1.36) 0.52 (- 
0.22; 1.26) 
Neuromuscular 
Electrical Stimulation 
. . -0.47 (-0.84; - 
0.09) 
0.32 (- 
0.34; 0.97) 
0.37 (-0.17; 0.91) 0.07 (-0.66; 0.81) -0.44 (-0.97; 0.08) Physical therapy 
+ Creative Art 
. -0.02 (- 
0.39; 0.35) 
-2.13 (-2.93; 
-1.33) 
-2.08 (-2.79; - 
1.37) 
-2.38 (-3.25; - 
1.51) 
-2.90 (-3.60; -2.20) -2.45 (-3.15; - 
1.76) 
Psychological 
Intervention 
2.43 ( 
1.84; 3.02) 
0.30 (- 
0.25; 0.84) 
0.35 (-0.05; 0.74) 0.05 (- 
0.59; 0.69) 
-0.47 (-0.84; -0.09) -0.02 (- 
0.39; 0.35) 
2.43 ( 1.84; 3.02) Treatment As 
Usual 
 
 
 
 
 
 
 
Table 18. Treatment ranking for efficacy of treatments, PSA subnetwork two 
 
 P-score N, number of 
appearances in the 
network 
Neuromuscular 
Electrical Stimulation 
0.9742 1 
Physical therapy + 
Creative Art 
0.6530 1 
Treatment As Usual 0.6388 6 
Motivational 
Interviewing 
0.5746 1 
Group ACT 0.3613 1 
Mechanotherapy 0.2980 1 
Psychological 
Intervention 
0.0000 1 
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Frequentist treatment ranking was calculated using P-scores for prediction of efficacy 
of these treatments relative to each other, neuromuscular electrical stimulation ranked the 
highest (P= 0.9742), indicating that it may be the most helpful treatment, whereas 
psychological intervention ranked the lowest (P= 0.000), as shown on Table 18. The relative 
treatment estimates are visualised in Figure 7, where a forest plot is graphed against 
‘Treatment As Usual’. 
 
 
 
Figure 7. Forest plot, PSA subnetwork two 
 
 
 
 
 
 
 
Tests of heterogeneity & publication bias 
 
 
Within PSD sub-network one, tests of heterogeneity in this network were very high, 
I2= 87.6%, confirming that a random-effects model is warranted. The heterogeneity between 
treatment designs reflects the actual inconsistency in this network and is highly significant 
(p=0.0015). This high degree of heterogeneity is not unexpected in an NMA, considering 
the variability of studies being compared in the network. The I2 was unable to be calculated 
for PSD sub-networks two and three due to the small number of informative designs. 
 
To assess publication bias of the network, a comparison-adjusted funnel plot was generated. 
Funnel plots for PSD sub-network group one and two can be found as Appendix I, showing 
no evidence of publication bias or small study effects. Additionally, Egger’s Test statistic was 
available for PSD sub-network one (p=0.976) and two (p=0.8051), suggesting that funnel 
asymmetry is not present, indicating no publication bias. 
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Discussion 
 
 
This multi-domain NMA provides an overarching view of the existing body of literature 
about the current treatment (pharmacological and non-pharmacological) of post-stroke mood 
disorders. First and foremost, a central finding was the disproportionate focus among the three 
mood domains. Whilst it is widely known that post-stroke depression makes up the majority 
of existing research, this was demonstrated through a systematic search in this paper. Initial 
searches for PSD papers returned 1578 articles, PSA with 541 articles and PSE with 49, and 
similar difference ratio was maintained at each step of the paper identification process. 
Although researchers have cited depression to be the most prevalent of the mood disorders 
after stroke (20%; Lanctot et al., 2019), the prevalence of anxiety (20-25%; Campbell Burton 
et al., 2013) and emotionalism (one in five survivors; Gillespie et al., 2018) after stroke remains 
significant. In fact, stroke clinicians have known that emotionalism tends to go under- 
recognised (Allida et al., 2019) and can be misdiagnosed for depression. 
 
In the treatment of PSD, final network meta-analyses included twenty-three clinical trials, 
comprising  seven different pharmacological interventions, five types of control groups, three 
group interventions (one based on a specific psychological model), three different psychological 
therapies, two exercise interventions, two rTMS interventions (low/high frequency), one music 
therapy, one motivational interviewing, and one CBT intervention. The wide-ranging 
variability of interventions reflects the multitude of approaches to PSD, which in turn 
highlights the many factors that affect a person’s mood and provides stroke survivors and 
clinicians with many potential options for treatment. However, there is sparsity in evidence for 
these interventions. In the available literature, even the most frequently evaluated treatments 
for PSD, Citalopram and Fluoxetine, both appeared just four times within the network. 
Furthermore, psychological interventions are rarely considered against pharmacological 
interventions, and in only one case has CBT been considered in a placebo-controlled trial. 
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Without the availability of well researched, replicated and reported data to evidence these 
interventions, estimates of treatment effect and ranking that were performed in the network 
meta-analysis have to be interpreted with caution. Interventions that have stronger direct 
evidence from research (e.g. Citalopram and Fluoxetine) will produce more accurate 
predictions of indirect treatment estimates than those that are cited just once, using data from a 
small sample size. 
 
The same discretion should be made – and perhaps even to a greater degree- when 
interpreting the network analysis results of PSA interventions. From the ten analysed trials, 
three types of exercise/physical interventions, three broad ranges of psychological 
interventions (one group), one intervention combining art and physical therapy, one 
mechanotherapy and one neuromuscular stimulation were compared and grouped on two 
types of control groups. No interventions studied the efficacy of pharmacological 
interventions on PSA in our review. Similar to the results found in the PSD analyses, current 
evidence in the literature covers a wide range of interventions, with few or no replicated 
studies. 
 
Due to the unavailability of appropriate data, this paper could not review the evidence of 
PSE interventions in a network analysis. Unfortunately, the difficulty that exists with reviewing 
existing research for this domain echoes the comprehensive effort of Allida et al. (2019), who 
reported the lack of appropriately published data in emotionalism research. One potential 
drawback for PSE research at this stage is the absence of a standardised, reliable and valid tool 
to measure and outcome emotionalism. Although this paper did not analyse PSE data, the 
description of PSE studies included (Table 3) shows limitations in both diagnosing and rating 
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emotionalism. Many existing studies and clinical practice still rely on subjective ratings of 
crying or laughing frequency to determine PSE presence, or on the clinician (or researcher’s) 
subjective impression of this mood disorder. The lack of a theoretically derived, validated 
outcome measure for PSE will continue to hamper the work of researchers to determine 
evidence- based treatments and hamper the efforts of clinicians to accurately detect and 
manage this commonly occurring disorder. 
 
Overall, there exist many gaps and inconsistencies in the body of evidence considering 
psychological and emotional outcomes post-stroke, which is reflected in the limitations of this 
paper. In efforts to include the widest range of evidence available, we did not exclude trials 
based on the diagnostic criteria used or outcome measures reported, as other network meta- 
analyses on PSD have (Sun et al.,2017; Deng et al., 2017). This contributed to even more 
variability in the available data, not taking into account the variation arising from the use of 
different outcome measures of depression and anxiety. Other factors such as time since 
stroke, length of intervention and dose of medication may have added to the variability. 
 
Further, this review was not able to replicate the results reported by the NMAs 
mentioned or the findings from Wang et al.’s (2018) meta-analysis, which provided 
promising results on the effects of CBT on PSD. Unfortunately, most of the articles cited in 
Wang et al. (2018)’s paper were unavailable for interpretation in the present analysis. Most of 
these trials were conducted in China, published in journals that could not be accessed, or 
reported in Mandarin language. 
 
Although there appears to be a plethora of Traditional Chinese Medicine intervention 
studies relevant to post-stroke mood disorders, very few studies report their findings in English. 
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Moreover, of English-published papers reported by Wang et al. (2018)  in their CBT for PSD 
review, we could not include the important seminal research of Lincoln and Flannaghan 
(2003), who studied CBT against a placebo intervention and ‘treatment as usual’ control and 
the work of Kootker et al. (2017) - who tested augmented CBT intervention for PSD. Both 
these studies published outcome data on median values, which is not interpretable in this 
analysis. Such drawbacks may be due to the methodological limitations of choosing a 
network meta- analysis approach, as well as the lack of interpretable data reported by the 
authors. For example, studies that reported outcomes based on median values and percentage 
of change could not be included in this network meta-analysis and this is an important point to 
consider, for researchers in the field going forward. 
 
Additionally, the network meta-analysis reported here does not take into account 
reporting of adverse effects. This may be particularly important when talking about treatment 
efficacy of pharmacological interventions, whereby adverse effects may well have an impact 
on safety and a person’s decision to adhere to the medication. 
 
Conclusions and recommendations. 
 
This paper presents a review of existing research on the interventions for PSD, PSA and 
PSE. Given the limitations discussed, the estimates and rankings reported in this paper can 
only indicate the efficacy of treatments presented with minimal confidence, and only in 
relation to each other. It is also noted that all of the treatment estimates for both PSD and PSA 
interventions are reported with wide ranges in their confidence intervals, again reflecting the 
large extent of variance when it comes to interpreting the data. Nevertheless, this work 
provides a framework for further wide-scale network comparisons in treatment of post-stroke 
depression, anxiety and emotionalism. As it currently exists, NMAs within this field focus 
primarily on pharmacological interventions (Qin et al., 2018, Sun et al., 2017), whereas one 
NMA included only one psychological intervention in its comparisons (Deng et al., 2017). 
Within stroke services, psychological therapies are often employed in treating these mood 
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disorders – however, this is poorly reflected in the current literature. Moreover, as discussed 
in this paper, even the most commonly reported (pharmacological) interventions are not well 
studied with respect to the most common mood domain (PSD). 
 
There are several overarching recommendations that can be made in conclusion of this 
paper. First, it is hoped that additional research and future evidence on post-stroke mood 
intervention will continue to develop within the field. Additionally, standardised reporting of 
outcome measures will provide the necessary details for future reviews to be conducted 
successfully and conclusions to be drawn with more accuracy. The lack of a standard 
outcome measure of any sort currently, for PSE, is a good example. This paper recommends 
for future researchers that they report data that can be included in meta-analyses such as mean and 
standard deviation or standard error statistic of its outcomes, which is needed to calculate the 
SMD. 
 
Stroke occurs to more than 100,000 people every year in England (Burton & Tyson, 
2015). It is the fourth biggest cause of mortality in the UK and the second leading cause of 
death worldwide (Stroke Org, 2018). When such a traumatic and life-threatening occurrence 
can have a wide-ranging impact on our abilities and daily living, it is not surprising that it may 
have a profound impact on a person’s mood. Given the prevalence of stroke and the 
corresponding prevalence of post-stroke mood disorders, it is vitally important to study the 
existing interventions to enable clinicians to treat these conditions in the safest and most 
efficacious way. 
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CHAPTER FIVE: General discussion and critical review 
 
 
 
 
This chapter summarises the findings from both the systematic review and the 
empirical paper. A critical appraisal of themes within the papers is presented in the context of 
relevant literature.
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This thesis intended to explore the wide range of interventions currently employed in the 
treatment of depression, anxiety and emotionalism following stroke. Despite advances and 
progress in stroke research and practice, rehabilitation and treatment of these post-stroke mood 
disorders persists as a challenge worldwide. At present, NICE guidelines for managing post- 
stroke depression refer to the recommendations made for depression in adults with a chronic 
physical health problem and generalised anxiety disorder (NICE, 2013) suggesting a stepped- 
care approach considering psychological and pharmacological interventions, or both. This 
generalised approach towards mood disorders after stroke may be met with some difficulties. 
First, pharmacological interventions, which are commonly employed (Wannagat, Zielasek & 
Gaebel, 2013) cannot fully address the profound psychological, social and environmental 
impacts of a stroke, and the inherent adjustments necessary to the inevitable changes to life 
after it. This approach also does not take into the account the high rates of adverse effects from 
pharmacological interventions (Hackett et al., 2009), which is a particularly worrying factor 
for the stroke population, who are generally of older age. Additionally, there should be caution 
in given the increased risk of stroke recurrence associated with antidepressants (Jung, Chen & 
Chien, 2015; Biffi, Scotti & Corrao, 2017; Trajkova et al., 2019). Furthermore, 
recommendations for post-stroke anxiety and emotionalism - both of which show a high 
prevalence post-stroke – do not have specific associated treatment recommendations (Knapp 
et al., 2017;Gillespie et al., 2016). 
 
Although literature related to the general treatment of depression and anxiety may inform 
the treatment of these presentations post-stroke, an associated evidence base for this population 
is lacking. This is largely known by clinicians and researchers in the field and is noted across 
reviews of all three post-stroke domains (Wang et al., 2018; Knapp et al., 2017; Allida et al., 
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2020). The network meta-analysis in Chapter Four aimed to provide an overarching view of 
evidence-based treatments for mood disorders after stroke and to highlight gaps within this 
literature. In this pursuit, it attempted to synthesise the most researched interventions and, 
where possible, make multiple-treatment comparisons to indicate which interventions are most 
efficacious. A network meta-analysis is able to perform this by synthesising both direct (within- 
trial evidence of randomised groups) and indirect (estimations calculated between trials) 
comparisons of multiple interventions that may not have been compared in the same trial, thus 
maximising the use of available evidence (Molloy et al., 2018). This advantage of NMA has 
drawn attention from researchers, leading to a large increase of its use in the last decade (Lee, 
2014). Within the stroke literature however, the focus of NMA studies has been solely on PSD 
(Sun et al., 2017; Deng et al., 2017; Qin et al., 2018), and they lean heavily on 
pharmacological research. To our knowledge, this thesis presents the first paper employing 
NMA methodology across multiple mood disorder / emotion disorder domains, and to consider 
both pharmacological and psychological interventions in tandem. 
 
In considering the results, it must be reflected that the conclusions from the NMA broadly 
mirror those reported in the conventional MA’s (Knapp et al., 2017; Allida et al., 2020). i.e. 
that a lack of stroke-specific treatment research hampers making clear clinical 
recommendations. More specifically, results from the network analyses were unable to draw 
firm conclusions of efficacious interventions across all domains. Treatment ranking was 
estimated based on a wide range of interventions across relatively few studies. Although there 
are indications pointing towards Trazodone, Behavioural Activation Therapy and high- 
frequency transcranial magnetic stimulation for PSD, as well as neuromuscular electrical 
stimulation and self-help relaxation interventions for PSA, these results should be interpreted 
with significant caution. Many of the indirect effects are based on direct effects obtained 
from single studies with small samples or research papers of relatively low quality. More 
high-quality trials investigating these existing interventions are badly needed, before definite 
clinical recommendations can be made. For example, the most researched intervention within 
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the largest network (sub-network one for PSD), relied on data from only three trials. For 
PSA, two networks were produced, but neither one compared interventions that were studied 
in more than two trials. And finally, for PSE, it was not possible to produce a network at all, 
reflecting the particular paucity of treatment research focused on this common sequela of 
stroke. Overall, the findings arising from the NMA emphasizes the particular scarcity of 
treatment research within this field – a scarcity that applied to both pharmacological and 
psychological treatments, and particularly studies considering such treatments in comparison 
- and further affirms the disproportionate focus of research across the three mood domains. 
This finding also highlights the need for researchers to make available valuable data from their 
studies in a format that allows subsequent synthesis, reporting statistical means and standard 
deviations / standard errors which will allow for its conversion to a standardised mean for 
comparison, improving accessibility for future research.  
The importance of a strong evidence-base for the treatment of post-stroke mood 
disorders cannot be over emphasised. Stroke is a common clinical problem, impacting up to 
230 people every day in the United Kingdom alone (NHS, 2020). Moreover, for acute 
ischemic stroke at least, survival rates are improving with the introduction of new reperfusion 
techniques (intravenous alteplase) (Anderson et al., 2019). As a result, more people than ever 
survive with ischemic stroke and accordingly live with the consequent mood effects we know 
from the epidemiology literature commonly arise. Approximately one third of stroke survivors 
will develop clinical depression, one quarter post-stroke anxiety and one fifth post-stroke 
emotionalism (Hackett et al., 2014; Knapp et al., 2020; Gillespie et al., 2016). It is known that 
if left untreated, PSD negatively impacts rehabilitation efforts, length of hospital stays,
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functional outcome, mortality (Ahn et al., 2015; Gunal, Baskurt & Baskurt, 2019), and also 
stroke survivor quality of life. 
Indeed, the particular importance of considering quality of life after stroke is considered 
in Chapter Two, where a comprehensive and updated review of HR-QOL measures used for 
people who have sustained a stroke, is presented. The review of HR-QOL measures in stroke 
replicated a methodology first adopted by Golomb, Vickrey and Hays (2001) nineteen years 
ago, but updated with the addition of reviewing the clinical utility of the measures using the 
framework outlined by Burton and Tyson (2015a; 2015b) in their stroke research. 
Interestingly, alongside physical functioning, emotional wellbeing is the only other domain 
(out of eleven) that was covered in all seventeen identified HR-QOL measures for stroke. As 
noted in the conclusion, whilst the review was able to offer recommendations in terms of the 
best available HR-QOL measures for researchers and clinicians, expert judgement needs to be 
employed when considering choice of measure. 
Taken together, the systematic review and network meta-analysis provide a 
comprehensive review and synthesis of current research pertaining both to HR-QOL 
measurement in the stroke context, and to evidence-based treatment approaches 
(pharmacological and psychological) for the most common post-stroke mood disorders. Firstly, 
practical implications can be drawn from the findings of the systematic review of HR-QOL 
measures. Given the information synthesised in the review, the resulting flow-chart provides a 
simple tool for stroke clinicians and researches across the multidisciplinary team to evaluate 
the best suited measure that will meet a patient’s needs. This will take into account the cost of 
the measure, the length of time available for assessment and the specific HR-QOL domains 
that may be specifically important for a person (i.e. someone who was affected physically from 
the stroke may be more suited to using a measure that takes into account a physical / functioning 
domain). Additionally, the network meta-analysis may encourage stroke clinicians to 
critically appraise the evidence for post-stroke mood interventions. Despite the common 
prescription of SSRIs and TCAs for PSD, PSA and PSE, it is noted in this paper that the 
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effectiveness of these interventions is not well proven and replicated. Observations of the 
current literature which includes non-psychological and non-pharmacological approaches to 
treat post-stroke mood disorders (i.e. exercise interventions reported for PSA) suggest that a 
holistic, multi-disciplinary approach may be beneficial to people who have experienced a stroke. 
This ties in with the recommendations for choosing HR-QOL measures, where it is important 
for clinicians to exercise their expert judgement specific to the person in need of HR-QOL 
assessment or post-stroke mood treatment. 
However, both the systematic review presented in Chapter Two and the network meta- 
analysis presented in Chapter Four are not without limitations. First, the framework on which 
the systematic review of HR-QOL measures was performed is methodologically driven by 
existing work - which may be both a strength and a limitation. Where Burton and Tyson 
(20015a; 2015b) and Golomb, Vickrey and Hays (2001) have contributed a systematic 
methodology for assessing measures, the present work assimilates the strength of both 
approaches. This adds to research replicability, allowing for straightforward and direct 
comparisons between the reviews. However, this in turn means that the present review is 
bound to the same limitations of the prior, therefore not suggesting favourability of this 
methodology over others. Therefore, this methodology may be limited in terms of how much 
it advances in this area.  
The network meta-analysis approach for post-stroke mood disorders may also be 
considered to have some limitations. Whilst it is an advancing method of research, the results 
from this present paper suggest that the scarcity and quality of existing RCTs available mean 
that it is unable to provide a meaningful analysis of treatment efficacy ranking. Previous NMAs 
conducted by Sun et al. (2017) and Qin et al. (2018) have only looked at antidepressant 
interventions, and Deng et al. (2017) was stringent in their criteria and only included studies 
reporting Hamilton Depression Rating Scale (HAMD) scores. In an attempt to capture a wide, 
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inclusive snapshot of current evidence, the present NMA employed loose inclusion criteria. 
This is reflected in the variability of interventions found, and the multiple sub-network groups 
that were categorised for PSD and PSA interventions, instead of a singular network. This factor, 
added to the unavailability of appropriate data for analysis, meant that analyses of indirect 
treatment estimates may be inaccurate. 
 
Even within the scarcity of available evidence, there additionally appeared to be a 
distinct favourability to PSD research (in comparison to the other mood domains), and within 
that – favourability to pharmacological interventions, although even here it is fair to describe 
the state of research as limited. As discussed, the framework of other interventions were wide- 
ranging and variable. However, it is important to note that a large body of research on 
Traditional Chinese Medicine (TCM) is not included in the review. The practice of TCM is 
long-standing and is widely used across Asia (Liu, Ding & Wen, 2018). This covers a range of 
natural medication, acupuncture and physiotherapy interventions, most of which are adapted 
to current times and have reportedly few adverse effects (Tang, Liu & Ma, 2008; Liu, Ding & 
Wen, 2018). However, the majority of this research is published in the Mandarin language and 
Chinese journals, making it difficult to access. This is a common problem in trying to 
synthesise and compare research internationally, with the potential of missing novel, 
innovative or alternative efficacious treatments that are practised around the world. 
 
Nonetheless, notwithstanding the above limitations, both the systematic review and 
network meta-analyses provide a comprehensive framework for future research. The 
systematic review drew on already-proven methodologies to replicate and provided an update 
of existing HR-QOL measures, where we can already see development of more stroke-
specific HR- QOL measures in the field. However, as noted in Chapter Two, there still 
remains a gap in this field where no existing measure covered all HR-QOL domains. On the 
other hand, the 
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network meta-analyses provide an overarching view on the gaps in research and compares the 
existing literature across three post-stroke mood disorders. Although this paper was not able to 
confidently conclude on a best-available intervention for either of the domains, this 
encourages future triallists to replicate existing findings. 
 
Worldwide, stroke is the second leading cause of death and the third leading cause of 
disability (Johnson, Onuma, Owolabi & Sachdev, 2016) and it commonly leaves a significant 
and long-lasting impact on a person’s life, physical and/or psychological. This includes a 
range of significant mental health impacts. It is therefore unquestionable that improving mental 
health care for people who have suffered a stroke is and must remain a global priority. Across 
both the systematic review and network meta-analysis, the prevailing recommendation is for 
further quality research on stroke. In reporting outcomes for post-stroke mood interventions, 
or psychometric properties of HR-QOL measures, it is important to include appropriate and 
interpretable data. However, whilst there are many existing gaps in research focused on 
improving post-stroke mental health and quality of life care, there is at least some 
encouraging progress within this important field. This thesis portfolio adds to this gradually 
expanding body of work, highlighting the needs of future research for stroke mood 
interventions, and making recommendations based on an updated review of HR-QOL 
assessments. 
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(MM "Health Related 
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• The submitted work should be original and should not have been 
published elsewhere in any form or language (partially or in full), unless the 
new work concerns an expansion of previous work. (Please provide 
transparency on the re-use of material to avoid the concerns about text- 
recycling (‘self-plagiarism’). 
• A single study should not be split up into several parts to increase the 
quantity of submissions and submitted to various journals or to one journal 
over time (i.e. ‘salami-slicing/publishing’). 
• Concurrent or secondary publication is sometimes justifiable, provided 
certain conditions are met. Examples include: translations or a manuscript 
that is intended for a different group of readers. 
• Results should be presented clearly, honestly, and without fabrication, 
falsification or inappropriate data manipulation (including image based 
manipulation). Authors should adhere to discipline-specific rules for 
acquiring, selecting and processing data. 
• No data, text, or theories by others are presented as if they were the 
author’s own (‘plagiarism’). Proper acknowledgements to other works 
must be given (this includes material that is closely copied (near verbatim), 
summarized and/or paraphrased), quotation marks (to indicate words 
taken from another source) are used for verbatim copying of material, and 
permissions secured for material that is copyrighted. 
 
 Important note: the journal may use software to screen for plagiarism.  
 
• Authors should make sure they have permissions for the use of software, 
questionnaires/(web) surveys and scales in their studies (if appropriate). 
• Research articles and non-research articles (e.g. Opinion, Review, and 
Commentary articles) must cite appropriate and relevant literature in 
support of the claims made. Excessive and inappropriate self-citation or 
coordinated efforts among several authors to collectively self-cite is 
strongly discouraged. 
• Authors should avoid untrue statements about an entity (who can be an 
individual person or a company) or descriptions of their behavior or actions 
that could potentially be seen as personal attacks or allegations about that 
person. 
• Research that may be misapplied to pose a threat to public health or 
national security should be clearly identified in the manuscript (e.g. dual 
use of research). Examples include creation of harmful consequences of 
biological agents or toxins, disruption of immunity of vaccines, unusual 
hazards in the use of chemicals, weaponization of research/technology 
(amongst others). 
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• Authors are strongly advised to ensure the author group, the 
Corresponding Author, and the order of authors are all correct at 
submission. Adding and/or deleting authors during the revision stages is 
generally not permitted, but in some cases may be warranted. Reasons for 
changes in authorship should be explained in detail. Please note that 
changes to authorship cannot be made after acceptance of a manuscript. 
*All of the above are guidelines and authors need to make sure to respect third 
parties rights such as copyright and/or moral rights. 
 
Upon request authors should be prepared to send relevant documentation or 
data in order to verify the validity of the results presented. This could be in the 
form of raw data, samples, records, etc. Sensitive information in the form of 
confidential or proprietary data is excluded. 
 
If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher 
will carry out an investigation following COPE guidelines. If, after investigation, 
there are valid concerns, the author(s) concerned will be contacted under their 
given e-mail address and given an opportunity to address the issue. Depending 
on the situation, this may result in the Journal’s and/or Publisher’s 
implementation of the following measures, including, but not limited to: 
• If the manuscript is still under consideration, it may be rejected and 
returned to the author. 
• If the article has already been published online, depending on the nature 
and severity of the infraction: 
- an erratum/correction may be placed with the article 
 
- an expression of concern may be placed with the article 
 
- or in severe cases retraction of the article may occur. 
The reason will be given in the published erratum/correction, expression of 
concern or retraction note. Please note that retraction means that the article 
is maintained on the platform, watermarked “retracted” and the explanation for 
the retraction is provided in a note linked to the watermarked article. 
• The author’s institution may be informed 
• A notice of suspected transgression of ethical standards in the peer review 
system may be included as part of the author’s and article’s bibliographic 
record. 
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Fundamental errors 
 
 
Authors have an obligation to correct mistakes once they discover a significant 
error or inaccuracy in their published article. The author(s) is/are requested to 
contact the journal and explain in what sense the error is impacting the article. A 
decision on how to correct the literature will depend on the nature of the error. 
This may be a correction or retraction. The retraction note should provide 
transparency which parts of the article are impacted by the error. 
 
Suggesting / excluding reviewers 
 
 
Authors are welcome to suggest suitable reviewers and/or request the exclusion 
of certain individuals when they submit their manuscripts. When suggesting 
reviewers, authors should make sure they are totally independent and not 
connected to the work in any way. It is strongly recommended to suggest a mix 
of reviewers from different countries and different institutions. When suggesting 
reviewers, the Corresponding Author must provide an institutional email address 
for each suggested reviewer, or, if this is not possible to include other means of 
verifying the identity such as a link to a personal homepage, a link to the 
publication record or a researcher or author ID in the submission letter. Please 
note that the Journal may not use the suggestions, but suggestions are 
appreciated and may help facilitate the peer review process. 
 
Authorship principles 
 
 
These guidelines describe authorship principles and good authorship practices to 
which prospective authors should adhere to. 
 
Authorship clarified 
 
 
The Journal and Publisher assume all authors agreed with the content and that all 
gave explicit consent to submit and that they obtained consent from the 
responsible authorities at the institute/organization where the work has been 
carried out, before the work is submitted. 
 
The Publisher does not prescribe the kinds of contributions that warrant 
authorship. It is recommended that authors adhere to the guidelines for 
authorship that are applicable in their specific research field. In absence of 
specific guidelines it is recommended to adhere to the following guidelines*: 
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All authors whose names appear on the submission 
 
1) made substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data; or the creation of new software 
used in the work; 
 
2) drafted the work or revised it critically for important intellectual content; 
 
3) approved the version to be published; and 
 
4) agree to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. 
 
* Based on/adapted from: 
 
ICMJE, Defining the Role of Authors and Contributors, 
 
Transparency in authors’ contributions and responsibilities to promote integrity 
in scientific publication, McNutt at all, PNAS February 27, 2018 
 
Disclosures and declarations 
 
 
All authors are requested to include information regarding sources of funding, 
financial or non-financial interests, study-specific approval by the appropriate 
ethics committee for research involving humans and/or animals, informed 
consent if the research involved human participants, and a statement on welfare 
of animals if the research involved animals (as appropriate). 
 
The decision whether such information should be included is not only dependent 
on the scope of the journal, but also the scope of the article. Work submitted for 
publication may have implications for public health or general welfare and in 
those cases it is the responsibility of all authors to include the appropriate 
disclosures and declarations. 
 
Data transparency 
 
 
All authors are requested to make sure that all data and materials as well as 
software application or custom code support their published claims and comply 
with field standards. Please note that journals may have individual policies on 
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(sharing) research data in concordance with disciplinary norms and expectations. 
Please check the Instructions for Authors of the Journal that you are submitting 
to for specific instructions. 
 
Role of the Corresponding Author 
 
 
One author is assigned as Corresponding Author and acts on behalf of all co- 
authors and ensures that questions related to the accuracy or integrity of any 
part of the work are appropriately addressed. 
 
The Corresponding Author is responsible for the following requirements: 
• ensuring that all listed authors have approved the manuscript before 
submission, including the names and order of authors; 
• managing all communication between the Journal and all co-authors, 
before and after publication;* 
• providing transparency on re-use of material and mention any unpublished 
material (for example manuscripts in press) included in the manuscript in a 
cover letter to the Editor; 
• making sure disclosures, declarations and transparency on data 
statements from all authors are included in the manuscript as appropriate 
(see above). 
* The requirement of managing all communication between the journal and all 
co-authors during submission and proofing may be delegated to a Contact or 
Submitting Author. In this case please make sure the Corresponding Author is 
clearly indicated in the manuscript. 
 
Author contributions 
 
 
In absence of specific instructions and in research fields where it is possible to 
describe discrete efforts, the Publisher recommends authors to include 
contribution statements in the work that specifies the contribution of every 
author in order to promote transparency. These contributions should be listed at 
the separate title page. 
 
Examples of such statement(s) are shown below: 
 
• Free text: 
196 
 
 196 
All authors contributed to the study conception and design. Material preparation, 
data collection and analysis were performed by [full name], [full name] and [full 
name]. The first draft of the manuscript was written by [full name] and all 
authors commented on previous versions of the manuscript. All authors read and 
approved the final manuscript. 
 
Example: CRediT taxonomy: 
 
• Conceptualization: [full name], …; Methodology: [full name], …; Formal 
analysis and investigation: [full name], …; Writing - original draft preparation: 
[full name, …]; Writing - review and editing: [full name], …; Funding acquisition: 
[full name], …; Resources: [full name], …; Supervision: [full name],…. 
 
For review articles where discrete statements are less applicable a statement 
should be included who had the idea for the article, who performed the literature 
search and data analysis, and who drafted and/or critically revised the work. 
 
For articles that are based primarily on the student’s dissertation or thesis, it is 
recommended that the student is usually listed as principal author: 
 
A Graduate Student’s Guide to Determining Authorship Credit and Authorship 
Order, APA Science Student Council 2006 
 
Affiliation 
 
 
The primary affiliation for each author should be the institution where the 
majority of their work was done. If an author has subsequently moved, the 
current address may additionally be stated. Addresses will not be updated or 
changed after publication of the article. 
 
Changes to authorship 
 
 
Authors are strongly advised to ensure the correct author group, the 
Corresponding Author, and the order of authors at submission. Changes of 
authorship by adding or deleting authors, and/or changes in Corresponding 
Author, and/or changes in the sequence of authors are not accepted after 
acceptance of a manuscript. 
 
• Please note that author names will be published exactly as they appear 
on the accepted submission! 
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Please make sure that the names of all authors are present and correctly spelled, 
and that addresses and affiliations are current. 
 
Adding and/or deleting authors at revision stage are generally not permitted, but 
in some cases it may be warranted. Reasons for these changes in authorship 
should be explained. Approval of the change during revision is at the discretion of 
the Editor-in-Chief. Please note that journals may have individual policies on 
adding and/or deleting authors during revision stage. 
 
Author identification 
 
 
Authors are recommended to use their ORCID ID when submitting an article for 
consideration or acquire an ORCID ID via the submission process. 
 
Deceased or incapacitated authors 
 
 
For cases in which a co-author dies or is incapacitated during the writing, 
submission, or peer-review process, and the co-authors feel it is appropriate to 
include the author, co-authors should obtain approval from a (legal) 
representative which could be a direct relative. 
 
Authorship issues or disputes 
 
 
In the case of an authorship dispute during peer review or after acceptance and 
publication, the Journal will not be in a position to investigate or adjudicate. 
Authors will be asked to resolve the dispute themselves. If they are unable the 
Journal reserves the right to withdraw a manuscript from the editorial process or 
in case of a published paper raise the issue with the authors’ institution(s) and 
abide by its guidelines. 
 
Confidentiality 
 
 
Authors should treat all communication with the Journal as confidential which 
includes correspondence with direct representatives from the Journal such as 
Editors-in-Chief and/or Handling Editors and reviewers’ reports unless explicit 
consent has been received to share information. 
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Please note that standards could vary slightly per journal dependent on their peer 
review policies (i.e. single or double blind peer review) as well as per journal 
subject discipline. Before submitting your article check the instructions following 
this section carefully. 
 
The corresponding author should be prepared to collect documentation of 
compliance with ethical standards and send if requested during peer review or 
after publication. 
 
The Editors reserve the right to reject manuscripts that do not comply with the 
above-mentioned guidelines. The author will be held responsible for false 
statements or failure to fulfill the above-mentioned guidelines. 
 
Disclosure of potential conflicts of interest 
 
 
Authors must disclose all relationships or interests that could influence or bias 
the work. Although an author may not feel there are conflicts, disclosure of 
relationships and interests affords a more transparent process, leading to an 
accurate and objective assessment of the work. Awareness of real or perceived 
conflicts of interests is a perspective to which the readers are entitled and is not 
meant to imply that a financial relationship with an organization that sponsored 
the research or compensation for consultancy work is inappropriate. Examples of 
potential conflicts of interests that are directly or indirectly related to the 
research may include but are not limited to the following: 
Compliance with Ethical Standards 
 
To ensure objectivity and transparency in research and to ensure that accepted 
principles of ethical and professional conduct have been followed, authors should 
include information regarding sources of funding, potential conflicts of interest 
(financial or non-financial), informed consent if the research involved human 
participants, and a statement on welfare of animals if the research involved 
animals. 
 
Authors should include the following statements (if applicable) in a separate 
section entitled “Compliance with Ethical Standards” when submitting a paper: 
• Disclosure of potential conflicts of interest 
• Research involving Human Participants and/or Animals 
• Informed consent 
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In addition, interests that go beyond financial interests and compensation (non- 
financial interests) that may be important to readers should be disclosed. These 
may include but are not limited to personal relationships or competing interests 
directly or indirectly tied to this research, or professional interests or personal 
beliefs that may influence your research. 
 
The corresponding author collects the conflict of interest disclosure forms from 
all authors. In author collaborations where formal agreements for representation 
allow it, it is sufficient for the corresponding author to sign the disclosure form on 
behalf of all authors. Examples of forms can be found 
 
here: 
 
The corresponding author will include a summary statement on the title page 
that is separate from their manuscript, that reflects what is recorded in the 
potential conflict of interest disclosure form(s). 
 
See below examples of disclosures: 
 
Funding: This study was funded by X (grant number X). 
 
Conflict of Interest: Author A has received research grants from Company A. 
Author B has received a speaker honorarium from Company X and owns stock in 
Company Y. Author C is a member of committee Z. 
• Research grants from funding agencies (please give the research funder 
and the grant number) 
• Honoraria for speaking at symposia 
• Financial support for attending symposia 
• Financial support for educational programs 
• Employment or consultation 
• Support from a project sponsor 
• Position on advisory board or board of directors or other type of 
management relationships 
• Multiple affiliations 
• Financial relationships, for example equity ownership or investment 
interest 
• Intellectual property rights (e.g. patents, copyrights and royalties from 
such rights) 
• Holdings of spouse and/or children that may have financial interest in the 
work 
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If no conflict exists, the authors should state: 
 
Conflict of Interest: The authors declare that they have no conflict of interest. 
 
Research involving human participants, their data or biological material 
 
 
Ethics approval 
 
 
When reporting a study that involved human participants, their data or biological 
material, authors should include a statement that confirms that the study was 
approved (or granted exemption) by the appropriate institutional and/or national 
research ethics committee (including the name of the ethics committee) and 
certify that the study was performed in accordance with the ethical standards as 
laid down in the 1964 Declaration of Helsinki and its later amendments or 
comparable ethical standards. If doubt exists whether the research was 
conducted in accordance with the 1964 Helsinki Declaration or comparable 
standards, the authors must explain the reasons for their approach, and 
demonstrate that an independent ethics committee or institutional review board 
explicitly approved the doubtful aspects of the study. If a study was granted 
exemption from requiring ethics approval, this should also be detailed in the 
manuscript (including the reasons for the exemption). 
 
Retrospective ethics approval 
 
 
If a study has not been granted ethics committee approval prior to commencing, 
retrospective ethics approval usually cannot be obtained and it may not be 
possible to consider the manuscript for peer review. The decision on whether to 
proceed to peer review in such cases is at the Editor's discretion. 
 
Ethics approval for retrospective studies 
 
 
Although retrospective studies are conducted on already available data or 
biological material (for which formal consent may not be needed or is difficult to 
obtain) ethics approval may be required dependent on the law and the national 
ethical guidelines of a country. Authors should check with their institution to 
make sure they are complying with the specific requirements of their country. 
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Ethics approval for case studies 
 
 
Case reports require ethics approval. Most institutions will have specific policies 
on this subject. Authors should check with their institution to make sure they are 
complying with the specific requirements of their institution and seek ethics 
approval where needed. Authors should be aware to secure informed consent 
from the individual (or parent or guardian if the participant is a minor or 
incapable) See also section on Informed Consent. 
 
Cell lines 
 
 
If human cells are used, authors must declare in the manuscript: what cell lines 
were used by describing the source of the cell line, including when and from 
where it was obtained, whether the cell line has recently been authenticated and 
by what method. If cells were bought from a life science company the following 
need to be given in the manuscript: name of company (that provided the cells), 
cell type, number of cell line, and batch of cells. 
 
It is recommended that authors check the NCBI database for misidentification 
and contamination of human cell lines. This step will alert authors to possible 
problems with the cell line and may save considerable time and effort. 
 
Further information is available from the International Cell Line Authentication 
Committee (ICLAC). 
 
Authors should include a statement that confirms that an institutional or 
independent ethics committee (including the name of the ethics committee) 
approved the study and that informed consent was obtained from the donor or 
next of kin. 
 
Research Resource Identifiers (RRID) 
 
 
Research Resource Identifiers (RRID) are persistent unique identifiers (effectively 
similar to a DOI) for research resources. This journal encourages authors to adopt 
RRIDs when reporting key biological resources (antibodies, cell lines, model 
organisms and tools) in their manuscripts. 
 
Examples: 
 
Organism: Filip1tm1a(KOMP)Wtsi  RRID:MMRRC_055641-UCD 
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Cell Line: RST307 cell line RRID:CVCL_C321 
 
Antibody: Luciferase antibody DSHB Cat# LUC-3, RRID:AB_2722109 
 
Plasmid: mRuby3 plasmid RRID:Addgene_104005 
 
Software: ImageJ Version 1.2.4 RRID:SCR_003070 
 
RRIDs are provided by the Resource Identification Portal. Many commonly used 
research resources already have designated RRIDs. The portal also provides 
authors links so that they can quickly register a new resource and obtain an RRID. 
 
Clinical Trial Registration 
 
 
The World Health Organization (WHO) definition of a clinical trial is "any research 
study that prospectively assigns human participants or groups of humans to one 
or more health-related interventions to evaluate the effects on health 
outcomes". The WHO defines health interventions as “A health intervention is an 
act performed for, with or on behalf of a person or population whose purpose is 
to assess, improve, maintain, promote or modify health, functioning or health 
conditions” and a health-related outcome is generally defined as a change in the 
health of a person or population as a result of an intervention. 
 
To ensure the integrity of the reporting of patient-centered trials, authors must 
register prospective clinical trials (phase II to IV trials) in suitable publicly 
available repositories. For example www.clinicaltrials.gov or any of the primary 
registries that participate in the WHO International Clinical Trials Registry 
Platform. 
 
The trial registration number (TRN) and date of registration should be included as 
the last line of the manuscript abstract. 
 
For clinical trials that have not been registered prospectively, authors are 
encouraged to register retrospectively to ensure the complete publication of all 
results. The trial registration number (TRN), date of registration and the words 
'retrospectively registered’ should be included as the last line of the manuscript 
abstract. 
 
Purely observational trials will not require registration. 
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Standards of reporting 
 
 
Springer Nature advocates complete and transparent reporting of biomedical 
and biological research and research with biological applications. Authors are 
recommended to adhere to the minimum reporting guidelines hosted by 
the EQUATOR Network when preparing their manuscript. 
 
Exact requirements may vary depending on the journal; please refer to the 
journal’s Instructions for Authors. 
 
Checklists are available for a number of study designs, including: 
 
Randomised trials (CONSORT) and Study protocols (SPIRIT) 
 
Observational studies (STROBE) 
 
Systematic reviews and meta-analyses (PRISMA) and protocols (Prisma-P) 
 
Diagnostic/prognostic studies (STARD) and (TRIPOD) 
 
Case reports (CARE) 
 
Clinical practice guidelines (AGREE) and (RIGHT) 
 
Qualitative research (SRQR) and (COREQ) 
 
Animal pre-clinical studies (ARRIVE) 
 
Quality improvement studies (SQUIRE) 
 
Economic evaluations (CHEERS) 
 
Summary of requirements 
 
 
The above should be summarized in a statement and placed in 
a “Declarations” section before the reference list under a heading of ‘Ethics 
approval’. 
 
Please see the various examples of wording below and revise/customize the 
sample statements according to your own needs. 
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Examples of statements to be used when ethics approval has been obtained: 
 
• All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. The study was approved by the 
Bioethics Committee of the Medical University of A (No. ... ). 
 
• This study was performed in line with the principles of the Declaration of 
Helsinki. Approval was granted by the Ethics Committee of University B 
(Date.../No .... ). 
 
• Approval was obtained from the ethics committee of University C. The 
procedures used in this study adhere to the tenets of the Declaration of Helsinki. 
 
• The questionnaire and methodology for this study was approved by the Human 
Research Ethics committee of the University of D (Ethics approval number: ...). 
 
Examples of statements to be used for a retrospective study: 
 
• Ethical approval was waived by the local Ethics Committee of University A in 
view of the retrospective nature of the study and all the procedures being 
performed were part of the routine care. 
 
• This research study was conducted retrospectively from data obtained for 
clinical purposes. We consulted extensively with the IRB of XYZ who determined 
that our study did not need ethical approval. An IRB official waiver of ethical 
approval was granted from the IRB of XYZ. 
 
• This retrospective chart review study involving human participants was in 
accordance with the ethical standards of the institutional and national research 
committee and with the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. The Human Investigation Committee (IRB) of 
University B approved this study. 
 
Examples of statements to be used when no ethical approval is 
required/exemption granted: 
 
• This is an observational study. The XYZ Research Ethics Committee has 
confirmed that no ethical approval is required. 
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• The data reproduced from Article X utilized human tissue that was procured via 
our Biobank AB, which provides de-identified samples. This study was reviewed 
and deemed exempt by our XYZ Institutional Review Board. The BioBank 
protocols are in accordance with the ethical standards of our institution and with 
the 1964 Helsinki declaration and its later amendments or comparable ethical 
standards. 
 
Authors are responsible for correctness of the statements provided in the 
manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right 
to reject submissions that do not meet the guidelines described in this section. 
 
Informed consent 
 
 
All individuals have individual rights that are not to be infringed. Individual 
participants in studies have, for example, the right to decide what happens to the 
(identifiable) personal data gathered, to what they have said during a study or an 
interview, as well as to any photograph that was taken. This is especially true 
concerning images of vulnerable people (e.g. minors, patients, refugees, etc) or 
the use of images in sensitive contexts. In many instances authors will need to 
secure written consent before including images. 
 
Identifying details (names, dates of birth, identity numbers, biometrical 
characteristics (such as facial features, fingerprint, writing style, voice pattern, 
DNA or other distinguishing characteristic) and other information) of the 
participants that were studied should not be published in written descriptions, 
photographs, and genetic profiles unless the information is essential for scholarly 
purposes and the participant (or parent/guardian if the participant is a minor or 
incapable or legal representative) gave written informed consent for publication. 
Complete anonymity is difficult to achieve in some cases. Detailed descriptions 
of individual participants, whether of their whole bodies or of body sections, may 
lead to disclosure of their identity. Under certain circumstances consent is not 
required as long as information is anonymized and the submission does not 
include images that may identify the person. 
 
Informed consent for publication should be obtained if there is any doubt. For 
example, masking the eye region in photographs of participants is inadequate 
protection of anonymity. If identifying characteristics are altered to protect 
anonymity, such as in genetic profiles, authors should provide assurance that 
alterations do not distort meaning. 
 
Exceptions where it is not necessary to obtain consent: 
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• Images such as x rays, laparoscopic images, ultrasound images, brain scans, 
pathology slides unless there is a concern about identifying information in which 
case, authors should ensure that consent is obtained. 
 
• Reuse of images: If images are being reused from prior publications, the 
Publisher will assume that the prior publication obtained the relevant 
information regarding consent. Authors should provide the appropriate 
attribution for republished images. 
 
Consent and already available data and/or biologic material 
 
Regardless of whether material is collected from living or dead patients, they 
(family or guardian if the deceased has not made a pre-mortem decision) must 
have given prior written consent. The aspect of confidentiality as well as any 
wishes from the deceased should be respected. 
 
Data protection, confidentiality and privacy 
 
When biological material is donated for or data is generated as part of a research 
project authors should ensure, as part of the informed consent procedure, that 
the participants are made aware what kind of (personal) data will be processed, 
how it will be used and for what purpose. In case of data acquired via a 
biobank/biorepository, it is possible they apply a broad consent which allows 
research participants to consent to a broad range of uses of their data and 
samples which is regarded by research ethics committees as specific enough to 
be considered “informed”. However, authors should always check the specific 
biobank/biorepository policies or any other type of data provider policies (in case 
of non-bio research) to be sure that this is the case. 
 
Consent to Participate 
 
 
For all research involving human subjects, freely-given, informed consent to 
participate in the study must be obtained from participants (or their parent or 
legal guardian in the case of children under 16) and a statement to this effect 
should appear in the manuscript. In the case of articles describing human 
transplantation studies, authors must include a statement declaring that no 
organs/tissues were obtained from prisoners and must also name the 
institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. For 
manuscripts reporting studies involving vulnerable groups where there is the 
potential for coercion or where consent may not have been fully informed, extra 
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care will be taken by the editor and may be referred to the Springer Nature 
Research Integrity Group. 
 
Consent to Publish 
 
 
Individuals may consent to participate in a study, but object to having their data 
published in a journal article. Authors should make sure to also seek consent 
from individuals to publish their data prior to submitting their paper to a journal. 
This is in particular applicable to case studies. A consent to publish form can be 
found 
 
here. (Download docx, 36 kB) 
 
Summary of requirements 
 
 
The above should be summarized in a statement and placed in 
a “Declarations” section under a heading of "Consent to 
participate" and/or "Consent to publish". The Declarations section should be 
placed on a title page that is separate from the manuscript. Please use the title 
page as outlined in the Title Page section of these Instructions for Authors for 
providing the statements. 
 
Please see the various examples of wording below and revise/customize the 
sample statements according to your own needs. 
 
Sample statements for "Consent to participate": 
 
Informed consent was obtained from all individual participants included in the 
study. 
 
Informed consent was obtained from legal guardians. 
 
Written informed consent was obtained from the parents. 
 
Verbal informed consent was obtained prior to the interview. 
 
Sample statements for “Consent to publish”: 
 
The authors affirm that human research participants provided informed consent 
for publication of the images in Figure(s) 1a, 1b and 1c. 
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The participant has consented to the submission of the case report to the journal. 
 
Patients signed informed consent regarding publishing their data and 
photographs. 
 
Sample statements if identifying information about participants is available in 
the article: 
 
Additional informed consent was obtained from all individual participants for 
whom identifying information is included in this article. 
 
Authors are responsible for correctness of the statements provided in the 
manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right 
to reject submissions that do not meet the guidelines described in this section. 
 
Images will be removed from publication if authors have not obtained informed 
consent or the paper may be removed and replaced with a notice explaining the 
reason for removal. 
 
English Language Editing 
 
 
For editors and reviewers to accurately assess the work presented in your 
manuscript you need to ensure the English language is of sufficient quality to be 
understood. If you need help with writing in English you should consider: 
 
 
• Asking a colleague who is a native English speaker to review your 
manuscript for clarity. 
• Visiting the English language tutorial which covers the common mistakes 
when writing in English. 
• Using a professional language editing service where editors will improve 
the English to ensure that your meaning is clear and identify problems that 
require your review. Two such services are provided by our affiliates 
Nature Research Editing Service and American Journal Experts. Springer 
authors are entitled to a 10% discount on their first submission to either of 
these services, simply follow the links below. 
English language tutorial 
Nature Research Editing Service 
American Journal Experts 
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Please note that the use of a language editing service is not a requirement for 
publication in this journal and does not imply or guarantee that the article will be 
selected for peer review or accepted. 
 
If your manuscript is accepted it will be checked by our copyeditors for spelling 
and formal style before publication. 
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Appendix C: Quality Ratings for Systematic Review 
 
 
Methodological quality of each study per questionnaire and measurement property. Studies marked with an asterisk (*) indicate co-rated quality assessment by an 
independent rater.  
 
Study Measure Structural 
Validity 
Internal 
Consistency 
Cross cultural 
validity 
/Translation 
Reliability Measurement 
Error 
Content 
Validity 
Hypotheses 
Testing 
Responsiveness Overall 
*Bohannon, 
Maljanian, Lee 
& Ahlquist 
(2004) 
SF-12 Fair Excellent N/A Excellent Fair Poor N/A Good Fair 
*Buck et al. 
(2003) 
NEWSQOL Poor Excellent N/A Good Poor Good Poor Poor Fair 
Chen et al. (2012) SS-QoL-12 Good Poor N/A Poor Poor Excellent Poor Excellent Fair 
Chen et al. (2016) EQ-5D-5L; 
EQ-VAS; 
SIS 3.0 
Poor Poor N/A Poor Good Good Good Good Fair 
Duncan et al. 
(1999) 
SIS 2.0 Poor Excellent N/A Poor Poor Good Good Good Fair 
Guo, Togher, 
Power & Koh 
(2016) 
SAQOL-39 Poor Excellent N/A Excellent Poor Poor Good Good Fair 
*Hamedani et al. 
(2001) 
HSQuale Poor Poor N/A Good Good Poor Poor Poor Poor 
Hilari, Byng, 
Lamping & 
Smith (2003) 
SAQOL-39 Poor Excellent N/A Good Poor Good Excellent Excellent Good 
Hilari et al. 
(2009) 
SAQOL-39 Poor Poor N/A Excellent Poor Good Good Good Fair 
*Hobart et al. 
(2009) 
SF-36 Poor Poor N/A Poor Poor Good Good Good Fair 
Hunger et al. 
(2012) 
EQ-5D; SIS 
2.0 
Poor Poor N/A Excellent Poor Good Excellent Excellent Fair 
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Kerber et al. 
2013) 
SSQOL Poor Excellent N/A Good Poor Good N/A Good Fair 
*Kwon et al. 
(2006) 
SIS Excellent Poor N/A Poor Excellent Excellent Poor Poor Fair 
Luo et al. (2015) Stroke- 
PROM 
Poor Excellent N/A Poor Good Excellent Good Excellent Good 
MasIsaac et al. 
(2016) 
SF-SIS Poor Excellent Fair N/A Poor Good Excellent Excellent Fair 
OjoOwolabi et al. 
(2010) 
HRQOLISP- 
40 
Poor Excellent Good Poor Poor Poor Good Good Fair 
Pickard et al. 
(2005) 
EQ-5D; SF- 
6D; HUI2; 
HUI3 
Poor Poor N/A Poor Poor Excellent Excellent Excellent Fair 
Possiant et al. 
(2003) 
PBSI Excellent Excellent N/A Poor Poor Excellent Excellent Excellent Good 
Post et al. (2011) Short SS- 
QoL 
Poor Excellent N/A Poor Poor Excellent Excellent Excellent Fair 
*Richardson et 
al. (2016) 
SIS 3.0 Poor Excellent N/A Poor Poor Excellent Excellent Poor Fair 
*Silva et al. 
(2016) 
SS-QoL Poor Excellent N/A Good Excellent Good   Good 
Strum et al. 
(2002) 
AQoL Poor Poor N/A Poor Poor Excellent Excellent Excellent Fair 
*VincentOnabajo 
et al. (2013) 
HRQOLISP- 
40 
Poor Poor N/A Good Good Excellent N/A N/A Fair 
*Williams et al. 
(1999) 
SS-QOL Poor Excellent N/A Excellent Good Excellent Poor Poor Fair 
AQoL. Assessment of Quality of Life; EQ-5D, EQ-5D-5L, EuroQoL 5-Dimensions Questionnaire; EQ-VAS, EuroQoL Visual analogue scale; (HUI2, 
Health Utility Index Mark 2; HUI3, Health Utility Index Mark 3;HSQuale, Haemorrhagic Stroke Quality of Life ; HRQOLISP-40, Health-Related Quality of Life in 
Stroke Patients 40-items; NEWSQOL, Newcastle Stroke-Specific Quality of Life Measure; PBSI, Preference-Based Stroke Index; SF-12, SF-6D, SF-36, Medical 
Outcomes Study Short-Form Health Survey (12 item, 6-dimensions, 36-item); SIS 2.0, 3.0, Stroke Impact Scale (Version 2.0, 3.0); SF-SIS, Short-Form Stroke 
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Impact Scale; Stroke-PROM; Stroke-Patient Reported Outcome Measure, SAQOL-39, Stroke and Aphasia Quality of Life Scale-39; SS-QOL, 12-item Stroke- 
Specific Quality of Life Scale, NA; Not Available, *, Co-rated quality assessment 
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Appendix D: Search terms for all databases for Empirical Paper 
 
 
MEDLINE via EBSCO Host: 
 
 
 
 
 Depression Anxiety Emotionalism 
(MM "Stroke+") OR (MM "Stroke Rehabilitation") OR (MM 
 
"Stroke, Lacunar") 
AND (MM "Depression") 
OR "depression" OR (MM 
"Depressive Disorder+") OR 
(MM "Depressive Disorder, 
Major") 
(MM 
 
"Anxiety+") OR 
"anxiety" OR 
(MM "Anxiety 
Disorders+") 
"post-stroke 
emotionalism" OR 
emotionalism OR 
"emotional lability" 
OR "pseudobulbar 
affect" 
AND (MM "Randomized Controlled Trial+") OR (MM "Randomized 
 
Controlled Trials as Topic") OR "randomised controlled trials" 
 49 18 3 
 
 
PsycINFO via EBSCO Host: 
 
 
 
 
 Depression Anxiety Emotionalism 
DE "Cerebrovascular Accidents" OR Stroke 
AND MM "Major 
Depression" OR MM 
"Depression (Emotion)" OR 
MM 
 
"Anxiety" OR 
MM "Anxiety 
Disorders" OR 
MM 
 
"Emotional 
Instability" OR 
"emotional lability" 
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 depression OR "depressive 
disorder" 
MM "Generalized 
Anxiety Disorder" 
OR "emotionalism" 
OR "pseudobulbar 
affect" 
AND MM "Randomized Controlled Trials" OR MM "Randomized 
 
Clinical Trials" 
 0 0 0 
 
 
Cochrane Library: 
 
 
 
 
 Depression Anxiety Emotionalism 
MeSH descriptor: [Stroke] explode all trees 
AND MeSH descriptor: 
[Depression] explode all 
trees 
MeSH 
descriptor: 
[Anxiety] explode 
all trees 
Emotionalism       
or “emotional 
lability” or 
“pseudobulbar affect” 
AND MeSH descriptor: [Randomized Controlled Trials as Topic] 
 
explode all trees 
 9 6 5 
 
 
EMBASE via Ovid: 
 
 
 
 
 Depression Anxiety Emotionalism 
stroke.mp. or cerebrovascular accident/ 
AND depression/ or 
post-stroke depression/ 
anxiety.mp. 
or anxiety/ or 
anxiety disorder/ 
emotionalism.mp. 
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AND randomised controlled trials.mp. or randomized controlled trial/ 
 635 394 8 
 
 
DORIS: 
 
 
*All studies on DORIS are related to stroke. 
 
 
 
 
 Depression Anxiety Emotionalism 
Selected categories: 
 
- Mood disturbance 
- All treatment stages 
- All stroke types 
- Completed RCTs 
Search term: Depress- Anxi- Emotional- 
Psychological 
 
therapy 
122 48 14 
 
(0 results 
from ‘emotionalism’ 
and ‘pseudobulbar 
affect’) 
Pharmacology 179 18 18 
 
(2 results 
from ‘emotionalism’ 
and 0 ‘pseudobulbar 
affect’ 
Complementary 
medical therapy 
64 13 5 
(0 results 
from ‘emotionalism’ 
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   and ‘pseudobulbar 
 
affect’) 
 365 79 37 
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Appendix E: NICE Quality appraisal checklist for Empirical Paper 
 
 
1. Is the source population or source area well described? 
 
• Was the country (e.g. developed or non-developed, type of healthcare system), 
setting (primary schools, community centres etc.), location (urban, rural), 
population demographics etc. adequately described? 
 
2. Is the eligible population or area representative of the source population or area? 
 
• Was the recruitment of individuals, clusters or areas well defined (e.g. 
advertisement, birth register)? 
• Was the eligible population representative of the source? Were important 
groups under-represented? 
 
3. Do the selected participants or areas represent the eligible population? 
 
• Was the method of selection of participants from the eligible population well 
described? 
• What % of selected individuals or clusters agreed to participate? Were there 
any sources of bias? 
• Were the inclusion or exclusion criteria explicit and appropriate? 
 
4. Were interventions (and comparisons) well described and appropriate? 
 
• Were interventions and comparisons described in sufficient detail (i.e. enough 
for study to be replicated)? 
• Were comparisons appropriate (e.g. usual practice rather than no 
intervention)? 
 
5. Was the study sufficiently powered to detect an intervention effect (if one exists)? 
 
• A power of 0.8 (that is, it is likely to see an effect of a given size if one exists, 
80% of the time) is the conventionally accepted standard. 
• Is a power calculation presented? If not, what is the expected effect size? Is 
the sample size adequate? 
 
For each item on the NICE checklist, 5 ratings are available: 
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++ Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
 
+ Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of bias for that 
particular aspect of study design. Should be reserved for those aspects of the study design in 
which significant sources of bias may persist. 
 
Not reported (NR) Should be reserved for those aspects in which the study under review 
fails to report how they have (or might have) been considered. 
 
Not applicable (NA) Should be reserved for those study design aspects that are not 
applicable given the study design under review (for example, allocation concealment would not 
be applicable for case control studies). 
 
The overall rating from the Cochrane tool and NICE appraisal checklist were merged, 
and studies were given a final rating of high, moderate, or low quality: 
 
• High: All or most of the criteria, across both the NICE and Cochrane checklists, scored 
well, where they have not met criteria the conclusions were very unlikely to alter or not 
meeting criteria were unavoidable. 
• Moderate: Some of the criteria across both the NICE and Cochrane checklists have 
scored well, and where they have not, or haven’t been adequately described, the 
conclusions were unlikely to alter. 
• Low: Few or no checklist criteria have been fulfilled across either the NICE or Cochrane 
checklists, and the conclusions were likely or very likely to alter. 
 
(Criteria were adapted from the NICE quality appraisal checklist for quantitative 
intervention studies, 2012). 
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Appendix F: Quality Ratings for Empirical Paper 
 
 
 
 
 
 
 
 
 
 
Ratings assigned using the Cochrane risk-of-bias tool 
for randomised trials (Sterne et al., 2019, Ver 2.) and the 
NICE quality appraisal checklist for quantitative 
intervention studies (NICE, 2012). “C1-C5” domains 
represent Domains 1-5 on the Cochrane tool, and “NICE 
1-5” represent the selected items from the NICE 
checklist (Appendix A). “Combined rating” represents 
the overall rating from both tools. The rating codes are: 
red circles = high risk of bias on Cochrane tool, “-“/ Not 
Reported on NICE tool; yellow circles = some concerns 
on Cochrane tool, “+” on NICE tool; green circles = low 
risk of bias on Cochrane tool, “++” on NICE tool. 
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Appendix G: Forest plot of studies with direct and indirect evidence for PSD 
subnetwork one (Empirical Paper) 
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Appendix H: Direct and indirect evidence plots for PSD and PSA sub-networks 
 
(Empirical Paper) 
 
 
PSD sub-network one: 
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PSD sub-network two: 
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PSD sub-network three: 
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PSA Sub-network group two: 
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Appendix I: Funnel plots for publication bias for PSD and PSA subnetwork groups 
 
(Empirical Paper) 
 
 
Funnel plot for PSD subnetwork one 
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Figure 7. Funnel plot, PSD subnetwork two 
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Figure 11. Funnel plot, PSD subnetwork three 
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PSA funnel plots for sub-network one: 
 
 
 
 
 
 
 
 
PSA funnel plots for sub-network two: 
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Appendix J: Journal of Rehabilitation Psychology – Instructions for Manuscript 
Submission (Empirical Paper) 
 
 
 
Prior to submission, please carefully read and follow the submission guidelines detailed 
below. Manuscripts that do not conform to the submission guidelines may be returned 
without review. 
Submission 
Rehabilitation Psychology® is now using a software system to screen submitted content 
for similarity with other published content. The system compares each submitted 
manuscript against a database of 25+ million scholarly publications, as well as content 
appearing on the open web. 
This allows APA to check submissions for potential overlap with material previously 
published in scholarly journals (e.g., lifted or republished material). A similarity report 
will be generated by the system and provided to the Rehabilitation Psychology editorial 
office for review immediately upon submission. 
To submit to the Editorial Office of Dawn M. Ehde, please submit manuscripts 
electronically through the Manuscript Submission Portal in Microsoft Word or Open 
Office format. 
Starting June 15, 2020, all new manuscripts submitted should be prepared according to 
the 7th edition of the Publication Manual of the American Psychological 
Association. APA Style and Grammar Guidelines for the 7th  edition are available. 
SUBMIT   MANUSCRIPT 
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To prevent institutional spam filters from preventing transfer of files from APA and 
Journals Back Office 
• Add apa.org to your list of "safe addresses" and consider asking your IT department to 
add it to their "white list" 
• Contact Charles Retzlaff if you do not receive confirmation of your submission within 
three business days 
When necessary, paper correspondence and express mail may be directed to: 
Dawn M. Ehde, PhD, Editor 
Rehabilitation Psychology 
University of Washington School of Medicine 
Department of Rehabilitation Medicine, Box 359612 
Harborview Medical Center 
325 9th Avenue 
Seattle, WA 98104-2499 
Email: Editorial Office 
Suitable Submissions 
Rehabilitation psychology deals with the interplay of biological, psychological, social, 
environmental, and political factors that affect the functioning of persons with chronic 
health conditions or disability. Given the breadth of rehabilitation psychology, the 
journal's scope is broadly defined. 
Submissions are welcomed from authors in psychology and other health related 
disciplines. 
Suitable submissions include: 
Empirical Articles 
This format reports original empirical research which can include experimental 
investigations, survey research, evaluations of interventions, and outcome studies 
research. 
Brief Reports 
This format may be appropriate for empirically sound studies that are limited in scope, 
contain novel or provocative findings that need further replication, or represent 
replications and extensions of prior published work. Brief Reports must use a 12-point 
Times New Roman type and 1-in. (2.54-cm) margins, and not exceed 265 lines of text 
plus references. These limits do not include the title page, abstract, author note, 
footnotes, tables, or figures. 
Review Articles 
This format includes reviews of various types and formats. Reviews can include state- 
of-the art review of empirical research (meta-analysis), reviews of professional, 
theoretical or public policy issues, or reviews designed to help practitioners solve 
common clinical problems (clinical management reviews ). 
Commentaries 
This format supports a submitted or previously published manuscript including 
explanation, critique or illustration of rehabilitation related issues or topics. 
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Case Studies 
This format includes written analyses of one or more particular cases or case histories 
with a view to making generalizations in rehabilitation and that are of sufficient import to 
warrant attention. 
Cover Letter 
The cover letter accompanying the manuscript submission must include all authors' 
names and affiliations, addresses and phone numbers, as well as electronic mail 
addresses and fax numbers for possible use by the editorial office and later by the 
production office. 
The cover letter should identify the type of submission category and include 
• a statement of compliance with APA ethical standards in the conduct of the work 
reported in the manuscript 
• a statement that the manuscript or data have not been previously published and that 
they are not presently under consideration for publication elsewhere 
• a statement that all listed authors have contributed significantly to the work submitted 
for consideration 
• a statement that the paper has been seen and approved by all authors 
When the manuscript contains data or observations from a larger study, the cover letter 
should clarify the relationship between this submission and other papers from the study, 
specifically addressing potential overlap. Authors must be prepared to provide copies of 
related manuscripts or papers as part of the editorial review process. 
Authors may suggest qualified reviewers of the manuscript, but these are considered 
advisory only. 
Title 
Should be accurate, descriptive, and no longer than 12 words. 
Abstract and Keywords 
All manuscripts must include a structured abstract containing a maximum of 250 words 
typed on a separate page (page 2 of the manuscript). Abstracts must contain a brief 
statement about each of the following: 
• Purpose/Objective 
• Research Method/Design - including the number and type of participants 
• Results 
• Conclusions/Implications 
After the abstract, please supply up to five keywords. 
Impact and Implications Statement 
At the start of each paper the authors should provide 2-3 bullet points, with the header 
"Impact", that states what the current paper adds to the literature and one to two 
practice or policy implications the findings. This is not a statement of the conclusions, 
rather a thoughtful series of statements highlighting the novel contribution of the work 
and translation of the findings for practice or policy. This section should be no more than 
200 words. 
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Data Source 
It is important that readers have an accurate understanding of the data source the study 
is based on. Please include details in the Methods section as to the source of the data 
for this study. 
If the study is based on original data collected for the purpose of testing the hypotheses 
in this manuscript, please make a statement to that effect. If the paper is based on 
secondary data analyses of data collected for another purpose please indicate that in 
the Methods. 
If the data set used in this manuscript was also used in previous publications, please 
include these citations when describing the Methods in this submission. 
Human Participants 
The research section should include a statement indicating the Institutional Review 
Board that provided oversight for the research. 
Style of Manuscripts 
The journal considers theoretical, empirical, and commentary papers relevant to 
rehabilitation psychology. Brief reports are considered. 
Additional Information for Specific 
Publication Categories 
Randomized Clinical Trials 
Rehabilitation Psychology requires the use of the CONSORT (Consolidated Standards 
of Reporting Trials) reporting standards (i.e., a checklist and flow diagram) for 
randomized clinical trials. The checklist may be placed in an Appendix of the manuscript 
for review purposes. 
Visit the CONSORT Statement Web site for more details and resources. 
Nonrandomized Trials 
Rehabilitation Psychology encourages the use of the most recent version of the TREND 
criteria (Transparent Reporting of Evaluations with Non-randomized Designs for 
nonrandomized designs, available on the TREND Web site). 
Review Process 
Papers will be evaluated for their importance to the field, scientific rigor, novelty, 
suitability for the journal, and clarity of writing. Manuscripts that do not conform to the 
submission guidelines may be returned without review. 
A masked review process is used. To facilitate masked review, it is incumbent upon 
authors to see that the manuscript itself contains no clues to their identities. Authors' 
names, affiliations, and contact information should be included only in the cover letter. 
Rehabilitation Psychology encourages translation of information and strives to review 
submitted articles in a timely manner. 
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Manuscript Preparation 
Prepare manuscripts according to the Publication Manual of the American 
Psychological Association using the 7th edition. Manuscripts may be copyedited for 
bias-free language (see Chapter 5 of the Publication Manual). 
Review APA's Journal Manuscript Preparation Guidelines before submitting your article. 
Double-space all copy. Include line numbers and page numbers in the manuscript. 
Other formatting instructions, as well as instructions on preparing tables, figures, 
references, metrics, and abstracts, appear in the Manual. Additional guidance on APA 
Style is available on the APA Style website. 
Please ensure that the final version for production includes a byline and full author note 
for typesetting. 
Below are additional instructions regarding the preparation of display equations, 
computer code, and tables. 
Display Equations 
We strongly encourage you to use MathType (third-party software) or Equation Editor 
3.0 (built into pre-2007 versions of Word) to construct your equations, rather than the 
equation support that is built into Word 2007 and Word 2010. Equations composed with 
the built-in Word 2007/Word 2010 equation support are converted to low-resolution 
graphics when they enter the production process and must be rekeyed by the 
typesetter, which may introduce errors. 
To construct your equations with MathType or Equation Editor 3.0: 
• Go to the Text section of the Insert tab and select Object. 
• Select MathType or Equation Editor 3.0 in the drop-down menu. 
If you have an equation that has already been produced using Microsoft Word 2007 or 
2010 and you have access to the full version of MathType 6.5 or later, you can convert 
this equation to MathType by clicking on MathType Insert Equation. Copy the equation 
from Microsoft Word and paste it into the MathType box. Verify that your equation is 
correct, click File, and then click Update. Your equation has now been inserted into your 
Word file as a MathType Equation. 
Use Equation Editor 3.0 or MathType only for equations or for formulas that cannot be 
produced as Word text using the Times or Symbol font. 
Computer Code 
Because altering computer code in any way (e.g., indents, line spacing, line breaks, 
page breaks) during the typesetting process could alter its meaning, we treat computer 
code differently from the rest of your article in our production process. To that end, we 
request separate files for computer code. 
In Online Supplemental Material 
We request that runnable source code be included as supplemental material to the 
article. For more information, visit Supplementing Your Article With Online Material. 
In the Text of the Article 
If you would like to include code in the text of your published manuscript, please submit 
a separate file with your code exactly as you want it to appear, using Courier New font 
with a type size of 8 points. We will make an image of each segment of code in your 
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article that exceeds 40 characters in length. (Shorter snippets of code that appear in 
text will be typeset in Courier New and run in with the rest of the text.) If an appendix 
contains a mix of code and explanatory text, please submit a file that contains the entire 
appendix, with the code keyed in 8-point Courier New. 
Tables 
Use Word's Insert Table function when you create tables. Using spaces or tabs in your 
table will create problems when the table is typeset and may result in errors. 
Academic Writing and English Language 
Editing Services 
Authors who feel that their manuscript may benefit from additional academic writing or 
language editing support prior to submission are encouraged to seek out such services 
at their host institutions, engage with colleagues and subject matter experts, and/or 
consider several vendors that offer discounts to APA authors. 
Please note that APA does not endorse or take responsibility for the service providers 
listed. It is strictly a referral service. 
Use of such service is not mandatory for publication in an APA journal. Use of one or 
more of these services does not guarantee selection for peer review, manuscript 
acceptance, or preference for publication in any APA journal. 
Submitting Supplemental Materials 
APA can place supplemental materials online, available via the published article in the 
PsycARTICLES® database. Please see Supplementing Your Article With Online 
Material for more details. 
References 
List references in alphabetical order. Each listed reference should be cited in text, and 
each text citation should be listed in the References section. 
Examples of basic reference formats: 
• Journal Article: 
Hughes, G., Desantis, A., & Waszak, F. (2013). Mechanisms of intentional binding and 
sensory attenuation: The role of temporal prediction, temporal control, identity 
prediction, and motor prediction. Psychological Bulletin, 139, 133–151. 
http://dx.doi.org/10.1037/a0028566 
• Authored Book: 
Rogers, T. T., & McClelland, J. L. (2004). Semantic cognition: A parallel distributed 
processing approach. Cambridge, MA: MIT Press. 
• Chapter in an Edited Book: 
Gill, M. J., & Sypher, B. D. (2009). Workplace incivility and organizational trust. In P. 
Lutgen-Sandvik & B. D. Sypher (Eds.), Destructive organizational communication: 
Processes, consequences, and constructive ways of organizing (pp. 53–73). New York, 
NY: Taylor & Francis. 
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Figures 
Graphics files are welcome if supplied as Tiff or EPS files. Multipanel figures (i.e., 
figures with parts labeled a, b, c, d, etc.) should be assembled into one file. 
The minimum line weight for line art is 0.5 point for optimal printing. 
For more information about acceptable resolutions, fonts, sizing, and other figure 
issues, please see the general guidelines. 
When possible, please place symbol legends below the figure instead of to the side. 
APA offers authors the option to publish their figures online in color without the costs 
associated with print publication of color figures. 
The same caption will appear on both the online (color) and print (black and white) 
versions. To ensure that the figure can be understood in both formats, authors should 
add alternative wording (e.g., "the red (dark gray) bars represent") as needed. 
For authors who prefer their figures to be published in color both in print and online, 
original color figures can be printed in color at the editor's and publisher's discretion 
provided the author agrees to pay: 
• $900 for one figure 
• An additional $600 for the second figure 
• An additional $450 for each subsequent figure 
Permissions 
Authors of accepted papers must obtain and provide to the editor on final acceptance all 
necessary permissions to reproduce in print and electronic form any copyrighted work, 
including test materials (or portions thereof), photographs, and other graphic images 
(including those used as stimuli in experiments). 
On advice of counsel, APA may decline to publish any image whose copyright status is 
unknown. 
• Download Permissions Alert Form (PDF, 13KB) 
Publication Policies 
APA policy prohibits an author from submitting the same manuscript for concurrent 
consideration by two or more publications. 
See also APA Journals®  Internet Posting Guidelines. 
APA requires authors to reveal any possible conflict of interest in the conduct and 
reporting of research (e.g., financial interests in a test or procedure, funding by 
pharmaceutical companies for drug research). 
• Download Disclosure of Interests Form (PDF, 38KB) 
In light of changing patterns of scientific knowledge dissemination, APA requires 
authors to provide information on prior dissemination of the data and narrative 
interpretations of the data/research appearing in the manuscript (e.g., if some or all 
were presented at a conference or meeting, posted on a listserv, shared on a website, 
including academic social networks like ResearchGate, etc.). This information (2–4 
sentences) must be provided as part of the Author Note. 
Authors of accepted manuscripts are required to transfer the copyright to APA. 
• For manuscripts not funded by the Wellcome Trust or the Research Councils UK 
Publication Rights (Copyright Transfer) Form (PDF, 83KB) 
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• For manuscripts funded by the Wellcome Trust or the Research Councils UK 
Wellcome Trust or Research Councils UK Publication Rights Form (PDF, 34KB) 
Ethical Principles 
It is a violation of APA Ethical Principles to publish "as original data, data that have been 
previously published" (Standard 8.13). 
In addition, APA Ethical Principles specify that "after research results are published, 
psychologists do not withhold the data on which their conclusions are based from other 
competent professionals who seek to verify the substantive claims through reanalysis 
and who intend to use such data only for that purpose, provided that the confidentiality 
of the participants can be protected and unless legal rights concerning proprietary data 
preclude their release" (Standard 8.14). 
APA expects authors to adhere to these standards. Specifically, APA expects authors to 
have their data available throughout the editorial review process and for at least 5 years 
after the date of publication. 
Authors are required to state in writing that they have complied with APA ethical 
standards in the treatment of their sample, human or animal, or to describe the details 
of treatment. 
• Download Certification of Compliance With APA Ethical Principles Form (PDF, 26KB) 
The APA Ethics Office provides the full Ethical Principles of Psychologists and Code of 
Conduct electronically on its website in HTML, PDF, and Word format. You may also 
request a copy by emailing or calling the APA Ethics Office (202-336-5930). You may 
also read "Ethical Principles," December 1992, American Psychologist, Vol. 47, pp. 
1597–1611. 
Other Information 
Visit the Journals Publishing Resource Center for more resources for writing, reviewing, 
and editing articles for publishing in APA journals. 
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Appendix K: HR-QOL Flow chart for clinical and research use 
 
 
